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The transcription factor PRH/HHEX (Proline-Rich Homeodomain/Haematopoietically 
Expressed Homeobox) controls cell proliferation, cell differentiation and cell 
migration/invasion in a diverse range of cell types. Here I show that the gene encoding 
PRH is deleted in around 4% of sequenced samples from patients with prostate 
cancer. Additionally, I show that there is increased CpG DNA methylation at this gene 
in prostate cancer samples compared to samples from normal prostate and that PRH 
mRNA levels are reduced in prostate cancer. Using immunohistochemistry to stain 96 
samples of prostate neoplasia, I show that PRH expression is negatively correlated to 
tumour differentiation in prostate cancer.  
Recent published work has shown that the down-regulation of PRH expression in 
breast and prostate cancer cells results in increased cell proliferation and increased 
cancer cell invasion. Moreover, PRH inhibits breast and prostate cancer cell migration 
and invasion in part at least by activating the transcription of Endoglin, a Transforming 
Growth Factor β (TGF-β) co-receptor. Here I show that the treatment of immortalised 
prostate epithelial (PNT2-C2) cells and prostate adenocarcinoma (PC3) cells with 
TGF-β increases cell migration and induces an epithelial to mesenchymal transition 
(EMT), with up-regulation of the EMT transcription factor Snail and down-regulation of 
the epithelial marker E-Cadherin. TGF-β treatment down-regulates the expression of 
PRH/HHEX in prostate cell lines at both the protein and mRNA level. Moreover, 
chromatin immunoprecipitation (ChIP) experiments show that the regulation of 
PRH/HHEX by TGF-β may be via the direct binding of the TGF-β effector pSmad3 at 
the PRH promoter. I also investigate the effects of PRH over-expression on PC3 cells. 
PRH expression in these cells re-activates the expression of E-cadherin, reduces the 
migratory ability of these cells and inhibits cell proliferation. 
PRH over-expression also down-regulates the expression of multiple genes involved 
in the TGF-β signalling pathway including TGFB2 and TGFBR2. ChIP shows that PRH 
binds to both the TGFB2 and TGFBR2 gene bodies, suggesting a direct effect of PRH 
on the expression of these genes. Prostate cancer cells are exposed to TGF-β from 
multiple sources in vivo and blood platelets were tested as a possible source of TGF-
β using this model. Platelet treatment was able to increase cell migration, trigger EMT 
and down-regulate PRH expression in a similar way to TGF-β treatment. Platelets 
treatment resulted in the up-regulation of pSmad3 and the effect of platelets on cell 
migration were abolished when TGF-β signalling was blocked. 
In summary, the work described in this Thesis shows that TGF-β increases prostate 
cell migration in part at least by the down-regulation of PRH expression. PRH up-
regulates E-cadherin expression and down-regulates cell migration suggesting that 
TGF-β alters E-cadherin levels and increases cell migration via its effects on PRH. 
Since PRH also regulates several genes important in TGF-β signalling this creates a 
feedback loop that enables a more precise control of cell behaviour. Changes in PRH 
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The World Health Organization defines cancer as a generic term for a large group of 
diseases that can affect any part of the body. One of its features is the fast and 
uncontrolled proliferation of abnormal cells, which can then invade adjoining parts of 
the body and spread to other organs. This particular ability is the major cause of 
death by cancer, and it is called metastasis (WHO 2014). 
The development of novel technologies has allowed studies which utilize molecular 
biology to investigate the several kinds of cancer, aiming to understand its biology. 
These studies have helped to modernize cancer treatment enabling health 
professionals to customize treatment to individual patients. However, this disease is 
far from being defeated and research to understand cancer at a molecular level is 
the lead driving force in the development of effective therapies. 
According to the World Health Organization, cancer is the leading cause of death 
worldwide: 14 million cases and 8.2 million cancer deaths occurred in 2012 (WHO 
2014), causing an economic loss of $216.6 billion dollars in 2009 (ACS 2014). 
Prostate cancer is the fourth most common cancer in humans, and the second most 
common cancer in men. With an estimated 1 276 106 (7.1% of total cancer cases in 
both sexes) new cases and 358 989 (3.8% of total cancer deaths in both sexes) 
deaths in 2018, prostate cancer is the fifth leading cause of death from cancer in 
men (7.6% of the total men deaths) (Globocan 2018). An estimated 1.1 million men 
worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of the 
cancers diagnosed in men, with almost 70% of the cases (759,000) occurring in 
more developed regions (Globocan 2018). In Brazil alone, in 2018 there were 68.220 
new prostate cancer cases with approximately 2800 deaths per year. That means 
that in every 100 000 men we expect about 70 new cases (INCA 2018). These 
statistics show that a greater Ratio of diagnosis/death in Brazil when compared to 
the global statistics. This discrepancy could be a reflection of a lower life expectancy 
observed in Brazil when compared to other countries like the United Kingdom. 
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Hallmarks of cancer 
Uncontrolled tumour growth is only one of the characteristics of cancer. The 
hallmarks of cancer: The next generation (Hanahan & Weinberg 2011) listed the 
main ten capabilities of all cancers that make them such a dangerous set of 
diseases. These are: sustaining proliferative signalling, evading growth suppressors, 
avoiding immune destruction, enabling replicative immortality, promoting 
inflammation, activating invasion and metastasis, inducing angiogenesis, inducing 

















Figure 1.1. Hallmarks of cancer. source: (Hanahan & Weinberg 2011) 
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Unlike normal cells, cancer cells sustain a continuous proliferating stimulus. This 
cellular signalling can come from different sources: they can produce their own 
growth factors in an autocrine stimulation (Witsch et al. 2010); they can educate the 
stroma (surrounding non-cancerous cells and proteins associated with the tumour) to 
produce growth factors that activate growth stimuli in cancer cells (Bhowmick et al. 
2004); they can become hypersensitive to growth factors by augmenting the number 
of receptors in their cell surface (Korc et al. 1992; Rusch et al. 1997); they can 
constitutively activate the subcellular signals triggered when growth factors bind to 
their receptors (Huang et al. 2009); and finally they can disrupt negative feed-back 
mechanisms placed to control such growth signals (Amit et al. 2007; Jiang & Liu 
2009; Yuan & Cantley 2008). Cancer cells can benefit  from one or more of these 
mechanisms, however, excessive growth factor stimulation can trigger intrinsic 
cellular defence mechanisms that lead to senescence and cell death (Hanahan & 
Weinberg 2011). For that reason, to survive and continue unrestricted proliferation 
cancer cells must develop mechanisms to resist cell death. 
There are several mechanisms through which cancer cells avoid senescence (a 
state in which cells cease to divide and become enlarged) and crisis-induced cell 
death. The most common adaptation is the deactivation of growth suppressor 
proteins like retinoblastoma-associated (RB) protein and the TP53 protein (Hanahan 
& Weinberg 2011). These two systems are activated by different stimuli, RB is 
regulated mainly by external signalling, (as reviewed by Zheng & Lee 2001) and is 
mainly activated by anti-proliferative signals such as TGF-β signalling. TGF-β 
prevents the phosphorylation of RB (Massagué & Polyak 1995), and hypo-
phosphorylated RB sequesters members of the E2F family of transcription factors 
inhibiting E2F function and arresting the cell cycle in G1 phase.  RB can also repress 
transcription by recruitment of histone deacetylase (HDAC) complexes, (as reviewed 
by Burkhart & Sage 2008); the deacetylation of histones by HDAC leads to 
chromatin remodelling and transcription repression. RB is the prototype tumour 
suppressor gene (TSG) as it was the first to be discovered. Another important TSG 
is TP53. TP53 acts as a sensor in the cell responding mainly to crises situations, for 
example DNA damage or DNA replication error. The protein encoded by the gene 
TP53, P53, can recruit DNA repair proteins in the case of DNA damage, but its cell 
cycle arrest function is mediated by the transcription activation of several genes, for 
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example the gene encoding p21, a protein that binds to cyclin-dependent kinases 
(CDKs) that are important to the transition from the G1 phase to S phase (He et al. 
2005). In cases where the DNA damage is irreversible or extensive, P53 can activate 
apoptosis (a form of programmed cell death). The mechanisms underlying this 
activation are not fully understood, but the apoptosis repressor with caspase 
recruitment domain (ARC) is involved, as P53 can repress the transcription of ARC 
and thereby abrogate its anti-apoptotic activity (Li et al. 2008). Besides being 
activated by different signalling systems, both, P53 and RB, can regulate cell 
proliferation. 
Another important factor in the inhibition of cell proliferation is the effect of cellular 
contacts. The loss of contact inhibition present in normal cells by cancer cells allows 
them to continuously proliferate to the point of forming macroscopic nodes (Hanahan 
& Weinberg 2011). Uncontrolled proliferation, metabolic changes, constant DNA 
damage and mutations creates a chaotic environment in the cancer cell that can 
potentially trigger intrinsic defence mechanisms that lead to cell death. TGF-β is an 
important tumour suppressor molecule, however, tumours can evolve in a fashion to 
corrupt the TGF-β signal in such a way that it starts to stimulate cancer cell 
proliferation and genome instability through a process known as epithelial to 
mesenchymal transition (EMT) (Massagué 2008b). The role of TGF-β in cancer 
progression and the process of EMT are further discussed in the following sections.  
To survive, cancer must avoid triggering apoptosis and autophagy (a cellular process 
used to disassemble cellular organelles that are dysfunctional or during cell 
starvation) (Hanahan & Weinberg 2011). The most common dysregulation that 
cancer cells adopt to avoid such mechanisms is the loss of TP53 function. As 
explained above, TP53 is an important DNA damage sensor that is central in 
activating the apoptotic circuit in cells (Hanahan & Weinberg 2011).Autophagy 
signalling has been shown to have contradictory implications when it comes to 
cancer (White & DiPaola 2009). When one of the Beclin-1 alleles (encoding an 
autophagy activator) is deleted in mice, they are more susceptible to cancer (Qu et 
al. 2003). However, it has been demonstrated that some cancer cells activate 
autophagy to shrink and reach a state of reversible dormancy (a state where cell 
growth is stopped) during stress and  this process can protect the cancer cell from 
death, inflammation, and immunosurveillance (Degenhardt et al. 2006).  
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This contradictory effect of an apparently anti-cancer cellular system is also 
observed in the event of cellular necrosis. The main difference between necrosis and 
apoptosis is that necrotic cells burst and release cellular components, which does 
not happen in apoptotic events (Hanahan & Weinberg 2011; Vakkila & Lotze 2004). 
The release of cellular contents triggers a systemic inflammatory response. 
Inflammatory cells make their way to the tumour site where they can release factors 
intended to destroy cancer cells, however, inflammation can also promote cancer 
progression (O’Byrne & Dalgleish 2001; Ammirante et al. 2010). Therefore, tumours 
can benefit from a moderate degree of necrosis that attracts tumour promoting 
inflammatory cells that trigger vasculature genesis and promote genomic evolution 
(Hanahan & Weinberg 2011). 
As aforementioned, the excess growth factor stimulatory signals, often experienced 
by cancer cells, can lead to a senescent or apoptotic state (that acts as to block 
proliferation in response to stress). In general terms, cells possess a limited number 
of times that they can undergo cell division (Hanahan & Weinberg 2011; Shay & 
Wright 2000). This limitation is associated with the presence of multiple tandem 
hexanucleotide repeats known as telomeres at the end of the chromosomes (Blasco 
2005). Telomeres protect chromosomes against end-to-end fusions helping to 
maintain chromosomal integrity and avoiding the triggering of cellular crisis signalling 
(Blasco 2005; Hanahan & Weinberg 2011). However, in each cell division cycle the 
telomeres get shortened. The expression of a specialised polymerase complex 
called telomerase is associated an immortalised phenotype and cancer progression 
(Hanahan & Weinberg 2011). Telomerase also presents some telomere-independent 
effects, for example, the telomerase subunit telomerase reverse transcriptase 
(TERT) can modulate the expression of the Wnt/β-catenin pathway. Additionally, 
TERT is commonly mutated in several human cancers (Vinagre et al. 2013). TERT is 
the gene that codifies the catalytic subunit of telomerase. Two mutations in a non-
coding region of TERT promoter were discovered to be present in 71% of melanoma 
cancers and, the mutations were usually heterozygous (Horn et al 2013; Huang et al 
2013). They created a new binding site for transcription factors like the ones in the 
ETS family. The mutations were further identified in high frequency in several other 
types of cancer (reviewed by Bell et al 2016). A study in bladder cancer 
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demonstrated that promoter mutations were associated with increased telomerase 
activity and stable telomere length (Borah et al 2015). 
However, the role of telomeres and telomerases seems to be much more 
complicated than that. Cells that reached a senescent state can be revitalised by the 
epigenetic changes that induce telomerase expression in the senescence cell 
(Hanahan & Weinberg 2011; Chin et al. 2004). Furthermore, cancer cells can benefit 
from the mutations induced by chromosomal aberrations acquired during the 
senescence state before cell reactivation by telomerase expression (Karlseder et al. 
1999; Chin et al. 1999). This creates aggressive metastatic cancers with aberrant 
number and arrangement of chromosomes. 
Another essential event in cancer survival is the acquisition of nutrition for the tumour 
(Hanahan & Weinberg 2011). This happens by the advancement of tumour 
vascularisation. In normal tissues vascularisation is regulated by a balance of pro- 
and anti-angiogenic stimuli. The vascularisation switch that is activated during body 
growth is only reactivated transiently in the adult during specific events like wound 
healing (Roberts et al. 1986) and the oestrous cycle/pregnancy (Hobson & 
Denekamp 1984). However, in advanced tumours the vascularisation switch seems 
to be always turned on (Hanahan & Folkman 1996). In contrast, there are reports of 
cancers that present vast avascular stroma regions in earlier stages, followed by a 
variable intensity of ongoing neovascular formation (Olive et al. 2009; Hanahan & 
Weinberg 2011). This avascular state can have an impact on the metabolic changes 
that cancer cells undergo (discussed further below) and can induce, latter on, 
vascularisation. Hypoxic states can induce the expression of VEGFA (Vascular 
endothelial growth factor A) in tissues, therefore, the transient avascular environment 
can lead VEFG induced vasculature sprouting in cancer (Shweiki et al. 1992) 
bringing access to nutrition, evacuation and immune cells. VEGF signal transduction 
is a complex network of ligands, receptors and signal transductors that orchestrate 
not only angiogenesis but is also involved in proliferation, migration and cell survival. 
(reviewed by Koch and Claesson-Welsh 2012). Cancer cells can also can go through 
genomic evolution to overexpress the VEGFA gene and other genes that induce 
vascularisation (Hervé et al. 2008). VEGF has been used as a target to treat 
colorectal carcinoma, Figure 1.2 shows a diagram of VEGF signalling and its 
common therapeutic targets in cancer treatment. (reviewed by Lopez et al. 2019). 
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The inflammatory component of the cancer can be exacerbated by neovascular 
formation and vice versa. The neovascularization in tumours is often marked by 
precocious capillary growth, excessive branching and distorted vessels resulting in 
microhaemorrhage and inflammation. On the other hand, peritumoral inflammatory 
















The next step in cancer progression involves the activation of an invasion and 
metastasis programme. The most often observed alteration in these processes is the 
loss of E-cadherin and proteins associated with adhesion in epithelial cells in general 
(Hanahan & Weinberg 2011; Hoover et al. 1998; van Roy 2014). E-cadherin loss is 
associated with malignant behaviour (Birchmeier & Behrens 1994). Conversely, 
adhesion proteins associated with cell migration and transfer of cells through the 
endothelial barriers (diapedesis) are constantly up-regulated (Wheelock et al. 2008). 
Although, the invasion/metastasis process is complex, it involves a series of discrete 
Figure 1.2. Vascular endothelial growth factor (VEGF) pathway and targeted therapies. PIGF placental 
growth factor, VEGFR vascular endothelial growth factor receptor, PI3Kphosphoinositide 3-
kinase, Akt protein kinase B, NFκB nuclear factor kappa-light-chain-enhancer of activated B cells, RAS rat 
sarcoma, RAF rapidly accelerated fibrosarcoma, MEK mitogen-activated protein kinase, ERK extracellular 
signal-regulated kinases. *Regorafenib also inhibits multiple targets in addition to VEGFR-2, not shown in 
this figure: PDGFR, FGF, KIT, RET, RAF1, B-RAF, and B-RAF-V600E (Lopez et al. 2019). 
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events described as follows: local invasion of the surrounding tissue, intravasation of 
the cancer cells into local vessels, transportation of the cancer cell via lymphatic or 
hematologic streams, diapedesis of the cancer cell to a different tissue, the formation 
of micronodules and finally growth into macroscopic lesions (Hanahan & Weinberg 
2011). 
The regulatory programme referred as epithelial to mesenchymal transition (EMT) is 
intimately associated with the invasion and metastasis process (Krebs et al. 2017; 
Takeyama, Sato, Horio, Hase, Yoshida, Yokoyama, Nakashima, Hashimoto, Sekido, 
Adi F. Gazdar, et al. 2010; Brabletz et al. 2018; Heldin et al. 2012a; Shibue & 
Weinberg 2017). The activation of EMT can lead to increased ability to invade, to 
resist apoptosis and metastasise (Hanahan & Weinberg 2011). Interestingly, the 
EMT program is often only partially and/or transiently activated by cancer cells 
during the course of metastasis (Brabletz et al. 2018). This feature is thought to 
maintain phenotypic plasticity and adaptability, often helping  the metastatic cells to 
adapt to the new environments where they have taken residence (Brabletz et al. 
2018). 
Besides the loss of E-cadherin the EMT program confers a series of other 
characteristics to the cancer cells, including: conversion from polygonal epithelial 
cells to spindle-shaped fibroblastic morphology, higher expression of matrix 
degrading enzymes, increased motility and increased resistance to apoptotic signals  
(Hanahan & Weinberg 2011). The conversation between cancer cells and elements 
of the tumour microenvironment such as inflammatory cells and blood platelets, 
among others, can play an important role in the activation of this programme, by 
supplying matrix degrading enzymes and molecules such as growth factors 
(Karnoub & Weinberg 2007; Brabletz et al. 2001; Labelle et al. 2011). 
It is well known that tumours present heterogeneity at a molecular and cellular level 
(Roerink et al. 2018). The main components of the tumour microenvironment are 
fibroblasts, neuroendocrine cells, adipose cells, immunological and inflammatory 
cells, vasculature networks and the extracellular matrix (ECM). Cancer-associated 
fibroblasts (CAFs) are activated by several factors that can be released in response 
to injury such as TGF-β, epidermal growth factor (EGF), platelet-derived growth 
factor (PDGF) and fibroblast growth factor 2 (FGF2), reviewed by (Kalluri & Zeisberg 
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2006). The activated fibroblasts secrete an increased level of smooth muscle -actin 
(-SMA) and metalloproteases that degrade the ECM inducing alterations in the 
composition of the ECM. CAFs also secrete a range of growth factors that induce 
proliferative signals in epithelial cells (Bhowmick et al. 2004) and factors that attracts 
and modulate inflammation, induce angiogenesis and promote an invasive 
phenotype (as reviewed by Kalluri & Zeisberg 2006). 
In prostate cancer CAFs seem to play an important role, It was demonstrated that 
the non-tumorigenic prostate cell line BPH-1, when recombined with CAFs, went 
through transformation and became tumorigenic. New cell lines established from the 
tumours formed by CAFs activated BHP-1 inherited the tumorigenic ability (Hayward 
et al. 2001). Furthermore, heterogenetic mix of CAFs can influence the tumorigenic 
conditioning of the epithelial cells by CAFs. The heterogenic expression of the TGF-β 
receptor 2 (TGFβRII) in CAFs cell populations induced dysregulation on the 
expression of several factors including TGF-β1, and these changes induced 
epithelial proliferations and tumorigenesis (Franco et al. 2011). 
Inflammatory and immunological cells in the tumour microenvironment, provide 
immune surveillance and attempt to remove emerging tumour cells (Hanahan & 
Weinberg 2011). However, the role played by the immune system is complex. 
Communication between cancer cells and immune system can be divided into three 
phases: elimination, equilibrium and escape (Dunn et al. 2004). In the elimination 
phase, inflammatory and immunological responses can eliminate the nascent cancer 
cells.  In the equilibrium phase, the immune cells can no longer completely clear the 
cancer cells, instead they contain cancer growth, the surviving cells are then 
selected and a number of them can develop immune evading characteristics through 
mutations or through disrupted EMT signals.  Such cells will eventually enter the 
escape phase where the cancer cells can modulate the immuno-response and form 
solid tumours (Dunn et al. 2004). A component of the inflammatory system that is 
often overlooked are blood platelets. Platelets have been frequently implicated in 
cancer progression by supply of growth factors, cytokines and helping with immune 
evasion (Labelle et al. 2011; Carr et al. 2014; Im et al. 2004), this topic is further 
discussed in later sections. 
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Several other cell populations are reported to contribute to the creation of the tumour 
microenvironment and to aid cancer progression, among them are the blood and 
lymphatic vasculatures, which are important to tumour nutrition, secretion of 
metabolic waste and evasion of immune surveillance. Adipocytes can be a major 
source of energy to a tumour, plus they interact with the immune system recruiting 
immune cells and promote vasculogenesis (as reviewed by Wang et al. 2017). 
Many of the hallmarks acquired by cancer cells depend largely on genome 
alterations. These alterations arise from mutations or failure to repair DNA damage. 
However, intrinsic defence mechanisms of DNA surveillance can trigger apoptotic 
signals when mutations are detected. Cancer cells can benefit from genome 
instability and mutations if these signals are lost (Hanahan & Weinberg 2011). One 
of the main events seen in several cancers is deactivation of the TP53 DNA 
surveillance. TP53 is often referred to as the genome guardian. TP53 can detect 
DNA damage and arrest cell growth, and if the damage is irreversible, it can trigger 
apoptosis by repression of the anti-apoptotic protein ARC, as explained above 
(Hanahan & Weinberg 2011). P53 also has a role in the response to short telomeres; 
reduced numbers of telomere repeats triggers cellular growth arrest by 
destabilisation of P53 (Milyavsky et al. 2001). Deactivations of other proteins 
involved in DNA damage detection and repair can also enable genome instability in 
cancer cells (Hanahan & Weinberg 2011). 
As discussed, one of the main traits of cancer is the ability to continuously grow 
powered by growth signalling, avoidance of anti-proliferative signals and evasion of 
the intrinsic defence mechanism that can trigger cell death. However, the 
uncontrolled proliferation observed in cancer cells also involves adjustments of 
energy metabolism (Hanahan & Weinberg 2011). First observed in 1930, cancer 
cells fuel their cell divisions mostly by glycolysis, even in the presence of oxygen. 
Respiration still occurs in cancer cells, however, the respiration is not sufficient for 
these cells; measurements show that the glycolysis and glycolytic routes produce 
similar amounts of energy in cancer cells (Warburg 1956a; Warburg 1956b). This 
process is known as aerobic glycolysis and is thought to be used by the cancer cells 
because this metabolic route avoids the engagement of the metabolic products into 
‘low flux’ (slower metabolic processes like mitochondrial pyruvate importation) 
biosynthetic pathways naturally undertaken in the glycolytic route (DeBerardinis et al. 
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2008). The glycolytic route requires importation of pyruvate to the mitochondrial 
matrix and the next steps of the processing are carried by highly regulated enzymes, 
like pyruvate dehydrogenase (PDH), which overall may reduce the reaction speed 
(DeBerardinis et al. 2008). Indeed, the Vmax flux of glycolysis is much greater than 
the Vmax of PDH in highly proliferative cells (Curi et al. 1988). Instead, in cancer 
cells, the products of glycolysis are used as intermediates to biosynthetic pathways, 
for example, ribose sugars for nucleotides; glycerol and citrate for lipids; production 
of nonessential amino acids; and, through the oxidative pentose phosphate pathway, 
NADPH (DeBerardinis et al. 2008). Therefore, even though glycolysis produces less 
energy per sugar molecule, if the reaction is rapid enough and the availability of 
sugar is unlimited, the energy supply would not be a limitation for cancer cells. With 
this, aerobic glycolysis seems to supply the cancer cells with most of its biogenetic 
and biosynthetic needs. However, glycolysis is approximately eighteen folds less 
efficient than the glycolytic route. Because of the less efficient metabolic pathway 
used, cancer cells must up-regulate the expression of glucose transporters like 
GLUT1 augmenting the cellular glucose intake (Hanahan & Weinberg 2011). 
Interestingly tumours often present a mixed population of cells regarding energy 
production. Some of the cells in a tumour can use the lactate secreted by cells in 
aerobic glycolysis (Feron 2009). In these cells, the lactate is incorporated into the 
citric acid cycle to produce energy (Kennedy & Dewhirst 2010), creating a symbiotic 
relationship between the two cell populations, this feature is observed in tumours 
with large avascular regions (Feron 2009; Hanahan & Weinberg 2011). 
The inflammatory component of the cancer was already mentioned here as 
supporting the installation of other cancer hallmarks, therefore they were described 
as an enabling hallmark of cancer (Hanahan & Weinberg 2011). Inflammation can 
contribute to the tumour microenvironment by supplying bioactive molecules, 
including growth factors, pro angiogenic stimulation, metalloproteinases and signals 
that induce EMT (DeNardo et al. 2010; Qian & Pollard 2010). Inflammation can also 
provide reactive oxygen species that actively damage DNA, potentially accelerating 
genomic evolution of the tumour (Grivennikov et al. 2010). 
Finally, the attraction of inflammatory cells to the tumour site also represents an 
attempt by the immune system to clear the neoplastic lesion. There are compelling 
data demonstrating that mice deficient in components of the innate and the adaptive 
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immune response are more susceptible to cancer (Smyth et al. 2000; Dighe et al. 
1994). Transplantation experiments showed that tumours grown in immunodeficient 
mice were not competent to grow in immunocompetent mice after transplantation, 
but the reverse was not true, suggesting that inflammatory cells can destroy 
immunogenic cancer cells (Svane et al. 1996; Engel et al. 1997). This suggests that 
a mixed population of cells in the tumour presents different levels of immunogenicity, 
in immunocompetent mice a less immunogenic strain of cells is selected (Hanahan & 
Weinberg 2011; Syverton et al. 1950). Examples of immune cells from the innate 
and adaptive system that presents anti-tumoral activity are natural killer (NK) (Wu & 
Lanier 2003) and cytotoxic T cell (CTLs) (Martinez-Lostao et al. 2015). On the other 
hand, cancer cells can avoid immune detection by secreting factors that paralyse 
infiltration of CTLs and NK cells, for example, TGF-β (Yang et al. 2010; Murakami et 
al. 2002), and immunosuppressive cytokines (Shields et al. 2010) and by recruiting a 
population of regulatory lymphocytes to the tumour site (Takeuchi & Nishikawa 2016; 
Murakami et al. 2002). Therefore, the presence of inflammatory infiltrate in the 
tumour can be both beneficial or not to the patient depending on the context in which 




Epithelial to mesenchymal transition 
Epithelial tissue 
The body of mammalian animals is composed of four basic tissues: connective, 
epithelial, muscular and nervous. Epithelial tissue is found on the inner and/or outer 
surface of many organs in the body, for example the epithelium covering the inner 
surface of the gastro-intestinal tract. Epithelial cells can be classified in three 
morphologies, observed in different organs: squamous, columnar and cuboidal 
(Eurell et al. 2006). The epithelium can also be classified by the number of layers of 
cells stacked on top of each other. If the only one layer is present it is called simple 
epithelium and with two or more layers the epithelium is termed stratified. In some 
rare cases a simple columnar epithelium can be mistook for stratified epithelium due 
a lack of alignment of the nuclei, and this type of epithelium is called pseudo-
stratified (Eurell et al. 2006). 
The cells in an epithelium tissue are closely attached to each other by specialised 
adhesion proteins (Eurell et al. 2006). One of the main proteins responsible for cell 
adhesion in epithelial tissues is E-cadherin. E-Cadherin is a member of the Cadherin 
superfamily encoded by the CDH1 gene; it is a calcium-dependent cell-to-cell 
adhesion glycoprotein composed of five extracellular cadherin repeats, a 
transmembrane region and a conserved cytoplasmic region (Geiger and Ayalon, 
1992). The extracellular domain links to other adhesion proteins in adjacent cells, 
holding the two cells together.  
Another important feature of epithelial cells is the presence of specialised regions in 
their cellular membrane. This creates a polarisation on the cellular membrane 
allowing specialisation to develop. For example, the apical surface commonly 
develops a structure known as primary cilia, that increases the contact surface of the 
epithelial barrier. The formation of the primary cilia depends on the defined existence 
of an apical surface, and it is only observed in the luminal side of the cells (Adams et 
al 2008). The lateral surfaces of the cells is the region that impermeably separates 
the apical and basal surface of the cellular membrane. It does that through adhesion 
proteins that strong binds to adhesion proteins in the neighbouring epithelial cells. 
Dysfunctions of this barrier can be involved in pathological diseases (Lee at all 
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2018). The lateral surface presents agglomerates of adhesion proteins in structures 
called tight junctions (TJ) and adherent junctions (AJ) (Turner et al 2009; Adams et 
al 2008). TJs are usually formed by transmembrane Claudins and Occludins. In the 
intracellular portion of the proteins they interact with ZO-1 that anchor the adhesion 
proteins to fibres of F-actin and Myosin in the cytoskeleton (Lee et al 2018). In AJ the 
adhesion is less tight than at the TJ and the cytoplasmic termini of the adhesion 
proteins at the AJ are linked to the actin belt of the cells by β and α catenin proteins 




























Figure 1.3 Cell polarity in human prostate epithelium. The epithelium is composed of a double layer of 
cells (Luminal and Basal). The luminal layer is composer of secretory luminal cells. The Basal layer is 
composed of 3 different types of cells: Stem cells (capable of self-renew and differentiate), transient Basal 
cells (an intermediate progenitor line) and committed basal cell which originates the luminal population of cells. 
The luminal cells present a complex network or adhesion proteins that confers polarity to the epithelium. In 
tight junctions (TJ) Claudin and Occludinforms an impermeable junction between the epithelial cells, in the 
intracellular side these proteins interact with Actin and Myosin fibres from the cytoskeleton of the cell. Adherent 
junctions (AJ) are form by interactions between E-cadherin from neighbouring cells. Β-catenin interacts with 
the intracellular domain of the E-cadherin and throught interactions with α-catenin anchors the E-cadherin to 
the cellular actin belt. The TJ and AJ separate the cellular epithelial cellular membrane in 3 specialised 
surfaces: Apical, Basal and Lateral. 
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The apical membrane of an epithelium varies with the type of surface it is covering 
(Eurell et al. 2006). In epithelium covering the lumen of hollow organs it is not 
uncommon to find epithelial cells specialised in secreting substances, for example, 
the parietal cells that secrete acids into the stomach (Schubert 2012). Of note, some 
entire epithelial tissues also can specialise in secreting substances necessary to the 
maintenance of bodily function. These specialised epithelia are called glands. 
Glands are folds of specialised epithelial tissue that synthesise substances like 
hormones, like the pituitary gland (Vankelecom and Gremeaux 2010), or digestive, 
like the pancreas (Seo et al 2018) for example. They are classified by the histological 
appearance of the epithelium using the same epithelium classification described 
above. Glands can also be classified by the destination of the substances it 
produces. Endocrine glands secrete substances that are released into the 
bloodstream and that will have systemic effects. Exocrine glands secret substances 
on an epithelial surface, having most of its effects locally, some glands present both 
endocrine and exocrine functions (Yatchenko et al 2019). 
Another important classification of glands sorts them by the glandular morphology. If 
the gland has only one draining duct and presents no branching it is termed a simple 
gland. If the gland presents several branching ducts that terminate into a main 
secretory duct it is termed a compound gland. The histologic appearance of the 
whole gland is also used to group glands. Glands that shows tubular formation in 
histological observations are termed tubular glands. The second type of histological 
observations of glands is the acinar morphology. This term refers to morphologies 
resembling lobed-berries. Both acinar and tubular glands can be simple or 
compound, and cases where one gland presents both morphologies are not 
uncommon, in this cases the gland is called tubuloascinar (Eurell et al. 2006). 
All epithelia in the body rest on a basal membrane. The basal membrane is 
composed of ECM, giving architectural support to the epithelium (Eurell et al. 2006). 
The basal membrane is the connection between the epithelium and the underlying 
tissue. Since the epithelium is not vascularised itself, the nutrients, oxygen, growth 
factors and other molecules necessary for the basic functions of epithelial cells are 
provided by diffusion through the ECM, however, more recent research shows an 
active role of the ECM on regulating stimulation on the surrounding tissue, being 
able to transport factors like BMP enabling long distance interaction (Sedlmeier and 
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Sleeman 2017). In fact, the ECM in the basal membrane regulates cell metabolism, 
survival and differentiation. Epithelial cells rest on their basal membrane and, except 
in extraordinary occasions, never leave. In culture, epithelial cells present a round, 
poorly-spread morphology, with intermediated states of spreading associated with 
cell movement. With proliferation and movement the cells make contact with other 
cells, recovering polarization and forming cellular sheets (Brown & Middleton 1985).
EMT 
The extraordinary occasions where epithelial cells leave their basal membrane is 
called EMT (Nieto et al. 2016). EMT is seen during the early development and 
embryogenesis. EMT plays an important role on the differentiation of the 
embryologic tissues that later on form all the organs in an animal’s body (Nieto 2001; 
Shook & Keller 2003). In fully developed bodies EMT plays an important role in 
wound healing and fibrotic processes (Kalluri & Neilson 2003). After the inflammation 
process of wound healing, endothelial cells undergo EMT to promote re- 
epithelialisation (Kalluri & Neilson 2003). The EMT program in this case allow cells to 
become motile and resolve the wound. However, when epithelial cells become 
cancerous, they can initiate the EMT program present in these cells resulting in 
malignancy (Brabletz et al. 2018). EMT is thought to play a role in several cellular 
events involved with cancer progression. It can be involved not only in invasion and 
metastasis but also in immune evasion and avoidance of apoptosis/senescence 
(Terry et al 2017; Robson et al 2006). Published data describes TGF-β as a potent 
promoter of EMT in cancer cells (Li, et al, 2014; Katsuno et al 2013). This effect has 
been described in several cancers, such as colorectal, pancreatic and prostate 
cancer, and it is associated with a malignant phenotype. 
During EMT, one of the most notable changes is the down-regulation of adhesion 
proteins associated with epithelial phenotype like E-Cadherin, ZO-1, Lamin-1 
(among others). A cadherin switch is also commonly observed, during EMT levels of 
E-cadherin decrease and the levels of N-cadherin increases. N-cadherin can interact 
with surface proteins of the endothelium and aid cell extravasation (Zeisberg and 
Neilson 2009). EMT put cells through a series of morphological and biochemical 
changes culminating with the expression of end stage EMT markers (like Vimentin, 
smooth muscle actin α (α-SMA), N-cadherin, fibronectin, among others) and the 
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detachment of the epithelial cells from the basal membrane (Kalluri & Weinberg 
2009). However, E-cadherin loss seems to be heterogeneous; some tumours 
present separate areas of positive or negative E-cadherin expressing cells (Yang & 
Weinberg 2008). The detection of E-cadherin in distant metastases also indicates 
that the activation of the EMT program is, in most of the cases, partial or reversible 
(Bukholm et al. 2000). 
The concept of Epithelial to mesenchymal plasticity (EMP) offers a better explanation 
of the heterogeneity observed in cancer related EMT. Researchers observed that the 
EMT/EMP changes occurs in a spectrum due to the observation that cancer cells 
phenotype can be put somewhere between an epithelial and a mesenchymal state. 
On that context, the cells can change towards either way on a complete or partial 
alteration depending on tissue of origin, genetic and epigenetic evolutions and 
environment inputs, that characteristic seems to be advantageous to cancer cells 
from an adaptable point of view (Tam and Weinberg 2013; Lamouille et al 2014; 
Nieto et al 2016). 
Apart from the loss of epithelial markers and the gain of mesenchymal markers, cells 
undergoing EMT present specific characteristics like spindle-shape morphology, 
increased cell migration, ability of cells to invade other tissues, and the 
reorganization of the ECM (Kalluri & Weinberg 2009). In these steps, degradation of 
the ECM from the basal membrane allows the cancer cells to invade the surrounding 
tissue (Kalluri & Weinberg 2009). The cytoskeleton rearrangement redistributes the 
acting stress fibres and confers different morphology to the cell, making the cells 
more motile. The expression of proteins like vimentin, confers resistance to tensile 
stress, facilitating the movement through tight spaced like between endothelial cells 
(Mendez et al. 2010). And finally, the cell expresses different adhesion proteins that 
are displayed on the cell surface. Commonly E-cadherin is substituted by N-cadherin 
(this is called a Cadherin switch) (Li, et al, 2014). The N-cadherin allows the cancer 
cell to interact with endothelial cell adhesion proteins enabling the cancer cell to 
move through the endothelium and in and out of the bloodstream (Li et al, 2001). 
Cells that undergo EMT in the primary tumour are considered to be the cells that 
enter the later stages of invasion and metastasis (Fidler & Poste 2008). However, 
histologic observations of metastases show resemblance to the original tumour. This 
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indicates that the new environment where the cancer cell arrives does not provide 
the cells with the factors that initiated the EMT or that maintain the mesenchymal 
state (Fidler & Poste 2008). Therefore, the cell starts a process of reversion of EMT 
known as mesenchymal to epithelial transition (MET). Many studies indicate that 
activation of EMT and MET programmes in the context of cancer is rarely complete, 
this confers plasticity and adaptability to the cancer cell (Brabletz et al. 2018). Table 
1.1 shows a list of different criteria used to identify EMT (Zeisberg and Neilson 
2009). 
 
EMT transcription factors 
EMT can be induced and regulated by a number of signalling pathways, depending 
on the contextual genetic, epigenetic and environmental inputs. TGF-β is a classic 
inducer of EMT, however, a number of other signals can activate the EMT program. 
Tyrosine kinase receptor pathway can initiate EMT through the PI3K-AKT and ERK-
MAPK signalling (Lotz-Jenne et al 2016). Wnt signalling activation of EMT seems to 
be through the inhibition of β-catenin degradation which upregulates Slug, 
downregulating E-cadherin and contributing to the accumulation and nucleus 
translocation of β-catenin (as discussed in the next paragraph) (Gasior et al 2017). 
Several other possibilities of EMT activations are reported on Notch-signalling, 
Hedgehog signalling, and a number of inflammatory pathways (Lamouille et al 2014). 
Table 1.1. Major criteria for EMT in vitro – Modified from Zeisberg and 
Neilson (2009) 
Cadherin switch. 
Increase expression of HSP47, Collagen I (α1), Collagen 2 (α2), or Vimentin. 
New expression of FSP1 and possibly DDR2. 
Nuclear relocation of CBF-A or β-catenin/LEF or new expression of one of the 
following transcription factors: Snail, Slug, or Twist. 
Absence of epithelial markers; loss of cytokeratin or ZO-1. 
Spindle shape morphology with redistribution of stress fibres and loss of polarity. 
Resistance to apoptotic stimuli. 
Increased migratory capacity. 
Stable phenotype upon removal of inducing stimuli. 
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The expression modifications caused by the activation of these pathways are carried 
by transcription factors that are classically correlated to EMT, like Snail, Slug, Twist 
and β-catenin. 
The intracellular domain of the E-cadherin protein presents phosphorylated regions 
where β-catenin binds. β-catenin bound to the intracellular portion of the E-Cadherin 
links the cytoskeleton to the adhesion junction (Stockinger et al. 2001). However, β-
catenin also plays an important role in regulating the expression of several genes 
related to the cell proliferation and evading apoptosis, such as Cyclin D1 (CCND1) 
and Transcription Factor 7 (TCF/LEF) (Marrs and Nelson, 1996). The upregulation of 
Dishevelled (Dvl) by the Wnt signaling inhibits the degradation of β-catenin, which 
accumulates in the cytoplasm and eventually gets translocated to the nucleus. β-
catenin helps the expression of EMT-TF Slug, which supress E-cadherin expression, 
in absence of E-cadherin, β-catenin is not sequestered at the cellular membrane, 
exacerbating the accumulation of β-catenin (Stockinger et al. 2001). 
The β-catenin expression effects on the cell can also be activated by silencing of the 
E-cadherin gene CDH1. In prostate cancer, the hyper-methylation of the CDH1 gene 
was reported to occur in 70% of the high grade tumours (reviewed by Chin et al 
2011). 
Several transcription factors are known to regulate EMT, they are known as EMT-
TFs. The transcription factors Snail, Slug, ZEB1 and TWIST1 can all reduce the 
expression of E-cadherin leading to EMT (Zeisberg and Neilson, 2009). Most of 
invasive cancer cell lines express one or more of these transcription factors (Yang & 
Weinberg 2008). Slug was shown to repress E-cadherin expression in breast cancer 
(Hajra et al. 2002) and this EMT-TF is related to the EMT program in several 
different cancers (Medici et al. 2008; Villarejo et al. 2014; Heldin et al. 2012a; 
Brabletz et al. 2018). 
ZEB1 is implicated in the initiation of EMT programs in prostate cancer (Graham et 
al. 2008), lung cancer (Takeyama et al. 2010) and pancreatic cancer (Krebs et al. 
2017). The use of tumour-cell-specific TWIST1 knockout mice in a oncogene-
induced spontaneous breast tumour model showed that TWIST1 causes EMT and 
tumour-cell-specific TWIST1 knockout reduced appearance of lung metastasis (Xu et 
al. 2017). Cooperation between TWIST1 and the oncogenic transcription factors c-
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Myc can inhibit the intrinsic cellular defence mechanism that activates cell death in 
case of cellular crises (Valsesia-Wittmann et al. 2004) indicating that EMT program 
helps with death evasion in this model. Myc is a gene family that encodes 
transcription factors that are commonly dysregulated in human cancers, and Myc 
over-expression  drives increased in cellular proliferation facilitating several aspects 
of tumour initiation and progression (Venkateswaran & Conacci-Sorrell 2017).  
Snail, is part of the zinc-finger transcriptional repressor complex that binds to two E-
boxes located in the E-cadherin promoter, down-regulating E-cadherin expression 
(Thiery 2002). Snail is reported to participate in EMT programs in several cancers 
(Wang et al. 2013). For example, Snail was reported to be necessary to lymph node 
metastasis of breast cancer cells in in vivo models using BALB/c 
immunocompromised mice (Olmeda et al. 2007). Notch is a transmembrane protein 
family that receives signals from close cell to cell contact or from ECM components 
(juxtracrine signalling). Its activation triggers gene regulation through Notch activated 
transcription factors (Pursglove & Mackay 2005). Notch is reported to activate Snail 
expression in ovarian cancer cells mediating EMT and invasion (Sahlgren et al. 
2008). 
It has been reported that the induction of EMT by overexpression of EMT-TF or 
treatment with TGF-β in immortalized human mammary epithelial cells (HMLE) 
stimulated the expression of cell surface stem cell markers (Sendurai et al 2008). In 
this study the cells overexpressing Snail or Twist, presented EMT markers like 
downregulation of e-cadherin gene and upregulation of vimentin genes. 
Concomitantly, nearly 100% of these cells presented stem cell markers 
(CD44high/CD24low), fact also observed with TGF-β treated cells (Sendurai et al 
2008). Interestingly, the same group demonstrated that the downregulation of e-
cadherin gene resulted in EMT in the same cell line (Tamer et al 2008). They used 
two different approaches to achieve e-cadherin downregulation, the expression of a 
shRNA targeting e-cadherin or the expression of truncated e-cadherin protein lacking 
its ectodomain, which results in a protein that cannot perform the normal adhesion 
observed in wield-type protein. The results showed that the downregulation of e-
cadherin results in EMT, demonstrated by the loss of cellular adhesion up-regulation 
of vimentin and n-cadherin. The expression of the truncated protein prevented 
cellular adhesion, but did not induce the expression of mesenchymal markers. The 
40 
 
authors also showed that the translocation of β-catenin to the nucleus was important 
to the induction of the mesenchymal phenotype observed in the e-cadherin 
downregulated cells, explaining why the expression of the truncated e-cadherin was 
not able to induce the appearance of mesenchymal markers (Tamer et al 2008). 
Additionally, several EMT-TF has been shown to be implicated in other vital 
processes for cancer progress. They can promote and maintain cancer cell 
stemness and tumorgenicity, and they can help the cell to escape from senescence 
and regulate both pro-inflammatory and immunosuppressive cytokines (Puisieux et 
al. 2014; Nieto et al. 2016), giving even more importance to the understanding of 



















Figure 1.4. Epithelial to mesenchymal transition. A diagram of EMT and the associated markers with each stage. The transitional states presents a mixture of markers 
from both states. Epithelial cells express a number of proteins involves in epithelial cells adhesion. During EMT the cells lose their polarity and pass through cytoskeleton 
rearrangement with the appearance of actin stress fibres. Free β- catenin can translocate to the nucleus and exacerbate EMT signalling, however several transcription 
factors are capable of activating EMT program. The dissolution of the Basal membrane is important event in cancer related EMT because the growing tumour can invade 
the surrounding tissue. 
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Prostate cancer EMT 
Cancer cells use the intrinsic EMT mechanisms within the human genome to 
become invasive acquiring the ability form metastasis. The life quality of patients with 
prostate cancer drastically declines during metastasis, with nearly all prostate cancer 
caused death being associated with metastasis (Odero-Marah et al 2018). Different 
cell signalling programs are associated with EMT in prostate cancer, among them 
androgen receptor (AR) signalling, oestrogen signalling, TGF-β, IGF and EGF 
commonly flagged as activators (as reviewed by Montanari et al 2017). 
The reports of the role of androgens in the prostate cancer related EMT are 
conflicting. Treatment with Dihydrotestosterone (DHT) caused cadherin switch in 
PC3 cells (Zhu and Kyprianou 2010). The castration of nude mice bearing a classic 
human prostate xenograft tumour (LuCaP35) caused tumour regression and 
expression profiles changes in the tumour tissue. Cadherin switch was observed 
associated with Vimentin, ZEB and TWIST upregulation (Sun et al 2012). The 
conflicting data is still to be clarified, but the clinical outcome of patients that undergo 
hormone deprivation treatment develops into catastrophic cancer progression, 
suggesting that the maintenance of androgen signalling would be necessary for EMT 
regulation. 
Recent insights showed EMT in PC3 cells induced by osteoblast differentiation 
medium (ODM). When treated with ODM PC3 cells lost expression of E-cadherin 
and β-catenin, while the expression of N-cadherin, Snail and Slug were upregulated. 
The authors also demonstrated that ODM treatment in PC3 promotes cell migration 
and colony formation through the activation of the NF-B pathway. These effects 
were confirmed by tumour formation and metastasis assays in nude mice (Tong et al 
2018). 
Oestrogen receptor (ER) signalling is reported to act through H1F1α to activate the 
VEGF pathway that can influence the expression of Snail in prostate cancer. EGF is 
reported to act through multiple signalling pathways that regulates EMT, for example 
the activation of Ros and ultimately expression of EMT-TF Twist. EGF can also up-
regulate Snail which directly down regulates E-caderin (reviwed by Montanari et al 
2017) A summary of the signalling pathways that can regulate EMT in prostate 
cancer is in Figure 1.5. 
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TGF-β is reported to play a major role on prostate cancer related EMT, plus TGF-β 
and AR signalling share common gene targets making this crosstalk an important 
element of prostate cancer EMT (reviewed by Zhu and Kyprianou 2008). It was 
demonstrated that the AR expression influences the prostate cancer cell response to 
TGF-β induced apoptosis via, at least partially, AR-Smad4 interaction (Zhu et al 
2008). 
The TGF-β regulation of EMT in prostate cancer seems to be important in both early 
and late stated of cancer. TGF-β signals in prostate cancer can be grouped in two 
categories: smad-dependent pathway and smad-independent ones. Some authors 
associate Smad-independent pathways with the pro-tumour progression and EMT 
effects of TGF-β (as reviewed by Montanari et al 2017). However, it is reported that 
TGF-β induced EMT involves MAPK, Smad and AP-1 pathways (Davies et al 2005). 
Details about the TGF-β signalling pathway is given on the next sections. 
Inputs from stroma cells seem to be one important component of the TGF-β 
mediated activation of the EMT program in prostate cancer (Hu et al 2014). It was 
reported that heterogeneity in the expression of TGFβRII in prostatic stroma cells 
resulted in elevated expression and secretion of growth factors including TGF-β1, 
driving formation of prostatic intraepithelial neoplasia (PIN) and carcinogenesis 
(reviewed by Barron and Rowley 2012). This shows the context importance for the 
TGF-β signalling in prostate cancer EMT. TGF-β signalling can be regulated at 
several stages by different co-regulators and cross-talking signals. Another example 
is the demonstration that genetic deletion of Smad4 in PTEN-null prostate cancer 
mouse model developed in 100% invasive, metastatic and lethal disease (Ding et al 
2011). Recently, it was shown in pancreatic ductal adenocarcinoma (PDA) that the 





The prostate gland 
Morphology and physiology 
The human prostate gland is an organ formed by glandular and non-glandular 
components enclosed by a capsule formed of fibromuscular tissue (prostate 
capsule). The prostate capsule is composed of a bundle of smooth muscle cells that 
merges with the smooth muscle cells in the bladder neck. There are five 
distinguishable zones observed in the prostate gland: peripheral zone, central zone, 
transition zone, periurethral gland region, and anterior fibro-muscular zone. The 
peripheral zone forms about 70% of the prostate gland mass, with vast areas of 
glandular ducts that exit from the posterolateral recesses of the urethra wall. This 
region is the most susceptible to inflammation and it is the region where prostate 
cancer most commonly arises. The central zone corresponds about 25% of the 
glandular mass, this portion arises from the seminal colliculus region of the urethra 
with its ducts branching towards the base of the prostate along the course of the 
ejaculatory duct, and almost the whole base of the prostate is formed by the tissue 
from this zone. The transient zone comprises approximately 5-10% of the prostate 
glandular tissue, being composed of two small lobes with each duct leaving from a 
single point in the proximal urethra epithelium, both departing from the lower border 
of the prostatic sphincter and spreading around its distal border, curving around 
sharply towards the bladder neck. The periurethral gland region is the approximate 
size of the transient zone but it is formed of non-functional glandular tissue. The 
anterior fibro-muscular zone extends from the bladder neck to the prostate apex. The 
lateral sides of this zone blend with the prostatic capsule. The glandular tissue of 
prostate gland presents a compounded tubuloascinar morphology. As explained 
before, tubuloascinar glands are the ones that presents both tubular and acinar 
morphology in histological sections. It presents an exocrine secretion of a fluid called 
prostate fluid. In humans the prostate fluid composes 30% of the semen volume, 
being responsible for maintaining the alkaline pH in the environment and 
counteracting the acid pH of the female vaginal tract. This enhances the sperm cell 
performance and aids fertilization (McNeal 1988) (Figure 1.5). The prostatic fluid 
presents high contents of polyamines, which presents functions related to cellular 
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proliferation and secretory activities, however no clarifications are needed for the 
reasons for its secretion on the seminal fluid (Schipper et al 2003; Jasuja et al 2014). 
Some biochemical studies of seminal fluid revealed that the polyamines can serve as 
amine donor substrates for transglutaminases (Romijn 1990). Additionally, its 
expression had been associated with higher grades of prostate tumours (reviewed 












Histologically, the prostate epithelium is a bilayer of basal and luminal cells inserted 
into the fibromuscular stroma. The bilayer is composed of luminal (60%) and basal 
(40%) cells. There are four types of cells in the prostate epithelium, the basal portion 
is composed of stem cells, transient amplifying (TA) cells and committed basal (CB). 
The luminal portion is composed of luminal cells (reviewed by Packer and Maitland 


















Prostate adenocarcinomas are most commonly derived from glandular epithelium 
neoplasia (which are tumour neo formations in the gland epithelium) (Dermer 1978). 
In the early stages of prostate carcinomas the most common local invasion is to the 
stroma tissue, and local spread into the surrounding adipose tissue, bladder neck 
and seminal vesicle, is also common, but more serious complications happen when 
the invasion develops into motile cells reaching the bloodstream and forming 
metastases (McNeal 1988). The High-grade prostatic intraepithelial neoplasia (PIN) 
is accepted as a precursor of the invasive prostate adenocarcinoma. Because PIN 
cells resemble invasive adenocarcinoma cell morphology, there are also compelling 
data from zonal co-localisation between PIN and adenocarcinoma. Furthermore both 
diseases share important molecular changes like ETS gene rearrangements and 
loss of PTEN (reviewed by De Marzo et al 2016). The most common metastasis 
observed in prostate adenocarcinoma are in the lymph node of the pelvis and bone 
marrow tissues  
The origin of the prostate cancer is currently a field for debate. The heterogeneity of 
the organ hampers the search of origin for the cancer, additionally, there is no 
epidemiologic marker that supports the high frequency of the prostate malignancy 
(reviewed by Packer and Maitland 2016). The controversy starts on the origin of the 
heterogeneity of the tumour itself. There are two theories to explain this observation, 
firstly, the Stochastic model where a definitive driver mutation activating an 
Figure 1.6. Diagrammatic representation of a normal prostatic acinus. The epithelial bilayer of basal and 
luminal cells, surrounded by fibromuscular stroma. The relative content of different epithelial cells in the 
normal prostate are summarised graphically; luminal (60%), basal (40%) with the stem cells constituting ~ 
1% of total epithelia. Transient Amplifying (TA) cells and Committed Basal (CB) (Packer and Maitland 2016). 
47 
 
oncogene or deactivating a tumour suppressor gene happens, and the subsequent 
cell division generates an identical cell with equal propagating potential. In this model 
the heterogeneity is created by subsequent mutations on the clonal expansion. The 
second is the cancer stem cell (CSC) model, where only a small subpopulation of 
stem cells pool (capable of self-renew and differentiation) in the tumour are can 
initiate tumour formation. In this model the genetic variation is introduced by cellular 
differentiation. As it is commonly observed in prostate cancers, several cancer driver 
alterations in the genome are heterozygous. When stem cells differentiate the 
mutation is carried in one branch of the cell expansion process (reviewed by Packer 
and Maitland 2016).  
Of course, the two theories are not mutually exclusive. Subsequent mutations could 
happen in a copy of the original cell and kept in a neutral evolutional fashion, 
enhancing furthermore the heterogeneity (reviewed by Packer and Maitland 2016). 
The genetic variability in the CSC pool is likely to generate progenitor cells that could 
be dominant in later stages upon changes in the tumour microenvironment brought 
by crisis inducing events like chemotherapy (Anderson et al 2011). 
The origin of the progenitor CSC is also debated, if the original cell comes from a 
luminal or a basal cell still not 100% clear. It was identified that progenitor cells that 
present with a luminal phenotype and pluripotent markers in mice models of prostate 
cancer (Wang et al 2010; Chua et al 2014). However, the key histologic differences 
between the mice and human prostate , such as the absence of a double epithelial 
layer in mice could mean that the prostate cancer is just different between the two 
species (reviewed by Archer et al 2017). 
On the other hand, human basal stem cells isolated from human prostate cancer 
show capacity of self-renew and differentiate into AR+ luminal cells (Collins et al 
2005). It was also reported that human basal cells and not luminal were able to 
induce tumorigenesis with luminal phenotype in NOD/SCID/IL2Rγnull mice induced by 
the expression of AKT, ERG and AR (Goldstein et al 2010). In contrast, a luminal 
CSC was found in the BM18 xenograft model. This small subpopulation of the 
tumour was able to establish a tumour upon introduction of androgen (Germann et al 
2012). However, Archer et al argued that the BM18 xenograft model was not serially 
transplanted into mice, and that the model have been passed many times since its 
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establishment in 2005, which likely inserted evolutionary modifications to the cells 
(reviewed by Archer et al 2017). 
Several mutation drivers could be responsible for the appearance of prostate cancer. 
As an isolated microenvironment is observed in these tumours, the creation of an 
independent niche or the ability to create an independent niche is potentially a key 
cancer driver (reviewed by Archer et al 2017). The presence of niches is also 
favourable to the accumulation of driver mutations by fixing passenger mutations. 
When mutations happen they can maintained by symmetric division of the stem 
cells, in this process changes in the niche creates successions that select 
advantageous mutations. The niche successions is a cyclic process that takes 
approximately 8.2 years to occur in the stem cells of the colon epithelial crypts, in 
prostate epithelium this process presumable takes much longer (reviewed by Archer 
et al 2017). The prostate stem cell that will originate the cancer probably is the able 
to maintain its stemness by keeping pathways associated with stem phenotype 
activated or hyper activated, that way mutations that would be deleterious to 
differentiated cells could be tolerated, that way these cells accumulate mutations 
through an individual’s life time until tumour initiating change comes along. 
Epigenetic regulations of the gene expression represent a way for the cancer cells to 
beneficiate from the adaptability of the more de-differentiated states while not relying 
on more inflexible changes such as genetic mutations or deletions. In prostate 
cancer DNA hyper methylation was able to predict gene downregulation (Pellacani at 
al 2014). 
An important epigenetic phenomenon observed in cancer is the random monoallelic 
expression (RME). This phenomenon can contribute to the accumulations of genetic 
alteration, as, for example, activation of an oncogene in early in normal stem cells 
could be initially silenced in that fashion and later on be reactivated (reviewed by 
Archer et al 2017). In REM an allele present in a daughter cell had a stochastic 
activation when that cell is originated from a stem cell. The expression of a gene 
regulated by REM could be bi-allelic, maternally mono-allelic, paternally mono-allelic 
or the gene could not be expressed at all. The expression pattern observed in the 
daughter cell is phenotypically stable in non-stem cells generated by asymmetric 
division (Gendrel et a 2014).The REM is controlled by an asymmetric chromatin 
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signature, where the histones of the activated gene bodies are tri-methylated at 
H3K36 while the ones in the silenced allele are tri-methylated at H3K27 (Nag et al 
2013). 
Inflammatory responses present itself as potential driver for prostate cancer 
generation. In the event of infections, for example, the invasion of lymphocytes 
provides an external supply of IL-6, the presence of this interleukin in the niche 
promotes an adaptive changes into the stem cell pool creating an inflammatory 
environment that will confer advantage to stem cells that produce IL-6 and enter the 
an autocrine positive feedback loop of inflammatory signal (reviewed by Archer et al 
2017). It is noteworthy that upon AR downregulation, IL-6 expression is upregulated 
and its consequent activation of STAT3 pathway acts as a bypass to androgen 
dependency during androgen deprivation therapy in prostate cancer (Schroeder et al 
2014). However, the world health organisation consider that there is no concrete 
correlation between prostate cancer and any infectious disease (WHO 2014). 
Molecularly speaking the four most common alterations observed in prostate cancer 
are: amplification of the androgen receptor (AR), fusion of TMPRSS2 and ETS 
genes, disruption of the TP53 gene and dysregulation of PTEN. The carcinogenic 
implications of the gene TP53 were discussed previously in this thesis. Studies 
showed that dysregulation of PTEN gene happen in approximately 41% of prostate 
cancer patients and that this dysregulation can occur due to alterations on the gene 
copy number, structural rearrangements and/or mutations of the gene. The effects of 
PTEN in as a tumour suppressor gene is due to its effects on the inositol ring of the 
PI3K, inhibiting PI3K proliferative effects (reviewed by wise et al 2017). Genomic 
aberrations are another commonly detect event in prostate cancer. These 
aberrations include numerical chromosomal aberrations (aneuploidy) and structural 
chromosome changes, aneuploidy is a reflection of mitotic defects while structural 
changes requires strand breaks that are left unrepaired or are repaired in a wrong 
fashion (Pecqueux et al 2018). It was reported that genomic instability plays a crucial 
role in the progression of prostate cancer (reviewed by Tapia-Laliena et al 2014). 
Single catastrophic chromosomal events could result in extensive DNA damage, 
however evidence shows that theses catastrophic events actually happens in 
prostate cancer causing rapid DNA evolution (Zhang et al 2013), in contrast to the 
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findings that shows that the damage accumulates over a long period of time 
(reviewed by Archer et al 2017). 
The common phenomenons observed in prostate cancer that lead to genomic 
aberrations are: chromothripsis and chromoplexy. Chromothripsis are alterations that 
happens in clusters in a single chromosome, the mechanisms on how it happens are 
unclear but it is suggested that mutations on TP53 or DNA repair machinery are 
involved. In this processes the shattering of chromosomes cause random re-
attachment by the DNA repair system of the cell (reviewed by Tapia-Laliena et al 
2014). The locus 10q23 where the gene PTEN is inserted, is frequently affected by 
this process in prostate cancer (Feilotter et al. 1998). 
Chromoplexy is the formation of “chain” patterns in chromosomal rearrangements 
created by the repair of a break where the some length of DNA is lost (Berger et al 
2011), the genes in the lost strand of DNA simply disappear, these lost genes are 
called “deletions bridges” (Baca et al 2013). In prostate cancer chromoplexy is 
observed on the rearrangements of the gene ERG, where DNA repair induced gene 
fusion (reviewed by Tapia-Laliena et al 2014). TMPRSS2:ERG fusions are the most 
common genomic alteration in prostate and it results in overexpression of the 
overexpression of ERG, oncogene that encodes a transcription factor which presents 
key roles on the regulation of cell proliferation, differentiation, angiogenesis, 
inflammation and apoptosis (reviewed by Wang et al 2017).  
Molecular risk of prostate cancer is increased by androgen, androgen receptor and 
growth factor activity (WHO 2014). The androgen receptor (AR) is a transcription 
factor activated by several ligands. AR ligands are steroids and peptide hormones. 
This transcription factor is essential for normal prostate epithelium cellular 
proliferation, and it is also involved in apoptosis, cell migration and cell 
differentiation. AR is commonly expressed in prostate cancer cells and metastases, 
providing an uncontrolled cellular proliferation signal (reviewed by Lamb et al. 2014; 
Culig & Santer 2014). For that reason, androgen deprivation therapy (ADT) is a 
common therapeutic approach to treat prostate cancer at all stages (Lu-Yao et al. 
2009; Picard et al. 2012). ADT is a type of therapy where drugs that inhibit the 
secretion of androgens are used and it is commonly known as chemical castration. 
However, this treatment presents side effects, because hormonal deprivation can 
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interfere with the body metabolism and with calcium homeostasis in the bone. ADT is 
associated with increased incidence of diabetes, clinical fractures, and 
cardiovascular disease (Saylor & Smith 2010). Furthermore, ADT causes long term 
selection of prostate tumours leading to evolution into ADT-resistant tumours 
(castration resistant prostate adenocarcinoma) (Liu et al. 2014). There are several 
mechanisms through which prostate cancers can evolve into castration resistance, 
one example involves expression of a constitutively activated AR lacking the ligand 
binding domain (Dehm et al. 2008). Recent reports explore the allosteric alterations 
on the AR. More than 20 variations of the protein were identified, lacking different 
portions of the ligand-binding domain. Allosteric variations of the receptor were 
associated with ADT therapy, and specifically the variation AR-V7, it was 
demonstrated that the presence of this variation in patients predicted resistance to 
treatments with antiandrogen drugs (reviewed by Takuma et al. 2017). This can limit 
the application of ADT, however, alternative therapeutic approaches suggest that 
patients could benefit from an intermittent androgen deprivation (IDA) (Brungs et al. 
2014).  
Another treatment option for localised prostate cancer is radical prostatectomy, 
which is reported to present an improved survival rate alongside external beam 
radiotherapy (Hoffman et al. 2013). For patients initially diagnosed with advance 
prostate adenocarcinomas, ADT still might be a treatment option, however, for 
patients that developed castration resistant tumours after ADT treatment, 
chemotherapy is the next line treatment available (Ahmed et al. 2016). As TGF-β is 
an important driver of prostate cancer progression, new therapeutic strategies have 
investigated the efficacy of TGF-β blockage using antibodies. However, further 
contextual knowledge is needed to identify patients that would benefit from this 
treatment (de Gramont et al. 2017). Disruptions of the expression of the CDH1 gene 
(encoding E-cadherin) represent an increased risk of prostate cancer (WHO 2014). 
There is no concrete correlation between prostate cancer and any infectious disease 
(WHO 2014). However, inflammation in the prostate is an important event in prostate 
carcinogenesis (WHO 2014; McNeal 1988). 
The clinical diagnosis of prostate neoplasia is commonly made by the measurement 
of the blood levels of prostate‐specific antigen (PSA). PSA is a glycoprotein 
synthetized in the prostate gland and its primary function is to enzymatically degrade 
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the cervical mucus to aid in spermatic mobility. Despite being widely used to 
diagnose prostate cancer, PSA is not a method with high specificity, blood levels of 
PSA shows high sensitivity (70%) as the antigen is organ specific, however, the 
predictive positive values is not very high (37%) (Bunting 2012) as the serum 
elevation of this marker can be triggered by other prostatic problems like: benign 
prostatic hypertrophy (BPH), recent manipulations of the prostate due to massage or 
biopsy, prostatitis (inflammation in the prostate), or age (Pezaro et al. 2014). 
However, PSA screening is still an important predictive tool. A recent population-
based cohort study evaluated the impact of PSA screening for prostate cancer 
surveillance in men. The evaluation showed that PSA screening at age 50–54 
significantly reduces the prostate cancer-specific mortality, concluding that the 
screening of younger man increases the chances of diagnosis before the disease 
becomes incurable (Carlsson et al 2017). These authors recommend an initial 
assessment of PSA levels for men at the middle or late 40’s, if they presented PSA 
concentration <1.0 µg/L they would be invited for reassessment in their 50s and 60s 
(Vickers et al 2013). 
Benign prostate hyperplasia (BPH) is the non-cancerous enlargement of the prostate 
gland. BPH is usually occurs in the transitional zone of the prostate gland and it is 
characterised by an increase in the prostate volume that results in compression of 
the urethra and partial bladder obstruction (Aaron et al. 2016). A study that analysed 
the database of the Irish Tertiary Referral Centre showed that 35% of men with 
prostate cancer had normal PSA levels (Walsh et al. 2014). The same study 
highlighted that digital rectal examination (DRE) is an important method of diagnosis 
that can diagnose early stage prostate cancer independently of PSA. DRE showed a 
sensitivity of 81% and a positive predictive value of 42%, making it the current best 
form of early diagnose for prostate cancer (Walsh et al. 2014). 
The severity stage of prostate adenocarcinomas are measured with histopathological 
examinations of needle biopsies or tissues from radical prostatectomy (surgical 
removal of the prostate gland) (WHO 2014). The severity and the features 
associated with malignancy are describes by a grading score proposed by Gleason. 
The Gleason score was created in 1966 by the pathologist Donald F. Gleason. This 
classifies prostate neoplasia into five distinct grades with specific characteristics. The 
description to each grade is based in a systematic study conducted with 270 
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samples, searched for patterns to group samples by severity (Gleason 1966). To 
grade the tumour the pathologist grades, based on Gleason’s descriptions, the two 
more common patterns observed in the histological section (grading varying from 2 
to 10). The final tumour score is a sum of the two grades given (Gleason 1966).  
In 1977, Gleason updated some information on this grading system. He proposed 
that the analysis should be conducted under low microscope magnification such that 
the whole tissue is considered in the analyses, and so that small areas of fused 
glands or disorganised cells would not bias the pathologist analysis (Epstein et al. 
2005). In 2005, aiming to standardise controversial areas of the Gleason’s score by 
pathologist around the world, a Consensus Conference was hosted by the 
International Society of Urological Pathology (ISUP) (Epstein et al. 2005). The 
consensus was that the Gleason pattern of 1+1 =2 grade should only be diagnosed, 
regardless of the type of specimen, in extremely special situations (Epstein et al. 
2005). Another modification was the decision not to assign the so called “low grade 
Gleason’s” (3 and 4) on a needle biopsy (Epstein et al. 2005). The reasons for that 
decision were based on the fact that this presented poor reproducibility even among 
experts, a low correlation between two cuts from the same tumours, one coming of a 
needle biopsy and the other coming from a radical proctectomy, was observed, and 
the misdiagnosis of a low-grade tumour could mislead clinicians basing their practice 
on the pathological examinations. The grade 4 is also controversial on a needle 
biopsy because one cannot see the edge of the tumour and therefore cannot 
guarantee that the whole lesion is completely circumscribed (Epstein et al. 2005). 
The description of each Gleason’s score band is described in detail in the 
methodology section.  
In 2014 further modifications were made to the Gleason scoring system due to 
changes in prostate cancer practices, lack of consensus in some issues in 2005, 
new research information being published and the realization that some gland issues 
were not covered in 2005. Among the discussions made in 2014 the grading of 
cribriform glands was one of the focus. Is was postulated that cribriform glands 
should be assigned Gleason pattern 4. Regarding the grading of glomeruloid glands, 
these glands should also be assigned as a Gleason pattern 4, regardless of 
morphology. Regarding mucinous glands, the grading of these glands should be 
based on its underlying growth pattern rather than grading them all as a pattern. 
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Regarding the grading of intraductal carcinoma of the prostate (IDC-P), in the 
absence of an invasive carcinoma, IDC-P should not be assigned a Gleason grade. 
The consensus conference also proposed a new grouping system to guide prostate 
cancer prognosis prediction and treatment (Epstein et al. 2016). Figure 1.7 shows a 











Age is highly associated with the risk of prostate cancer. The chance of diagnosis for 
men older than 65 years old is 40 times higher than for men younger than 65 (WHO 
2014). Additionally, only approximately 1% of clinically diagnosed prostate cancers 
are found in men younger than 50 years (WHO 2014). The risk of prostate cancer is 
also increased with family history (Johns & Houlston 2003). About 25% of patients 
clinically diagnosed with prostate cancer have family history of this disease (Walsh & 
Partin 1997). The risk factor indicates that a man with a prostate cancer family 
history has a risk 3 times higher to have prostate cancer then a man with no family 
history (WHO 2014). This indicates that a genetic component could increase the risk 
for the population of men. In fact, when a close relative is diagnosed in ages younger 
than 40 years old, the prostate cancer risk increases up to 11 times greater than a 
man with no family risk (WHO 2014). In agreement, a study with twins indicated a 
42% hereditary risk of prostate cancer (Lichtenstein et al. 2000). 
Figure 1.7 Prostatic adenocarcinoma (histologic patterns). Original (left) and 2015 Modified ISUP Gleason 
schematic diagrams (Epstein et al. 2016). 
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The genetic component of prostate cancer risk is also observed in ethnicity 
correlations. In the United States, African Americans are 1.6 times more likely to 
have prostate cancer than Caucasians (WHO 2014), This increased risk is a 
reflexion of a higher incidence of polymorphism in the loci 8q24 and 17q21 
(Henderson et al. 2012). However, increased risk rates were also observed in 
migrants who moved from low risk regions to high risk regions, suggesting an 
environmental risk (WHO 2014). The diets typical of high-risk countries seem to play 
a role in the increased environmental risk, mainly diets rich in processed red meat, 
dairy products and saturated fat presents an increase in the risk of prostate cancer, 
while tomatoes, marine food, soy and cruciferous vegetables possibly decrease the 




Transforming growth factor β 
Virtually all human cell types are responsive to Transforming Growth Factor beta 
(TGFβ) (Massagué 2008). There are 3 types of TGF-β protein, TGF-β1, TGF-β2 and 
TGF-β3, and they all signal through the same signal receptor system. The TGF-β 
proteins are growth factors that control cell migration, differentiation and proliferation 
(Reynisdóttir et al. 1995; Kingsley, 1994; reviewed by David and Massagué 2018), 
and in addition, they play an important role in several diseases. The TGF-β 
superfamily signal through the transmembrane serine-threonine kinase class of 
receptors (Wrana 2000; reviewed by David and Massagué 2018). Physiologically, 
TGF-β mainly acts through the Smad pathway, activating several regulatory genes, 
which normally up-regulate Cyclin-Dependent Kinase Inhibitors (CDKIs) preventing 
progression of the cell cycle. TGF-β can also induce apoptosis (Rotello et al. 1991; 
Oberhammer et al. 1992; reviewed by David and Massagué 2018), through 
mechanisms involving Smad7 (Landström et al. 2000). However, Caspase 8 (Shima 
et al. 1999) and Bcl-XL (Saltzman et al. 1998) are also reported to be involved in 
this.  
TGF-β1 is commonly upregulated in cancer cells and from this point TGF-β1 will be 
referred to as TGF-β (Derynck et al. 2001). TGF-β is commonly secreted in an 
inactive form, which is formed by a TGF-β dimer. This dimer is normally activated by 
proteases cleavage (Robertson et al. 2015). Inactive TGF-β can be sequestered by 
the extra cellular matrix (ECM) and activated by degradation of the ECM by, for 
example, macrophage action (Munger et al. 1997; Robertson et al. 2015).  
Smad activation is the best-known pathway for the TGF-β signalling. When TGF-β 
binds to the type II TGF-Β receptor (TβRII), it forms a heterodimer with a Type I 
TGF-β receptor (TβRI). There are three type I receptors (ALK1/TSR-1, ALK2/Tsk7L, 
ALK5/TβRI). Most gene expression responses are thought to be mediated by the 
TβRI receptor (Derynck et al. 2001; reviewed by David and Massagué 2018). When 
the receptor heterodimer is former, TβRII phosphorylates TβRI at a glycine and 
serine rich motif (GS). Downstream to the GS in TβRI is a kinase domain, the kinase 
domain phosphorylates receptor regulated Smad transcription factors (R-Smads) at 
the MH1 and MH2 domains, and these phosphoproteins migrate to the nucleus to 
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implement TGF-β effects on gene expression (figure 1.8). (Santibañez et al, 2011). 
The R-Smads regulated by TβRI are Smad3 and Smad2. Normally, once 
phosphorylated Smad2 and Smad3 form a heterodimer before being translocated to 
the nucleus. The effects of R-Smads are also under the regulation of several 
cytoplasmic proteins, including other members of the Smad family such as common 
mediator Smads (co-Smad) and inhibitory Smads (I-Smad). Smad3 phosphorylation 
is commonly used to indicate TGF-β pathway activation (Santibañez et al. 2011). 
TGF-β signalling can be regulated at different levels: the sequestration of the ligands 
by the ECM actively regulates the triggering of the pathway on the neighbouring 
cells. At the membrane levels interactions of the receptors with several coreceptors 
can modify the consequent signal to be transduced. The expression levels of 
intracellular mediators can also alter the event triggered by the activations of the 
TGF-β signal. The regulations of the signalling pathway were reviewed in detail by 
David and Massagué (David and Massagué 2018). 
An important part of the TGF-β co-receptor complex is Endoglin (or CD109). 
Endoglin is a glycoprotein consisting of a homodimer of 180 kDa expressed in a 
broad spectrum of proliferating cells (Cheifetz et al, 1992). Endoglin plays a crucial 
role in angiogenesis, in cancer growth and in cancer cell migration, and also, 
regulates important cellular functions such as cell proliferation and cell adhesion 
(Valluru, et al. 2011). It has been reported that Endoglin deficient mice injected with 
Lewis lung carcinoma cells, presented reduced tumour vascularization and tumour 
growth (Düwel, el at. 2007). Endoglin can interact with both TβRI and TβRII, and 
through this interaction it can regulate the subcellular signalling of these receptors. In 
endothelial cells, Endoglin interacts with the TGF-β receptor complexes and changes 
the subsequent phosphorylation pathways (Guerrero-Esteo, et al. 2002; Bernabeu, 
et al. 2009). 
As explained above, the cellular effects of TGF-β include different forms of cell 
proliferation inhibition, such as cellular arrest in G1 phase of the cell cycle 
(Mukherjee et al. 2010), promotion of terminal differentiation (Sánchez et al. 1998) 
and activation of cell death mechanisms (Rotello et al. 1991). Reports also link TGF-
β activity (through Smad protein mediation) to epigenetic modifications, such as 
specific DNA de-methylation and relaxation of the chromatin structure through the 
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interactions with P300/CBP (reviewed by Bai and Xi 2017). However, in cancer cells, 
the effects of TGF-β on cell proliferation are altered, and pathway activation does not 
stop the cell cycle when it is needed. On the contrary, TGF-β stimulation leads 
cancer cells to proliferate. It also promotes immunosuppression of leukocytes, which 
would otherwise attack the cancer cells, and it promotes angiogenesis, contributing 
to the tumour progression (Hanahan & Weinberg 2011; Massagué 2008). Several 
cancer shows alterations in TGF-β signalling, including colon, gastric, biliary, 
pulmonary, ovarian, oesophageal, and head and neck carcinomas, (reviewed by 
Levy & Hill 2006). 
The effects of TGF-β signalling are highly dependent on context. This comes from 
the observation that the regulation of different genes by TGF-β is achieved by the 
sharing of enhancer element configurations with other cofactors that interact with 
Smads, and thus the presence or absence of a cofactor in a cell line can make the 
TGF-β signalling display different patterns of regulation (reviewed by David and 
Massagué 2018). This characteristic creates a TGF-β signalling feature named 
“synexpression groups” of co-regulated genes (Silvestri et al. 2008; Gomis et al. 
2006; Niehrs & Pollet 1999). The “synexpression groups” are thus genes co-
regulated by TGF-β signalling and other elements that interact with TGF-β pathway. 
TGF-β is a potent promoter of EMT. This effect has been described in several 
cancers, such as colorectal, pancreatic and prostate (Heldin et al. 2012). Our current 
understanding of the role of TGF-β in EMT and cancer still does not allow the use of 
TGF-β pathway inhibition in patients treatment (Biswas et al. 2007; Jones et al. 
2009) mostly due to the highly context-dependent nature of TGF-β regulation 
(Massagué 2008; Massagué 2012; Gupta & Maitra 2016). Better understanding of 
the context in which TGF-β promotes its effects in each tumour could, in the future, 
help to direct treatments. This study will show that a novel EMT-TF regulates EMT in 




Figure 1.8. TGF-β Signalling pathway. TGF-β that is produced by stroma cells, immune cells and cancer 
cells is sequestrated by the ECM through latent TGF-β binding proteins (LTBPs). Rearrangements of the ECM 
and proteases can release and activate TGF-β. The TGF-β ligand binds to a hetero dimer of TGF-β receptor 
1 (R1) and TGF-β receptor 2 (R2) creating an intracellular signalling cascade. Several cell membrane co-
receptors can regulate intracellular response following TGF-β receptor activation. Among them are Endoglin 
and BAMBI TGF-β co-receptors. TGF-β intracellular signals through a broad range of mediators influencing 
different cellular functions. The classic TGF-β intracellular mediator is the Smad protein superfamily, however, 




Platelets are anuclear cells derived from megakaryocytes in the bone marrow. The 
process of blood cell formation in the bone marrow consists of a sequence of cell 
number expansion steps initiated by a stem progenitor cell and each step of this 
process leads to a higher cellular differentiation degree (Parise 2016). In the case of 
platelets, initially, the colony forming unit CFU-GEMM (colony forming unit that 
generates myeloid cells) is stimulated by cytokines such as IL-1, IL-3 andIL-6 to 
mature into a high proliferative potential–colony-forming unit–megakaryocyte (HPP-
CFU-MK). In the next generation of cells, a burst-forming unit–megakaryocyte (BFU-
MK) is generated, this is able to make a clonal expansion creating several 
megakaryocytic colony-forming units (CFU-Meg), The CFU-Meg undergo maturation 
steps generating megakaryoblasts, that are the precursors of the megakaryocytes 
which produce platelets (Naeim et al. 2013). 
The major function of platelets is in homeostasis of the blood. Platelets play an 
important role in injury resolution. In these situations, platelets aggregate to clog the 
damage to the blood vessel preventing blood loss. In the bloodstream, platelets do 
not aggregate normally and this keeps the fluidity of the blood (Yip et al. 2005). The 
inhibition of platelets activation in the blood is through the production of nitric oxide 
(Riddell & Owen 1999), prostacyclin (Jones et al. 2012) and CD39 (Marcus et al. 
2005) by the intact endothelium. However, in the event of an injury, components of 
the basal membrane of the endothelium (like collagen) bind to receptors present in 
the platelet’s membrane triggering subcellular signals via a tyrosine kinase cascade, 
which activates the production of thromboxane A2 and decreases the production of 
prostacyclin (Yip et al. 2005). This initiates platelet aggregation to clog the blood leak 
(Yip et al. 2005). Platelets are also important in the immune response and 
inflammation. Platelets have roles in the innate immune response because they can 
adhere to pathogens within the vasculature, participating actively in their detection, 
sequestration and destruction (Jenne et al. 2013). Furthermore, cytokines are 
released when platelets adhere to pathogens recruiting inflammatory cells to the 
infection site (Jenne et al. 2013). Platelet released cytokines can directly regulate the 
activity of neutrophils, endothelium and lymphocytes, giving importance to the 
understanding of platelet functions, especially in pathological events (Jenne et al. 
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2013). A important immunomodulator molecule secreted by platelets is TGF-β; 
platelets can release and activate latent TGF-β when they are activated (Labelle et 
al. 2011; Blakytny et al. 2004a). An increased quantity of circulatory platelets is 
observed during inflammation, this effect is thought to be a reflection of increased 
production of IL-6 (Kaser et al. 2001). It was shown that the administration of IL-6 in 
primates increases the circulating platelet count and has effects on megakaryocyte 
morphology that result in cell death over long periods of administration (Stahl et al. 
1991). 
In the cancer context, platelets are reported to play a role in metastasis. Experiments 
with mice showed that a reduced blood platelets count (thrombocytopenia) was 
related to reduced metastatic activity of TA3 ascites tumour cells (Gasic et al. 1968). 
Furthermore, the use of a platelet aggregation inhibitor prevented the bone 
metastasis of B16 melanoma cells when injected in mice (Bakewell et al. 2003). One 
of the possible mechanisms through which platelets influence metastasis is surface 
shielding by platelet aggregation, an effect demonstrated in multiple cancer cell lines 
(fibrosarcoma, lymphoma and melanoma). Platelet aggregation protects cancer cells 
from natural killer cells destruction, by simple attaching to them (Toyoshima et al. 
1995). Jae Hong Im and collaborators showed that melanoma and sarcoma cells 
adhere to lung microvasculature independently of platelets adhesion, however, the 
inhibition of platelets adhesion reduced the permanency of the tumour cells in 
contact with the lung endothelium (Im et al. 2004). More recently, it was 
demonstrated that platelets can also provide a stimulatory signal for cancer cells in 
the circulation. In an elegant experiment, Labelle and colleagues showed that mice 
lacking TGF-β specifically in their platelets formed less metastases when injected 
with cancer cells (colon carcinoma and breast carcinoma cells) (Labelle et al. 2011). 
They also demonstrated that the TGF-β released by platelets is able to activated an 




Proline Rich Homeodomain 
PRH/HHEX stands for Proline Rich Homeodomain/ haematopoietically Expressed 
homeobox. HHEX is an orphan homeobox gene, located on chromosome 10, that 
encodes the protein PRH (Hromas et al. 1993). PRH/HHEX is expressed in many 
tissues of vertebrate animals, both in the adult and embryonic phase (Hallaq et al. 
2004; Martinez Barbera et al. 2000). The HHEX gene is highly conserved between 
species, especially in the homeodomain region. PRH is required for several 
developmental processes during embryogenesis especially in organogenesis of the 
brain, heart, liver, thyroid and thymus (Thomas et al. 1998; Hallaq et al. 2004; 
Martinez Barbera et al. 2000). It was shown that PRH knock out (KO) mice were not 
able to survive gestation. Foetal autopsy revealed malformation in the brain, liver, 
vascular system and haematopoietic system (Martinez Barbera et al. 2000). In 
adults, PRH/HHEX is required in hematopoietic cell differentiation, being essential to 
the commitment stages of lymphoid progenitor cells (Goodings et al. 2015). PRH is 
also implicated in pathological states, including cancer and diabetes (Puppin et al. 
2006; Sladek et al. 2007; Gaston et al. 2016). 
The PRH protein has 240 amino acids, with a theoretical molecular mass of 30 kDa. 
However, in SDS-page gels it presents an apparent molecular mass of 37 kDa (Soufi 
& Jayaraman 2008). The PRH proteins forms oligomers that are highly stable 
resisting chemically-induced denaturation or high temperatures treatments (Shukla 
et al. 2012). The protein possesses three domains: The proline-rich N-terminal 
domain is important for interactions with several proteins including eukaryotic 
translation initiation factor 4E, Groucho/transducing-like enhancer co-repressor 
proteins and the promyelocytic leukemic protein (Soufi & Jayaraman 2008). The N-
terminal domain can repress transcription when it is attached to a heterologous DNA 
binding domain such as the GAL4 DBD protein (Guiral et al. 2001). The N-terminal 
domain is also involved in the inactivation of PRH transcriptional activity. Protein 
kinase CK2 β subunit interacts with PRH N-terminal domain and the CK2 a subunit 
phosphorylates the PRH homeodomain at S163 and S177 (Soufi et al. 2009). This 
phosphorylation abrogates PRH’s ability to bind DNA inhibiting its transcriptional 
activities (Soufi et al. 2009). Furthermore, phosphorylated PRH becomes a target for 
proteasome processing. The proteasome then cleaves the C-terminal domain of 
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PRH (Noy et al. 2012). The cleavage product is a stable truncate PRH protein 
(PRHΔC) that can interact with PRH co-factors sequestering them, this creates a 
competitive inhibitory effect of PRHΔC on PRH activity at its target genes (Noy et al. 
2012). 
The second domain in PRH is the homeodomain (HD). The HD is the DNA 
recognition and binding region. The homeodomain is a 60 amino acids domain that 
contains a helix-loop-helix motif that can interact with DNA with sequence specificity 
(Billeter 1996). The specific DNA sequence bound by PRH was identified by gel 
retardation assays (Pellizzari et al. 2000). PRH can bind to the sequences 5’-CAAG-
3’ and 5’-ATTAA-3’ when they repeat in multiple occasions in an oligonucleotide. 
Multiple PRH target genes contain repeats of these sequences, for example the 
GSC (gene that encodes the Goosecoid protein) promoter contains many of these 
sequences (Pellizzari et al. 2000; Williams et al. 2008). 
The C-terminal domain is an acidic domain involved in transcriptional trans-
activation, by interacting with other transcription factors and co-activators. For 
example, PRH facilitates the binding of serum response factor (SRF) (a transcription 
factor) to its binding site in the SM22α gene (Oyama et al. 2004). Furthermore, PRH 
can activate expression of the sodium-dependent bile acid co-transporter (NTCP) 
promoter only with the presence of the C-terminal domain (Kasamatsu et al. 2004) 
(figure 1.9). 
The expression of PRH can be regulated by different factors in the context of 
different cell types. The Sp family of transcription factors can activate PRH 
expression in rat hepatoma and human leukaemia cells (Kikkawa et al. 2001). 
Meanwhile, GATA-1, GATA-2 and c-Myb activated PRH expression in leukaemia 
cells (Sato et al. 2004). During organogenesis, Wnt/β-catenin (Zorn et al. 1999), 
TGF-β (Zorn et al. 1999; Liu et al. 2004), fibroblast growth factor (FGF) (Zhang et al. 
2004) and bone morphogenetic protein (BMP) (Shin et al. 2007; Zhang et al. 2004) 
can all regulate PRH expression. Similarly, TTF-1 (Puppin et al. 2003) and Pax8 
(Puppin et al. 2004) can activate PRH transcription in thyroid cells (Puppin et al. 
2004). HNF3β and GATA-4 were shown to regulate the PRH promoter in hepatic 
cancer cells (Denson et al. 2000). Finally, PRH can also regulate HHEX gene 
expression in a positive auto-regulatory feedback loop system (Puppin et al. 2003).  
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PRH can repress or activate the transcription of different genes, and many PRH 
targets genes are implicated in cancer progression. PRH represses the expression 
of VEGFA and it’s the genes encoding VEGF receptors Vegfr-1 and Vegfr-2, these 
genes are involved in angiogenesis and are often found up-regulated in different 
cancers (Noy et al. 2010). Also, PRH represses the transcription of the gene 
encoding the homeodomain-containing repressor Goosecoid which is involved in 
EMT and over-expressed in highly metastatic cancers (Williams et al. 2008; Hartwell 
et al. 2006). ESM-1 (endothelial cell-specific molecule) is also repressed by PRH 
(Cong et al. 2006). ESM-1 is involved in cell migration and it is found over-expressed 
in some gastrointestinal tract cancers (Cong et al. 2006; Sarrazin et al. 2006). 
Meanwhile, PRH can up-regulate Endoglin expression, Endoglin is a TGF-β co-
receptor that regulates TGF-β signalling (Kershaw et al. 2014). Reports suggests 
that Endoglin expression can counter the effects of TGF-β in human prostate cancer 
cells (Lakshman et al. 2011) and mouse skin cancer cells (Perez-Gomez et al. 
2007). However, PRH effects can vary depending on the cell line context in which it 
is inserted, therefore, the extrapolation of its effects to other cells lines should be 
treated with caution. 
PRH also presents post-translational regulation effects.  PRH interacts with the 
translation initiation factor 4E (eIF4E), inhibiting the transport of some mRNAs from 
the nucleus to the cytoplasm. This mechanism is important for example in the PRH 
inhibition of Cyclin D1 in leukemic cells (Topisirovic et al. 2003). 
Mis-expression or mis-localization of PRH is correlated with the progression of 
different cancers. For example, in hepatocellular carcinomas (HCC) PRH expression 
is lost during the progression from well-differentiated tumours (grade II) to poorly-
differentiated tumours (grade III) (Su et al. 2012). Additionally, PRH over-expression 
in HCC cells injected into nude mice reduced tumour growth when compared to the 
control cells (Su et al. 2012). An example of PRH mis-localization is seen in breast 
ductal and lobular carcinomas (Puppin et al. 2006). While normal ductal and lobular 
epithelium show PRH immunostaining in the nucleus and cytoplasm, their cancerous 
equivalents lack significant nuclear staining for PRH (Puppin et al. 2006). A similar 
phenomenon is observed in thyroid carcinomas; in normal tissues and thyroid 
adenomas, the PRH protein is detected in the nucleus and cytoplasm of the 
epithelial cells, however, in their cancerous equivalents, nuclear expression is lost 
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(D’Elia et al. 2002). Recently, PRH mis-function was associated with prostate 
cancer. It was reported that Benign Prostatic Hyperplasia (BPH) samples presented 
higher staining for phosphorylated PRH than normal prostate tissues (Siddiqui et al. 
2017). 
Although some progress has been made, the mechanisms that lead to PRH mis-
function, mis-expression and mis-localization in cancer progression are not well 
understood. Part of the reason for this is due to its cell type specific effects. The work 
presented here will investigate the relevance of PRH in prostate cancer progression 
and its interaction with the TGF-β signalling pathway, proposing a mechanism that 












Figure 1.9. The PRH/HHEX protein and its interacting proteins. A diagrammatic representation of the 
human PRH protein. The PRH protein has three functional domains. The boxed and bracketed areas represent 
the regions of PRH that interact with the proteins indicated. The brackets indicate poorly mapped interactions. 




The general objectives of this research project are to elucidate the molecular 
pathways involved in the EMT processes stimulated by TGF-β in prostate cells, 
observing the involvement of the transcriptional factor PRH. 
 To achieve this goal, the specific objectives are: 
a) To investigate the influence of TGF-β treatment on EMT and the migratory ability 
of prostates cell lines.  
b) To investigate the role of PRH in EMT processes in these cells by over-expressing 
its gene. 
c) To investigate the co-regulation of EMT and MET by the crosstalk between TGF-β 
and PRH in prostate cancer cells.  

























List of chemicals 
Table 2.1 – Chemicals 
Reagents Manufacturer 
2-Mercaptoethanol Sigma® 
2x Rotor-Gene SYBR Green Polymerase chain 
reaction Master Mix 
Qiagen 
Ammonium persulfate (APS) Sigma® 
Bio-Rad protein assay BioRad® 
Bis-acrylamide Severn biotech ltd® 
bromophenol blue Sigma® 
Bovine serum albumin (BSA) Sigma® 
Calcein-acetoxymethyl (Calcein-AM) Thermo Fisher Scientific 
Calcium chloride Sigma® 
Cell Lysis Buffer (10X) Cell Signalling Technology® 
4′,6-diamidino-2-phenylindole (DAPI) Sigma® 
Dimethyl sulfoxide (DMSO) Thermo Fisher Scientific 
Doxycycline Sigma® 
Dynabeads-Protein G Thermo Fisher Scientific 
Ethylenediaminetetraacetic acid (EDTA) Sigma® 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid (EGTA) 
Sigma® 
Ethanol Sigma® 
Foetal Bovine Serum (FBS) Sigma® 
G418 Sigma® 
Glycerol Thermo Fisher Scientific 




Isopropanol Thermo Fisher Scientific 
Lysogeny broth (LB) agar MP biomedicals™ 
Lysogeny broth (LB) powder MP biomedicals™ 
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Phosphate buffered saline (PBS) Sigma® 
Polyethylenimine (PEI) Sigma® 
Penicillin/streptomycin Gibco™ 
Phenylmethanesulfonyl fluoride (PMSF) Sigma® 
PhoStop™ Roche 
Propidium iodide Sigma® 
Proteinase K Sigma® 
RNAse Sigma® 
RPMI-1640 medium Sigma® and Gibco™ 
Sodium dodecyl sulphate (SDS) Sigma® 
Sodium bicarbonate Sigma® 
2-ethylhexyl 2,3,4,5-tetrabromobenzoate (TBB) Sigma® 
Tetramethyl ethylenediamine (TEMED) Sigma® 
tetracycline Sigma® 
Transforming growth factor beta 1 (TGF-β) PeproTech® 
Triton X-100 Sigma® 
Trizma Sigma® 
trypsin Gibco™ 
Tween 20 Sigma® 
UltraPure™ distilled water  Invitrogen 





Table 2.2 – Commercial kits 
Kit list Manufacturer 






















Table 2.3 – Buffer recipes 
Buffers  
Western blotting  
4X Stacking 
buffer 
0.5M Tris; 0.4% SDS; pH 6.8 
4X Resolving buffer 1.5M Tris; 0.4% SDS; pH 8.8 
12% SDS-PAGE gel 
Distilled water 7 mL; 4X Resolving buffer 5 mL; Bis-
acrylamide 8mL; APS200 l; TEMED 20 l. 
10X Tris Glycine 0.25 M Trizma; 2 M Glycine. 
Running Buffer 
TRIS Glycine 100 ml; SDS 10 ml (10% stock); Distilled 
water, add dH2O up to 1000 mL. 
5X loading dye 
50% Glycerol; 300mM Tris-HCL pH: 6.8; 10% 2-
Mercaptoethanol; 5mg/ml bromophenol blue; 10% SDS. 
Transfer Buffer 
TRIS-Glycine 10x 100 ml; Methanol 200 ml; Distilled water 
add up to 1000 mL. 
Blocking buffer 5% BSA in TBS-T 
10X TBS 15 mM NaCl; 2 mM Tris-HCl pH: 7.6. 
TBS-T 1.4 mM NaCl; 0.2 mM Tris-HCl pH: 7.6; 0.001% Tween-20. 
ChIP  
BUFFER A 
10 mM HEPES, pH 8.0; 10 mM EDTA; 0.5 mM EGTA; 
0.25 % Triton X-100; 1uM PMSF and 1x PhoStop™. 
BUFFER B 
10 mM HEPES, pH 8.0; 200 mM NaCl; 1mM EDTA; 0.5 mM 
EGTA; 0.01 % Triton X-100; 1uM PMSF and 1x PhoStop™. 
CHIP BUFFER 
25 mM Tris-HCl, pH 8.0; 150 mM NaCl; 2 mM EDTA; 1 % 
Triton X-100; 0.25 % SDS; 1uM PMSF and 1x PhoStop™. 
3X CHIP DILUTION 
BUFFER 
25 mM Tris-HCl, pH 8.0; 150 mM NaCl; 2 mM EDTA; 1 % 
Triton X-100; 7.5 % Glycerol; 1uM PMSF and 1x 
PhoStop™. 
WASH BUFFER 1 
20 mM Tris-HCl (pH 8.0); 150 mM NaCl; 2 mM EDTA; 1 % 
Triton X-100; 0.1 % SDS. 
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WASH BUFFER 2 
20 mM Tris-HCl (pH 8.0); 500 mM NaCl; 2 mM EDTA; 1 % 
Triton X-100; 0.1 % SDS. 
LiCl BUFFER 
10 mM Tris-HCl (pH 8.0); 250 mM LiCl; 1 mM EDTA; 0.5 % 
NP-40; 0.5 % Na-deoxycholate. 
TE/NaCl BUFFER 10 mM Tris-HCl (pH 8.0); 50 mM NaCl. 
ELUTION BUFFER 100 mM NaHCO3; 1 % SDS. 
Tissue culture  
Complete media 
RPMI-1640 medium (Gibco® or Sigma®) supplemented 
with 10% FBS, 2 mM L-glutamine and 1% 
penicillin/streptomycin. Filtered sterile. 
Starvation media 
RPMI-1640 medium (Gibco® or Sigma®) supplemented 
with 2% FBS. Filtered sterile. 
Freezing media 
(PC3 and DU145) 
45% RPMI; 45% FBS; 10% DMSO. 
Freezing media 
(PNT2-C2) 





Plasmids, primers and antibodies 
Table 2.4 – Plasmid list 
Plasmid list Description Source 
pMDG2 
Plasmid encoding 










tagged PRH cDNA 
downstream to a 
doxycycline 
regulated promoter. 
The plasmid also 
expresses GFP 
constitutively and 
confers resistance to 
neomycin in 
mammalian cells. 
(Plasmid map as 
Appendix). 




human PRH (amino 
acids 7-270) tagged 
with the Myc9E10 
epitope; under the 
control of a CMV 
promoter (Swingler 





Plasmid is the empty 

















Table 2.5 – Antibodies 
Name Host 
species 








pPRH (YKN5) Rabbit In house 1:2500  
Phospho-Smad3 
(Ser423/425) 
Rabbit Cell Signalling 
technology® 
1:1000 9520 
E-Cadherin Rabbit Cell Signalling 
technology® 
1:1000 3195 
β-Actin Rabbit Cell Signalling 
technology® 
1:1000 4970 
Snail Rabbit Cell Signalling 
technology® 
1:1000 3879 
Endoglin Rabbit Cell Signalling 
technology® 
1:1000 4335 
Vimentin Rabbit Cell Signalling 
technology® 
1:1000 5741 
Slug Rabbit Cell Signalling 
technology® 
1:1000 9585 





β-catenin Rabbit Cell Signalling 
technology® 
1:1000 8480 
Lamin A/C Rabbit Cell Signalling 
technology® 
1:1000 2032 
Myc-tag Mouse Cell Signalling 
technology® 
1:1000 2276 
HRP-Anti-Mouse Rabbit Sigma® 1:5000 AP127P 
HRP-Anti-Rabbit Goat Sigma® 1:5000 AP156P 
 
Table 2.6 – Primers 
Name Sequence 
E-Cadherin F GTA ACG ACG TTG CAC CAA CC 
E-Cadherin R AGC CAG CTT CTT GAA GCG AT 
GAPDH F TCC TTG GAG GCC ATG TGG GCC AT 
GAPDH R TGA TGA CAT CAA GAA GGT GGT GAA G 
Snail F GAG GCG GTG GCA GAC TAG 
Snail R GAC ACA TCG GTC AGA CCA 
PRH F AAA CCT CTA CTC TGG AGC CC 
PRH R GGT CTG GTC GTT GGA GAA TC 
CH18 F TTC AGT CTG GTG GTG GTG AAC TA 
CH18 R GCC TTG GGA AAT CCA TCT TTT 
-3472 HHEX F TAG AGC AGC ACA GGG TTT GA 
-3472 HHEX R GCC TTG ATG TGG ATG AGT GC 
Smad7 F GCA AAT CCT TTC CAT CTC CA 
Smad7 R TGC TTT GTG ATT TGG CAG TC 
-4.5K CDH1 F AGA GCC AGA AGT GAA TCC AGG 
-4.5K CDH1 R GTG AAA CCC CAT CTC CCC AA 
+4.5K CDH1 AGC CTA GTA ACC ACA GCT GT 
+4.5K CDH1 TCA AGC AGC CAA ACC TCA AC 
+54K TGFB2 GGA ACC TGT GCT GCT TTG TA 
+54K TGFB2 AGG TGT GGG TAT GAA CGG AA 
-11K TGFBR2 TCA AAA CTG TGT TCC TGG CT 
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-11K TGFBR2 AGT TGC AGC CTC AGA TGA CT 
+30K TGFBR1 ACA GTA TCA GTT GAC CAC ATT GT 
+30K TGFBR1 AGA AGG GAA ACA GAT GGC ATT 
TGFB2 AGG AAA GGC GGG TAA TGG AA 
TGFB2 AAG GAC TGC TGG GAT GAC AA 
TGFBR2 AAA TGC TGG CTC TAC ACC CT 
TGFBR2 GGG GAT GTT GGA CAG GAA GA 
TGFBR1 CCC CAC TCC CCA CTT TAC AT 








Escherichia coli (E. coli) XL1 blue: Genotype - recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F′ proAB lacIq ZΔM15 Tn10 (Tetr)]. 
Preparation of media and agar plates 
LB broth was prepared by adding 25g of LB powder to 1L of boiling double-distilled 
water (ddH2O) and mixing until homogenous, the bottle was labelled, autoclaved at 
121⁰C for 15 mins and stored at 20°C.  
LB agar was prepared by adding 4 capsules of agar to 100mL of ddH2O, sterilized by 
autoclaving at 121⁰C for 15 mins and stored at 20°C. When needed, the LB agar 
was melted in a water bath over a Bunsen burner and left on the bench to cool. The 
relevant antibiotic was added when the temperature of the bottle was comfortable to 
touch, and 50mL was poured onto sterile disposable Petri dishes. 
Preparing competent cells 
First, the selection of E. coli XL1 blue was performed overnight at 37°C in a LB agar 
plate containing tetracycline (50 μg/μl). The following day a single colony was picked 
and inoculated into a starter culture (5 ml LB broth supplemented with 50 μg/μl 
tetracycline), it was then left to grow in a shaking incubator at 37°C, again overnight. 
The starter culture was diluted 200 times (100mL final volume) using the same type 
of broth and incubated in a shaking incubator at 37°C until A600 reach 0.6OD. It was 
chilled on ice for 10 minutes and aliquoted onto pre-chilled 50mL falcon tubes. The 
aliquots were centrifuged (Eppendorf centrifuge 5804 R - 5min at 1500 rpm and 4°C) 
and the pellets resuspended in 5ml ice cold 0.1M CaCl2, then left to rest in ice for 10 
minutes. Another centrifugation was performed, and the pellets were this time 
resuspended in 1ml ice cold 0.1M CaCl2 and incubated for 1 hour. After, 100 l of 
100% glycerol were add to each aliquot, they were further aliquoted into smaller 




A 100 L aliquot of XL1 blue competent cells was thawed on ice and 1 g of DNA 
(desired plasmid) was add to it, the mix was left to rest on ice for 30 minutes. 
Subsequently, a 2 minutes heat shock at 42°C followed by an ice incubation of 1 
minute allowed the cells to incorporate the foreign DNA. 700 L of LB broth was 
added to the cells, the Eppendorf tube was stuck on to the bottom of a 37°C shaker 
incubator and left there for 90 minutes, centrifuged (Eppendorf microcentrifuge 5415 
- 5000 rpm for 2 minutes) and the pellet resuspended in 100 l LB broth. LB agar 
plates were prior poured as aforementioned with the relevant antibiotic selector and 
left to dry in a 37°C incubator, once dried, the 100 L bacterial solution was spread 
across the agar using a plastic sterile disposable inoculation loop. The plate was 
then inverted inside a 37°C incubator overnight. 
A single colony picked from the plate was inoculated onto a starter culture (5mL LB 
broth) and put into a 37°C shaker for 8h; the starter culture was diluted 500 times 
into LB broth (this time containing relevant antibiotic selector) and left on the shaker 
incubator (37°C) overnight. The cells were then harvest by centrifugation (Eppendorf 
centrifuge 5804 R - 5000 rpm for 5 minutes at 4°C). 
Plasmid purification 
The plasmids were extracted from cell pellets and purified using Maxi prep kits 
(Qiagen®) according to the manufacturer’s protocol. Purified DNA was quantified 
using a nanodrop UV spectroscopy (Perkin Elmer lambda 14 UV/Vis spectrometer). 
The DNA concentration provided by the equipment is calculated using the 
absorbance at 260 nm (A260) considering A260 of 1.0 = 50 g/ml pure DNA 
plasmid; the A260 / A280 ratio is also calculated to determine the purity of the 
purified DNA plasmid, ratio between 1.9 and 2.1 were considered high-quality 
plasmid DNA. 
Lentivirus production 
HEK 293 cells were plated in aT75 flask at the confluence of 8x104 cells/cm2 and left 
to settle overnight (day 0). The next morning (day 1), the cells were transfected using 
the PEI protocol (section 2.5.1). In this protocol two falcon tubes with 20°C Opti-
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MEM™ media are prepared (to every T75 flask with cells), one of the falcon tubes 
received a final concentration of 2 M of PEI the other one received the DNA 
constructs to be transfected. For the creation of the PRH carrying lentivirus construct 
three plasmids were used: pMDG2 (viral coat), psPAX2 (packaging protein) and 
PRH overexpression plasmid (short for modified pcLVi(3G)-PRH-CopGFP-IRES-
Neo_BamHI-EcoRI). The three plasmids were added to the Opti-MEM™ media in 
the following quantities: 6.75 g of pMDG2, 18.75 g of psPAX2 and 25 g of PRH 
overexpression plasmid. The contents of each falcon tube were filtered (0.2 m pore 
filter) into a common fresh sterile falcon tube and the DNA-PEI mix was incubated 
under a fume hood for 20 minutes. The HEK 293 cells in the T75 flasks were washed 
with warm Opti-MEM™, and the DNA-PEI mix was added to it. The flasks were 
incubated in tissue a culture incubator for 4 hours at 37°C. After, the PEI-DNA 
mixture was aspirated using a vacuum pump attached to a sterile disposable Pasteur 
pipette and fresh media (10 mL per flask) was added to the flasks. The transfected 
cells were incubated for 48 hours at 37°C. After (day 3), the first viral harvest was 
performed. The 10 mL media containing lentivirus was pipetted out and safely stored 
in a 50 mL falcon tube at 4°C. Another 10 mL of fresh media was added to the cells 
and the flasks put in the incubator for another 24 hours. Next (day 4) a second 
harvest was made, the media extracted was added to the media stored on the 
previous day. The left-over cells and virus were terminated with Virkon™ and 
properly disposed. The media collected on the two harvests was filtered through a 
0.4 m pore filter to remove any cells or debris that might be present. Lenti-X™ 
concentrator (final volume was 1/3 of the total volume of viral solution) was used to 
concentrate the lentiviruses. The solution was incubated for 30 minutes at 4°C, after, 
the tubes were centrifuged (1500 xg at 4°C for 45 minutes). The supernatant was 
carefully decanted and properly discarded, and the viral pellet was resuspended in 
1mL of media to be frozen and stored at -80°C for use. All the materials used were 




Human tissue culturing and cell storage 
Media requirements 
PNT2-C2 is an adherent  cell line derived from a normal human prostatic epithelium 
immortalized by the transfection with SV40 DNA. These cells present a definite 
epithelioid shape and grow as colonies until full confluency. They express cytokeratin 
8, 18 and 19, while PSA and PAP were not detected in these cells. This cell line is 
dependent in serum to grow on culture and its doubling time in 10% serum media is 
approximately 36h (Berthon et al. 1995). 
PC3 is an  adherent cell line isolated from a bone metastasis of a prostate 
adenocarcinoma. They are cells of epithelial origin that form clusters in soft agar. 
They present a reduced dependency to serum and do not respond to androgens, 
glucocorticoids or epidermal or fibroblast growth factors. Its karyotype is aneuploid in 
the hypotriploid range . There are nearly 20 marker chromosomes commonly found 
while several normal markers are not found (N2, N3, N4, N5, N12, N15 and normal Y 
chromosomes). It expresses the antigens HLA A1 and A9 (Kaighn et al. 1979). 
DU145 is an adherent  epithelial cell line  isolated from a brain metastasis of a 
prostate adenocarcinoma. These cells grow in isolated islands on plastic and form 
colonies on soft agar. This cell line is hypotriploid with 64 chromosomes, the 
karyotypic analysis showed translocation Y chromosome, metacentric minute 
chromosomes and three large acrocentric chromosomes, while N13 is absent. This 
cell line expresses the antigens Blood Type O and Rh+ (Stone et al. 1978). 
PC3 and DU145 were both cultured in RPMI-1640 medium (Sigma®) PNT2-C2 cells 
in RPMI-1640 medium (Gibco®). All the culture media was supplemented with 10% 
FBS, 2 mM L-glutamine and 1% penicillin/streptomycin. The PC3 PRH 
overexpression cell line was derived from the PC3 line and created by Lentivirus 
transduction and subsequent selection (explained in the sections ahead), they were 
cultured in RPMI-1640 medium (Sigma®) supplemented with 10% FBS, 2 mM L-
glutamine and 1% penicillin/streptomycin 3mg/mL G418. All cells were maintained in 
a humidified atmosphere at 37°C and 5% CO2 during the selection steps, after they 
were grown in the same media as PC3 cells. The HUVEC cells used by Dr. Siddiqui 
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in extravasations assays were obtained from Promocell, they were maintained and 
grown in Promocell Endothelial Cell Growth Medium. 
Cell counting 
The cell suspension was placed by capillarity inside a Neubauer chamber, the 
chamber was observed under a bright field inverted microscope (CETI – Belgium) 
and the cells inside four 1 mm squares were counted. The average number of cells 
in the fours squares was used to calculate the cell concentration as follows. Each 
mm inside the chamber holds 0.1mm3, 1mL is equivalent to 1cm3, so by multiplying 
the average by 104, we obtain the number of cells/mL. 
Storage of cells 
Two storage methods were used to guarantee a viable stock in case of adversity. 
The cells were permanently stored in liquid nitrogen or a -80°C freezer. Briefly, Cells 
were resuspended in freezing media (45% RPMI; 45% FBS; 10% DMSO (PC3 and 
DU145) 70% RPMI; 20% FBS; 10% DMSO (PNT2-C2)) at 5x105cell/mL density and 
aliquoted into cryovials. The vials were placed into a Mr Frosty™ and it was placed 
into the -80°C freezer for 24h. Afterwards frozen the vials were transferred to 
permanent storage in liquid nitrogen until required. 
Transient transfection methods in human cells 
Poly(ethyleneimine) (PEI) 
PEI was used to transfect cells with plasmids. PEI self-assembles with nucleic acids 
to form polyplexes, PEI also acts as buffer, which helps the nucleic acids escape the 
endosome. The DNA PEI complexes were built in Opti-MEM™. Two experiment 
tubes were filled with 3.125 mL of Opti-MEM in the first tube, 2 M of PEI was 
added, to the second the DNA to be transfected. The content of the two tubes were 
filtered through a 0.2 m filter inside a third sterile tube and left at 20°C for 20 
minutes. Meanwhile the plated cells (80% confluency) were washed with warm Opti-
MEM™. After incubation the media was removed from the cells and the Opti-MEM 
containing the PEI DNA complexes were add to them. The plates were placed back 
in the tissue culture incubator and left there for 4 hours at 37°C. Next, the Opti-MEM 
containing the PEI-DNA complexes was removed and normal complete media was 
82 
 
added to the cell monolayer. After a 24h recovery step, the experiments were 
conducted. 
Trans-IT® prostate transfection kit 
TransIT® prostate transfection kit (Mirus, Madison, WI) was used following the 
manufacturer’s protocol to transfect prostate cells. The cells were plated overnight 
prior to transfection (3.4 x 104 cells/cm2). The appropriate transfection ratios TransIT 
reagent: DNA: Boost reagent were determined in previous standardization 
experiments and were: PNT2-C2 - 2.5:12.5; PC3 – 2.5:1:1. 
Stable cell lines 
A vial of PRH overexpression lentivirus (to preparation details refer to section 2.4.2) 
solution was thawed on ice. Appropriate quantities (3x105 cells per well) of PC3 cell 
suspension were incubated with the content of the lentivirus vial for 10 minutes at 
20°C in a sterile falcon tube. Afterwards, the mix of cells and virus were plated at a 
confluency of 3.4 x 104 cells/cm2 and left to settle for 24 hours (day 0), a no-virus 
control was also plated. Next day, the media content of each well was removed, 
placed into a tube with Virkon™ and properly disposed of. Fresh media was then 
added to each well and the cells were incubated again for another 48 hours (day 1). 
On day 3, the cells were taken to an inverted epifluorescence microscope to verify 
GFP expression. Afterwards, antibiotic (G148 2 mg/mL) was added to start the 
selection the transduced cells. The cells were observed daily and media with G148 
was changed ever two days. Selection was carried for two weeks in the plate where 
the cells were originally plated. During this time, all the cells in the no-virus control 
died from the selection, and a few cells survived the selection in the PRH 
overexpression virus infected wells. The surviving cells were expanded and occupied 
nearly all the surface available, at this point, cell pictures were taken, and the cells 
were passaged to a bigger flask (T25 flasks). The media removed from the infected 
cells was treated as virus containing media for 2 passages, and the cells were kept 
in selection media for 3 passages. At this point there were several flaks confluent 
with PC3 PRH LV cells. They were harvested and resuspended in freezing media 
the cells were frozen into a Mr. Frosty™ at -80°C for 24 hours to be subsequently 
stored in liquid nitrogen, ready to be thawed and used when necessary. 
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The stable cell line generated here is polyclonal. Arguably, monoclonal lines can 
offer better reproducibility over several passages, due to the higher possibility of 
epigenetic silencing of the cloned gene in polyclonal lines. However, the insertion of 
the lentiviral vector is random, and polyclonal lines can compensate for positional 
effects from the site of integration, because they possess different places of insertion 
in different cells. Additionally, the heterogeneity observed in polyclonal lines can be 
considered advantageous, as cancer tumour cells presents a vast heterogeneity, so 
the effects studied in vitro would also be subjected heterogenic conditions. 




Molecular analyses and migration 
Prostate cells were plated at the confluency of 1.7 x 104 cells/cm2 and left to settle 
overnight (day 0). Next morning, the cells received appropriate treatment (Vehicle, 
TGF-β, TGF-β + TBB, TBB or platelets 1:1 ratio) (day 1) and were incubated for 48 
hours. On the third day, the cells were harvested using appropriate cell dissociation 
solution (trypsin was used to pPRC and western blotting experiments, and non-
enzymatic cell dissociation solution was used if the cells were to be used in ChIP-
qPCR assays), in cases where trypsin was used, complete media was used to 
neutralize it. The concentration of the solution with cell suspension was counted 
using a haemocytometer (as described in section 2.4.4.2). The solution was then 
centrifuged at 20°C to a speed of 1000 RPM (Centurion centrifuge) for five minutes. 
The pellets were either frozen and stored at -80°C or further processing was carried 
out, according to the experiment in which the cells would be used. 
Immunofluorescence analyses 
A sterile square cover slip (22x22 mm and ~0.25mm thick) was placed in the bottom 
of a 6-well plate. Prostate cells were plated onto these cover slip-containing plates at 
the confluency of 1.7 x 104 cells/cm2 and left to settle overnight (day 0). Next 
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morning, the cells received appropriate treatment (Vehicle or TGF-β) (day 1) and 
were incubated for 48 hours. On the third day, the media was aspirated using a 
vacuum pump attached to a sterile disposable Pasteur pipette and the wells were 
washed with sterile PBS twice. The cells were fixed using appropriate fixing agent 
(4% paraformaldehyde) for ten minutes. The paraformaldehyde was pipetted out and 
properly disposed. Meanwhile, the wells were twice washed again using PBS. The 
cover slips containing cells were used for immunofluorescence staining or kept in 
4°C for a maximum of 4 days before staining. 
PRH overexpression experiments 
Molecular analyses and migration 
Adenoviral overexpression 
The adenovirus used were made and purified by Dr Graciela Sala-Newby. PC3 cell 
suspension was incubated with each adenovirus (E1, PRH, PRHCC or PRHM1) or 
no virus control at 100 MOI for 10 minutes at 20°C in a sterile falcon tube. 
Afterwards, the mix of cells and virus were plated at a confluency of 3.4 x 104 
cells/cm2 and left to settle for 24 hours (day 0). Next day, the media containing virus 
was pipetted out into a 50 mL falcon tube containing Virkon™ and properly disposed 
of. Fresh media was added to the cells and they were left to recover for another 24 
hours (day 1). On day 2, the cells received treatment (with TGF-β or vehicle) or left in 
the incubator for another 48h. On day 4, the cells were harvested using appropriate 
cell dissociation solution (trypsin was used for qPCR and western blotting 
experiments, and non-enzymatic cell dissociation solution was used if the cells were 
to be used in ChIP-qPCR assays), in cases where trypsin was used, complete media 
was used to neutralize it. The concentration of cells was determined using a 
haemocytometer (as described in section 2.4.4.2). The solution was then centrifuged 
at 20°C to a speed of 1000 RPM for five minutes (Centurion centrifuge). The pellets 
were either frozen and stored at -80°C or further processing was carried, according 
to the experiment. 
Stable cell line 
PC3 PRH LV (For preparation details refer to section 2.6) cells were plated at the 
confluency of 1.7 x 104 cells/cm2 with addition of 2 ug/mL of doxycycline or vehicle to 
85 
 
the media (day 0). Doxycycline was reconstituted in water and filtered sterilized to a 
stock concentration of 2mg/L, the stocks were kept up to 4 weeks at 4ºC. The cells 
were then incubated for 7 days, but fresh doxycycline and media was added daily. If 
the cells were close to reaching confluence they were passaged to a bigger surface. 
At the seventh day, the cells were either harvested or brought to an inverted phase 
contrast microscope for image acquisition. The harvesting was carried out using 
trypsin and complete media was used to neutralize the trypsin. The concentration of 
cells in the cell suspension was determined using a haemocytometer (as described 
in section 2.4.4.2), and the cells were then centrifuged at 20°C to a speed of 1000 
RPM (Centurion centrifuge) for five minutes. The pellets were either frozen and 
stored at -80°C or further processing was carried out. 
Trans IT transfection 
PC3 cells were plated at the confluency of 3.4 x 104 cells/cm2 in a 6-well plate and 
left to recover overnight (day 0). Next morning, the cells were transfected with the 
Trans-IT reagent as explained in the section 2.5.2 (day 1). After transfection the cells 
were incubated for 48 hours. At day 3 the cells were harvested using trypsin and 
complete media was used to neutralize trypsin after detaching. The concentration of 
cells was determined as above (as described in section 2.4.4.2). The solution was 
then centrifuged at 20°C to a speed of 1000 RPM for five minutes, and the cells were 
used for migration assays. 
Cell migration 
The cells used in this assay came from the treatments described in sections 2.7.1.1, 
2.7.2.1.1 , 2.7.2.1.2 and 2.7.2.1.3.  Cell migration assays were performed as 
described previously (Kershaw et al 2014). Briefly, chemotaxis assays were 
performed by seeding cells into 200 l Boyden chambers (Greiner Bio-One) in RPMI 
medium with 2% FBS in 24-well plates containing 800 l complete media. After, the 
media was removed from both chambers, serum free media with Calcein-AM was 
added to the bottom chamber and incubated for one hour. The media was then 
removed, and the wells were washed with PBS twice. Warm trypsin (500 l 37°C) 
was added to the bottom chamber and incubated for 10 minutes with gentle shaking 
being applied every 2 minutes. 200 L cell suspension in trypsin were placed into a 
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black flat-bottom 96-well plate and read in fluorescent reader flex station 
(wavelength: 495 nm excitation and 515 nm emission). The results were fitted to a 
standard curve by linear regression to obtain the total number of migrated cells. The 





The pellets used in this assay came from the treatments described in sections 
2.7.1.1, 2.7.2.1.1 and 2.7.2.1.2. The pellets were defrosted on ice and resuspended 
in 50 l of 1x cell lysis buffer (Cell signalling® added 1uM PMSF and 1x PhoStop™). 
The solution was then put in a water bath sonicator (Ultrawave™) with ice cold water 
for 10 minutes. The extracts were centrifuged (Eppendorf microcentrifuge 5415 - at 
11000RPM; 5min; 4°C) and 42 l of the supernatant (protein extract) were placed in 
a labelled fresh tube. 
Sample preparation 
2 l of the protein extract were used to determine the total protein concentration 
using the Bio-Rad® protein assay, following manufacture instructions and comparing 
the reads to a standard curve made with different concentrations of BSA. 
Subsequently, 10 l of 5x Loading dye were added to the remaining 40 l of protein 
extract, and the solution was boiled at 95°C for 5 minutes, the concentration was 
adjusted and the samples stored at -20°C until needed. 
Electrophoresis and western-blotting. 
Before loading into a 12% acrylamide SDS-PAGE gel, the samples were thawed and 
heated again at 95°C for 5 min. 5 g of total protein were added to the gel and the 
loading order was registered. The gel was run at 180 V until appropriate separation 
was observed by the coloured ladder control. The proteins were then transferred to a 
PVDF membrane using the BioRad® wet transfer system at 240 mA for 2 h. The 
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membrane with the proteins was blocked with 5% BSA in TBS-T overnight (ON) Next 
morning the primary antibody on appropriate concentration were diluted in 5% BSA 
in TBS-T and used to replace the blocking solution, the membrane was placed on a 
rocker at 20°C for 1 h and 30 min, followed by 3x10 min washes using TBS-T. The 
secondary antibody was properly diluted in 5% BSA in TBS-T, added to the 
membrane and placed on the rocker at 20°C for 1h, followed by 3 sets of washes as 
described previously. 
The luminescent reaction was made using BM Chemiluminescence (POD)™. 
Membranes were dipped into the solution for one minute and placed on a 
radiography cassette. The membranes were exposed to a radiography film and 
developed using an automatic radiography developer. 
Immunofluorescence 
The cells used in this assay came from the treatment described in sections 2.7.1.2. 
Permeabilization solution was added to cover slips carrying the fixed cells (500µl 
0.2% Triton X-100/PBS on ice for 15min. The cells were then washed 4 times with 
PBS to completely remove all detergent, followed by addition of 500µl of 3% 
BSA/PBS and incubated for 20min at 20°C to block non-specific binding. The cells 
were then washed 3 times with PBS and 200µl of the desired primary antibody at 
appropriate dilution (in PBS) was then carefully added to cover all cells and 
incubated for a further 1h at 20°C. The cells were again washed three times with 
PBS before adding 200µl of the desired secondary antibody and incubated for 
50min, in the dark, at 20°C. Finally, the cells were washed twice with PBS, and 
incubated with DAPI for 10 minutes. The DAPI was washed with PBS another two 
times and the coverslips were mounted with Immuno-Mount™ onto microscope 
slides. The coverslips were then sealed with nail varnish. Mounted coverslips were 
kept in the dark for at least 30min before imaging. Fluorescence microscopy was 
carried out using a Leica Q550 epifluorescence microscope fitted with DAPI, GFP, 
and TRITC filter sets. 
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Acid nucleic detection 
qRT-PCR 
The pellets used in this assay came from the treatments described in sections 
2.7.1.1, 2.7.2.1.1 and 2.7.2.1.2. Quantitative reverse transcriptase-mediated PCR 
(qRT-PCR) was performed as described previously (Kershaw et al., 2014) in 
quadruplicate for the gene of interest and Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal control. Data were analysed using 
Rotorgene 6 software (Corbett Research; Rotorgene RG-3000) and the fold-change 
determined using the efficiency adjusted quantitative PCR method (Kershaw et al. 
2017).  
ChIP-qPCR 
Cells were treated as explained in sections 2.7.1.1 and 2.7.2.1.1. Cells were pelleted 
and resuspended (1x107 cells per 5 ml of complete media). The cells were fixed by 
adding a final concentration of 1% methanol free paraformaldehyde for 10min at 
20°C. Glycine was then added to stop the cross-linking reaction, to a final 
concentration of 0.4 M, and then the cells were pelleted by centrifugation for 5 min at 
300 x g, 4°C, followed by two washes of the pellet in ice cold PBS. The pellet was 
resuspended in 5 ml of ChIP buffer A and incubated on rocker for 10 min at 4°C, 
next the solution was centrifuged for 5 min at 500 x g, 4°C. The pellet was then 
resuspended in ChIP buffer B and incubated at 4°C for another 10 min, to be 
subsequently pelleted down (5 min at 500 x g, 4°C), obtaining a nuclei pellet, which 
can be snap frozen or used immediately after centrifugation.  
After thawing, the nuclei pellet was resuspended in 1 ml ChIP buffer and disrupted 
on a vibra cell™ with a micro tip sonicator. The solution was kept on ice for 20 
minutes prior to disruption. The sonication cycles were set to 1 second pulse 
followed by 3 seconds rest at 60% power, where one cycle consisted of 4 pulses. 
Each sample received 3 cycles. Between cycles the samples were kept on ice for at 
least 3 minutes. The disruption was followed by a 10 min centrifugation at 16000 x g 
4°C, the supernatant was transferred to a fresh Falcon tube and 500 l of 3x ChIP 
dilution buffer was added.  
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The samples were divided in 3 different Eppendorf tubes, 675 l for the target 
antibody (pSmad3 or Myc-tag), 675 l for the normal rabbit IgG antibody and 150 l 
for the input control. 5 l of the relevant antibody and a final concentration of 0.5% 
BSA were added and the samples were incubated on a rotating wheel at 4°C 
overnight. Next morning, enough Dynabeads-Protein G (10 l per IP) were placed in 
a fresh tube and washed twice in phosphate buffer (pH 8.0). The beads were then 
resuspended in 0.5% BSA in phosphate buffer (pH 8.0) (10 l per IP). Subsequently, 
10 l of beads suspension was add to each sample and incubated at 4°C for 4 h.  
The beads were separated using a magnetic rack and a series of washes followed 
by magnetic separations were performed: 1 x Wash buffer 1; 2 x Wash buffer 2; 1 x 
LiCl buffer and 2 x TE/NaCl buffer. The beads were then transferred to a fresh tube 
and elution proceeded with 50 l of Elution buffer, on shaker for 15 min at 20°C. The 
beads were magnetically separated and the eluate transferred to a fresh tube and 
the elution step repeated, and the second eluate mixed with the first one.  
To reverse the crosslink, 1 l of RNAse A (10 mg/ml) were add and samples 
incubated for 30 min at 20°C. Next, 1 l of NaCl (5M), 2 l of EDTA (0.5 M) and 1 l 
of Proteinase K (50 mg/ml) were add and the samples incubated overnight at 60°C. 
The DNA was purified using AXYPREP™ magnetic PCR clean-up kit, following the 
manufacturer’s instructions. 
Quantitative PCR for ChIP samples was performed using 2x Rotor-Gene SYBR 
Green PCR Master Mix. For each primer pair, a Master Mix was produced (1.06x 
SYBR Green PCR Master Mix; 2.5 uM Reverse primer; 2.5 uM Forward primer) and 
aliquoted (8.5 l per tube) onto QIAGEN® strip tubes and 0.5 l of the sample added 
to the master mix. Each qPCR was performed in 4 replicates, with DNA from 3 
independent experiments. The analysis was performed as published by Miller and 
Palhan (2008) and the results expressed as percentage of input. 
Propidium iodide staining 
PC3 PRH LV cells were plated in 6-well plate plates at a confluency of 1.7 x 104 
cells/cm2 with addition of 2ug/mL of doxycycline or vehicle to the media (day 0). The 
cells were incubated for 7 days, but fresh doxycycline and media was added daily, if 
the cells were close to reaching confluence they were be passaged to a bigger flask. 
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One of the wells treated with vehicle were chosen to become the positive control, 
and on day 6, high concentrations of G418 (9 mg/mL) were added to the chosen 
well, and the plate was incubated for another day. Next day (day 7), the media was 
aspirated using a vacuum pump attached to a sterile disposable Pasteur pipette and 
the wells were washed with sterile warm PBS twice (37°C). Warm PBS (37°C) was 
left in the wells and the plates were taken to an inverter epifluorescence microscope 
to acquire images. 
Image analyses 
Cell counting 
Images obtained from the propidium iodide staining were opened on ImageJ 
(Schindelin et al. 2015). Each image was obtained with the same microscope and 
camera settings; therefore, each image was considered a microscope view for the 
purpose of counting. The setting for brightness and contrast were adjusted with the 
automatic settings in ImageJ. In each image field all of the propidium iodide stained 
cells were counted for a total of 10 fields/sample. 
Morphometry 
The images from the β-actin staining were opened in FIJI/ImageJ software 
(Schindelin et al. 2015). The images were saved in a stack with each two channels in 
a separate layer. The function ‘stack to images’ was used to separate the images. 
The option ‘merge channels’ was used to create a merged coloured image of the 
cells. In the ‘set measurements’ folder, the ‘fit ellipse’ option was selected. Using the 
tool ‘free hand selection’ each cell was circled as close as possible to the edge 
delimited by β-actin. The function ‘measure’ was activated after each cell was 
circled. The results were fed into a spreadsheet with 4 columns labelled: Label, 
Major, Minor, Angle. The Major column values were divided by the Minor column 
values to obtain the L/S ratio. A total of 150 cells per slide were measured across 15 




The immunohistochemistry images were obtaining by slide scan and kindly supplied 
by Dr. Sheela Jayaraman (University of Birmingham). The file had 96 prostate 
samples with different degrees of neoplasia, ranging from benign prostate 
hyperplasia (BPH) to advanced prostate adenocarcinoma. The images were opened 
in ZEN (Zeiss 2018). First, they were scored following Gleason’s scoring system for 
prostate cancer with the description modifications made by the 2005 International 
Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading 
of Prostatic Carcinoma (table 7).  
On another occasion, the samples were randomised and blindly re-accessed to 
obtain a scoring for PRH staining. The scoring system was carried as follows: Two 
factors were considered during the staining scoring. The first was the intensity of the 
staining, there were 3 degrees of intensity considered: weak, moderate and strong. 
The weak signals were given a score 1, the moderate a score 2 and the strong a 
score 3. The second factor was the frequency of the staining that was observed. The 
frequency was given in percentage ranging from 0% to 100%. The intensity score 
was multiplied by the frequency to obtain a PRH staining factor. This procedure was 
made for both nuclear and cytoplasmic staining. The results from the two spread 





Table 2.7. 2005 ISUP Modified Gleason System 
Pattern 1:  
       Circumscribed nodule of closely packed but separate, uniform, rounded to 
oval, medium-sized acini (larger glands than pattern 3). 
Pattern 2:  
       Like pattern 1, fairly circumscribed, yet at the edge of the tumour nodule there 
may be minimal infiltration; 
       Glands are more loosely arranged and not quite as uniform as Gleason 
pattern 1. 
Pattern 3:  
       Discrete glandular units; 
       Typically, smaller glands than seen in Gleason pattern 1 or 2  
       Infiltrates in and amongst nonneoplastic prostate acini  
       Marked variation in size and shape  
       Smoothly circumscribed small cribriform nodules of tumour; 
Pattern 4:  
       Fused micro acinar glands; 
       Ill-defined glands with poorly formed glandular lumina; 
       Large cribriform glands; 
       Cribriform glands with an irregular border; 
       Hypernephromatoid (resembles renal cell carcinoma). 
Pattern 5: 
       Essentially no glandular differentiation, composed of solid sheets, cords, or 
single cells  
       Comedocarcinoma (central necrosis within involved ducts) with central 
necrosis surrounded by papillary, cribriform, or solid masses. 






Western blotting images were obtaining by scanning the radiography films (add the 
fume type). The images were opened using the ‘1D gel analysis’ tool from 
ImageQuant (GE healthcare). The lanes for analyses were made manually and all 
had the same dimensions. The ‘automatic background subtraction’ tool was used 
with the radius set to 200. The bands were detected using the ‘click and detect wand’ 
tool. The volume subtracted from the background was used in normalization steps. 
To normalise the expression of interested proteins, the volume of their bands were 
divided by the volume of the loading control bands. 
MTT 
Cells were treated as described in section 2.7.2.1.2. After treatment, the cells were 
harvested and re-plated at the confluence of 3.1 x 104 cells/cm2. They were then 
incubated in tissue culture at 37°C overnight to settle. Next morning, 10 l of 
tetrazolium Bromide (4 g/l) was added and the plate incubated for 4 hours. 
Afterwards, the media was aspirated using vacuum pump and the plate was left to 
air dry for 15 minutes. Next, 150 l of DMSO was added, the colour was measured 
using VersaMax™ microplate reader (at 540 nm and 630 nm), and the 540 nm 
absorbance was subtracted from the 630 nm absorbance. 
EdU incorporation 
Cells were treated as described in section 2.7.2.1.2. After treatment, the cells were 
harvested and re-plated at the confluence of 3.1 x 104 cells/cm2. The EdU 
incorporation and detection was carried using the Click-iT® EdU Microplate Assay 
kit, following the manufacturer’s instructions.  
Dose response 
PC3 cells were seeded at 3.4 x 104 cells/cm2 in a 96-well plate and left to recover 
overnight (day 0). Next day increasing concentrations of Doxy or G418 were added. 
The plates were incubated for 48h then10 l of tetrazolium bromide (4 g/l) was 
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added and the plate incubated for 4 hours. Afterwards, the media was aspirated 
using a vacuum pump and the plate was left to air dry for 15 minutes. Next, 150 l of 
DMSO was added, the colour was measured using VersaMax™ microplate reader 
(at 540 nm and 630 nm), and the 540 nm absorbance was subtracted from the 630 
nm absorbance. 
Statistical analysis 
All statistical analyses were made using GraphPad Prism® (GraphPad Software 
2018). For the results expressed in fold-change, the statistical analysis used a was 
one-sample t-test to compare the column mean the 1. The error bars are standard 
error of the mean (SEM). The variables were considered statistically different when 
the p value was equal to or lower than 0.05. 
For the numerical variables with normal distribution such as percentage of migration 
and optical density, a two-tailed unpaired t-test was performed. The error bars are 
SEM, and variables were considered statistically different when the p value was 
equal to or lower than 0.05. 
For the numerical variables with multiple group comparison such as percentage of 
input. Standard two-way ANOVA followed by Bonferroni post-test to compare all the 
variables to the background (E1 IgG ChIP) was used. Statistical relevance was 
accepted when the p value was equal to or lower than 0.05. 
All correlation tests were made with the Pearson’s correlation test assuming that the 
data presents a normal distribution with the p values analysed by a two-tail test. A p 
value lower than 0.05 meant that the correlation was statistically significant. The 
Pearson’s r value was used to determine how strong the correlation was. Values 
approximately between 0 and +/- 0.5 were considered a weak correlation, values 
approximately between +/- 0.3 and +/- 0.7 were considered a moderate correlation 
and values approximately between +/- 0.7 and +/- 0.99 were considered a strong 
correlation. The r2 values were used to express how much of the variability in the first 














Chapter 3: TGF-β induces partial EMT 
and increased cell migration in 






TGF-β is known to induce EMT in some cells (Massagué 2008). The aim of this 
chapter is to characterise the EMT effects of TGF-β treatment on two prostate cell 
lines (PNT2-C2 and PC3) and to examine the effects that this treatment has on the 
migratory behaviour of these cells. Setting the milestones that will be used in the 
next chapters. PNT2-C2 is a normal immortalised prostate epithelial cell line that 
displays epithelial morphology and expresses typical epithelial markers such as E-
cadherin. PC3 is a prostate adenocarcinoma cell line isolated from a prostate 
adenocarcinoma bone marrow metastasis. PC3 displays a mesenchymal 
morphology in culture and express low levels of epithelial markers like E-cadherin. 
Actin immuno-staining will be used to analyse cell morphology and images will be 
analysed using Fiji (Schindelin et al. 2015) for cell measurements. Cell migration will 
be measured with a chemotaxis assays performed in Boyden Chambers. Western 
blotting and qPCR will also be used to find molecular markers that change with TGF-
β treatment. 
Results 
Morphological characterization of TGF-β treated PNT2-C2. 
Cells morphology was assessed by observation of cellular β-actin through 
immunofluorescence microscopy. β-Actin is a component of the cell cytoskeleton, 
that can be stained by immunofluorescence to study the cell morphology. As 
described in section 2.9.2, the cells were grown on coverslips, fixed, and incubated 
with rabbit monoclonal anti-Actin antibody. The coverslips were inverted and 
mounted onto a microscope slide, and the cells photographed using a Leica Q550 
epifluorescence microscope using the same exposure time, shuttle opening and gain 
through all of the pictures (Figure 3.1). The images were then taken to FIJI/ImageJ to 
analyses and a total of 200 cells were measured. For each cell a long axis (L) and a 
short axis (S) were measured, and each L was divided by the respective S to obtain 
a ratio that correlates to cell elongation (Figure 3.2).  
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Figure 3.1 shows that TGF-β treatment induced morphological changes in ‘normal’ 
immortalised prostate epithelial cells (PNT2-C2). A statistically significant (p<0.05) 
higher number of spindle-shaped cells appeared in the TGF-β treated group, when 
compared to the vehicle treated group (figure 3.2). The TGF-β treated cells 
presented signs of stress fibre formation and disruption of cell clusters. These are 
typical features of mesenchymal cells (Nieto et al. 2016; Heldin et al. 2012; Brabletz 
et al. 2018) Thus the morphological analyses of the TGF-β treated PNT2-C2 cells 
suggests that TGF-β induces EMT-like changes in these cells. 
Figure 3.3 show stress fibres (yellow arrows) in TGF-β treated PNT2-C2 cells. Stress 
fibres are formed while the cell pulls itself away from a cell cluster disrupting the 
adhesion to neighbour cells. The comparative images with similar numbers of cells to 
the vehicle treated cells shows a compact cluster with all of the cells in maximum 
contact with their neighbouring cells. In figure 3.4 we see a busier field, but both 
treatments have a similar number of cells in the fields shown. The vehicle treated 
cells are in clusters with all the cells making full contact with its neighbour cells. The 
TGF-β treated cells do not form clusters and appear more elongated (yellow arrows) 
and only touching their neighbours focally (blue arrows). In figure 3.4 we also see 































Figure 3.1. Photomicrography of β-actin stained PNT2-C2 cells (1). Immunofluorescence staining for β-actin. 
On the left, the cells treated with Vehicle for 48 hours. On the Right, the cells treated with TGF-β for 48h. The 
pictures were taken with a Leica Q550 epifluorescence microscope equipped with a LED monochromatic light 



























Figure 3.2. PNT2-C2 L/S ratio. Cell measurements obtained with FIJI-ImageJ from images of β-actin stained 
PNT2-C2 cells. The higher the ratio the more elongated is the cell. TGF-β treatment significantly augmented 
the average L/S ratio of PNT2-C2 cells. 200 cells/coverslip were measured using Fiji. Mean±Standard 

























Figure 3.3. Photomicrography of β-Actin stained PNT2-C2 cells (2). Immunofluorescence stain for β-actin. A 
similar number of cells in each field was taken for comparison. On the left, the cells treated with vehicle for 48 
hours. On the Right, the cells treated with TGF-β for 48 hours. Yellow arrows indicate stress fibres. The pictures 
were taken with a Leica Q550 epifluorescence microscope equipped with a LED monochromatic light source on 


























Figure 3.4. Photomicrography of β-Actin stained PNT2-C2 cells (3). Immunofluorescence stain for β-actin.  
Field with a similar number of cells in each treatment were imaged for comparison. On the left, the cells treated 
with vehicle for 48 hours presented the same growth pattern observed in figure 3.3, a tight cluster with maximum 
cell to cell contact. On the Right, the cells treated with TGF-β for 48 hours. Blue arrows indicate the cells connecting 
to neighbouring cells focally. Green arrows indicate cells with elongated morphology. Yellow arrows indicate actin 
stress fibres. The pictures were taken with a Leica Q550 epifluorescence microscope equipped with a LED 




Molecular characterization of TGF-β treated PNT2-C2 and PC3 cells 
The EMT is a well-characterised phenomenon, with markers that are accepted in the 
literature as defining points, although to diagnose EMT not all of the markers need to 
be present. To assess which EMT markers were relevant to the treatment with TGF-
β in PNT2-C2, whole cell protein extracts from three independent 48h TGF-β 
treatments (as described in section 2.7.1), were tested to the presence of seven 
antibodies that recognise different EMT markers (as described in section 2.9.1) 
(figure 3.5). Equal amounts of protein were loaded into 12% acrylamide SDS-PAGE 
gels and separated by electrophoresis. The proteins were then transferred to an 
Immobilon-P membrane and probed with specific antibodies. β-Actin or Lamin A/C 
were used as loading controls.  
After 48h TGF-β incubation E-cadherin protein expression was down-regulated in 
PNT2-C2 cells when compared to the loading control β-actin. On the other hand, 
Snail protein expression was up-regulated in PNT2-C2 cells treated with TGF-β. 
Endoglin and β-catenin showed some changes in expression, but the changes were 
not consistent through repetitions of these experiments. The marker proteins 














Figure 3.5. EMT marker screening in PNT2-C2 cells. Photoradiography of seven different EMT markers 
analysed by western blot using PNT2-C2 whole cell protein extracts. On the left, protein extracted from PNT2-
C2 cells treated with vehicle. On the right, protein extracted from PNT2-C2 cells treated with TGF-β (5ng/mL) 
for 48h. The expression of each EMT marker was compared to the expression of a house keeping protein (β- 
Actin or Lamin A/C). E-cadherin expression was consistently down-regulated with the TGF-β treatment in 3 
experiments. Snail expression was up-regulated with the TGF-β treatment. The end stage marker Vimentin did 
not show a difference between the treatments, the same was observed with Slug and ZO-1 antibodies. 


















Detailed morphological and cell metric analysis was not carried with PC3 cells as this 
has transitioned through EMT, and the cells present a mesenchymal morphology 
with elongated cells and fewer EMT markers were assessed in these cells. After the 
markers were screened in PNT2-C2 cells, only the ones that showed changes in 
expression in TGF-β treated PNT2-C2 were tested with PC3 protein extracts, along 
with the end stage marker Vimentin. Endoglin showed conflicting expression 
changes through the repetitions in PNT2-C2 cells, so it was also assessed in PC3. 
Whole cell protein extracts from three independent 48h TGF-β treatments (as 
described in section 2.7.1), were tested using four different EMT marker antibodies 
(as described in section 2.9.1) (figure 3.6). Equal amounts of protein were loaded 
into 12% acrylamide SDS-PAGE gels and separated by electrophoresis. The 
proteins were transferred to an Immobilon-P membrane and probed as above. β-









  Figure 3.6. EMT marker screening in PC3. Photoradiography of four different EMT markers analysed by 
western blot using PC3 whole cell protein extracts. On the left, protein extracted from PC3 cells treated with 
vehicle. On the right, protein extracted from PC3 cells treated with TGF-β (5ng/mL) for 48h. The expression of 
each EMT marker was compared to the expression of a house keeping protein (β- Actin or Lamin A/C). TGF-β 
down-regulated E-cadherin expression consistently. Snail expression was up-regulated with the TGF-β 
treatment. The end stage marker Vimentin did not show difference between the treatments. Endoglin showed 












The EMT marker changes observed in PNT2-C2 cells were confirmed in PC3 cells. 
E-cadherin presents a low expression in this cell line, but with a longer exposure it 
was still possible to detect it by western blot. TGF-β incubation down-regulated E-
cadherin expression in PC3 cells when compared with the loading control β-actin. 
Snail expression was up-regulated in PC3 cells treated with TGF-β. Endoglin 
showed some changes in expression, but the changes were again not consistent 
through the repetitions. Expression of the end stage marker Vimentin did not change 
with the TGF-β treatment. 
To compare the EMT markers changes in PNT2 (figure 3.7) and in PC3 (figure 3.8). 
The western blots for E-cadherin and Snail were scanned and their densitometry 
analysed with ImageQuant (A and C respectively). Immunofluorescence images for 
E-cadherin staining (as explained in section 2.9.2) were made to corroborate the 
western blot findings (E), all the images were obtained with the same exposure time 
and gain. 
Densitometry of 3 independent E-cadherin western blots are in figure 3.7 A, E-
cadherin was reduced in TGF-β treated cells when compared to vehicle treatment in 
a statistically significant manner. The densitometry analysis of Snail bands showed 
that, in PNT2-C2 cells, the TGF-β treatment significantly (p<0.05) up-regulated Snail 
expression (figure 3.7 C). Representative photomicrographs of the western blots 
analysed show downregulation of E-cadherin and up-regulation of Snail compared to 
β-acting and Lamin A/C (figure 3.7 F). Western blotting for pSmad3 shows that there 
is activation of TGF-β signalling. In figure 3.7 E, representative immunofluorescence 
photomicrographs confirm that the E-cadherin protein expression is downregulated 
in the TGF-β treated PNT2-C2 cells, when compared to vehicle control. 
To assess if the regulation of E-cadherin (B) and Snail (D) happened at the 
transcriptional level, whole cell mRNA extract was use in a reverse transcription 
reaction to make cDNA that was analysed by qPCR (as explained in section 2.10.1). 
In PNT2-C2 cells (figure 3.7), TGF-β treatment significantly (p<0.05) reduced E-
cadherin mRNA levels (figure 3.7 B), and significantly (p<0.05) up-regulated Snail 
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Figure 3.7. PNT2-C2 EMT phenotype. PNT2-C2 cells were treated with Vehicle or TGF-β for 48h prior to analysis. 
E-cadherin expression was downregulated by TGF- β treatment when compared to Vehicle treatment at both the 
protein (A) and mRNA level (B). Snail was up-regulated with TGF- β treatment at the protein (C) and mRNA (D) 
level. (E) Lower E-cadherin signal on immunofluorescence stain of PNT2-C2 cells treated with TGF- β when 
compared to Vehicle. Images were obtained using a Leica Q550 epifluorescence microscope equipped with a LED 
monochromatic light source on 40x magnification and were taken with the same exposure time and gain. (F) 
Representative radiomicrography of western blots for E-cadherin, Snail, pSmad3 and housekeeping proteins. In 
column 1 are the Vehicle treated cell extracts and in column 2 the TGF- β treated cell extracts. M+SD, n=3, *p>0.05. 
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Densitometry graphs of 3 independent western blots for E-cadherin (figure 10 A) and 
Snail (figure 3.8 C), shows statistically significant (p<0.05) changes in PC3 cells. E-
cadherin expression was reduced and Snail expression up-regulated. 
Representative photomicrographs of the western blots analysed are in figure 3.8 F. 
E-cadherin expression is low to begin with in PC3 cells, but E-Cadherin can still be 
detected by western blot by using a longer exposure. With 30 minutes exposure E-
cadherin bands are visible in vehicle treatment, but TGF-β treatment further reduced 
E-cadherin expression in PC3 cells. Snail expression is upregulated when compared 
to its loading control (Lamin A/C). The pSmad3 blot demonstrate activation of TGF-β 
signalling. Representative immunofluorescence photomicrographs of E-cadherin 
protein show downregulation of E-cadherin protein expression when PC3 cells were 
treated with TGF-β. In PC3 cells (figure 3.8), TGF-β treatment also significantly 
(p<0.05) reduced E-cadherin mRNA levels (figure 3.8 B), and up-regulated Snail 
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Figure 3.8. PC3 EMT phenotype. PC3 cells were treated with vehicle or TGF-β for 48h prior to analysis. E-
cadherin expression was downregulated by TGF- β treatment when compared to Vehicle treatment in both protein 
(A) and mRNA level (B). Snail was up-regulated with TGF- β treatment at the protein (C) and mRNA (D) level. (E) 
Lower E-cadherin signal on immunofluorescence staining of PC3 cells treated with TGF- β when compared to 
vehicle. Images were obtained using a Leica Q550 epifluorescence microscope equipped with a LED 
monochromatic light source on 40x magnification and were taken with the same exposure time and gain. (F) 
Representative radiomicrography of western blots for E-cadherin, Snail, pSmad3 and housekeeping proteins. In 




TGF-β induced migration of prostate cells.. 
A characteristic of mesenchymal cells acquired by cells that undergo EMT is a higher 
migratory ability. To assess if TGF-β treated PNT2-C2 and PC3 cells acquire higher 
migratory competence, the cells were treated with TGF-β for 48h prior to performing 
chemotaxis assays in Boyden chambers. The chemotaxis assay was performed with 
addition of hydroxyurea to inhibit cell division. Hydroxyurea inhibits the enzyme 
ribonucleotide reductase decreasing the production of nucleic acids and inhibiting 
cell proliferation. This causes the cell cycle to stop and the cells cannot, for this 
experiment is important to add hydroxyurea to the media because when you 
discount the cell division factor, all the cell detected in the bottom chamber of the 
Boyden chamber arrived there by trespassing the membrane that divides the two 
chambers. The cells were counted and suspended in starvation media (as explained 
in section 2.8) before being put in the upper chamber of the Boyden chamber. The 
lower chamber was filled with complete media, and the cells were incubated for 12h, 
before being stained with Calcein-AM and trypsinised. The migrated cells were put in 
a black flat bottom 96-well plate and read using a flex station. The readings were 
fitted to a standard curve and the percentage of migrated cells obtained by dividing 
the number of migrated cells by the total amount of seeded cells. Figure 3.9 has 
graphs with the percentage of migrated cells in 3 independent experiments with 
PNT2-C2 (A) and PC3 (B) cells. 
The results show that PNT2-C2 and PC3 cells treated with TGF-β migrate more than 
the equivalent cells treated with vehicle in both cases. TGF-β treatment increased 
the number of migrated PNT2-C2 and PC3 cells in the chemotaxis assay in a 



















































Figure 3.9. TGF-β treatment induced migration. PNT2-C2 (A) and PC3 (B) cells were treated with 5ng/mL TGF-
β for 48 hours, they were then trypsin dissociated, counted and suspended in starvation media. 8x10^4 cells were 
placed in the upper chamber of a Boyden’s chamber, the bottom was filled with complete media to create a FBS 
gradient. Hydroxyurea was added to all the media used in the chemotaxis assay to inhibit cell division. TGF-β 




The initial part of this project aimed to examine the effects of TGF-β on two prostate 
cell lines. This chapter describes the screening of the EMT markers and the final 
EMT phenotype pattern shown by PNT2-C2 and PC3 cell lines following TGF-β 
treatment.  
β-actin is a component of the cytoskeleton often used in immunofluorescence 
staining to define the body shape of cells (Xiang & Rensing 1999; Ferret-Bernard et 
al. 2008; Goldman et al. 1996). Detailed manual search of the images of TGF-β or 
vehicle treated PNT2-C2 cells was performed to detect the presence of EMT 
associated morphological changes. During EMT β-actin fibres align paralleled to the 
long axis forming stress fibres (Taiyab et al. 2016), the cells loses polarity and the 
characteristic clusters formed by epithelial cells are dispersed with the loss of cell 
adhesion proteins (Moreno-Bueno et al. 2008). The β-actin immunofluorescence 
images of TGF-β treated PNT2-C2 cells showed changes in its morphology, the cells 
became more elongated and lost their polarity. In culture, epithelial cells keep 
contact with their neighbouring cells with the aid of adhesion proteins, the cells then 
form clusters that grow as extensive sheets of cells over time. The strong connection 
between adhesion proteins on the lateral surfaces of the cells keeps the epithelial 
cell polarity in place (Eurell et al. 2006). TGF-β treatment made most of the PNT2-C2 
cells grow with little contact with neighbouring cells, this indicates a loss in cell 
polarity. Further evidence of cell polarity loss is seen in a rearrangement of the 
cytoskeleton with the formation of stress fibres (Kaunas et al. 2005; Hirata et al. 
2007), here the presence of stress actin fibres was often observed in TGF-β treated 
PNT2-C2 cells.  
The phosphorylation of Smad3 is used to show activation of TGF-β signalling 
(Massagué 2012). Here pSmad3 was detected with a 5ng/mL dose of TGF-β for 48h. 
With this condition, a screening of EMT markers was conducted by western blot 
where several end-point EMT markers and EMT-TFs were assayed. The loss of E-
cadherin protein expression and up-regulation of Snail protein expression were seen 
in TGF-β treated PNT2-C2 and PC3 cells, which agrees with the EMT literature 
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available (Heldin et al. 2012; Takeyama et al. 2010; Krebs et al. 2017; Nieto et al. 
2016; Brabletz et al. 2018; Heldin et al. 2012). 
TGF-β is implicated in several human diseases including cancer (Gordon & Blobe 
2008). It is also reported as an important inducer of EMT in cancer (as reviewed by 
Heldin et al. 2012). In early stages of carcinogenesis TGF-β1 has a growth-inhibitory 
effect, yet in advanced carcinomas this grow factor loses this inhibitory effect and 
promotes cancer growth and EMT (Levy & Hill 2006). TGF-β regulation of EMT is 
well-studied and a number of transcription factors (EMT-TFs) are reported to co-
regulate each other in a complex and highly context-dependent orchestration. The 
most common reported TGF-β associated EMT-TFs are basic helix-loop-helix (Twist 
and E47), zinc finger proteins (Snail and Slug) and zinc finger and homeodomain 
proteins (ZEB1 and ZEB2) (Heldin et al. 2012). The main effect of these EMT-TFs is 
on regulation of E-cadherin expression for example. TGF-β treatment of 
differentiated mammary epithelial cells or the ectopic up-regulation of Snail or Twist 
stimulated the expression of stem markers and down regulate E-cadherin expression 
(Mani et al. 2008).Here, only Snail was up regulated with the TGF-β treatment in 
PC3 and PNT2-C2, which agrees with published reports where Snails upregulation 
was shown to trigger EMT in colon carcinoma and melanoma cells (Medici et al. 
2008). Interestingly, Snail expression is seen in untreated PNT2-C2 cells, with 
increase following TGF-β treatment. In contrast, Snail protein expression is not seen 
in untreated PC3 cell, but it is notably expressed following TGF-β treatment. 
Snail is a transcriptional repressor responsible for regulating genes involved in cell 
adhesion and is reported to be an important mediator of TGF-β related EMT 
(reviewed by Thiery et al. 2009). Its up regulation here could explain the loss of E-
Cadherin expression. As previously demonstrated, transcription factor Snail binds 
strongly to E-box of the E-Cadherin promoter, and it was demonstrated that Snail 
repression of E-Cadherin expression is enough to induce EMT (Villarejo et al. 2014). 
Finally, over-expression of Snail can induce EMT in prostate cancer cell lines 
ARCaP and LNCaP (Odero-Marah et al. 2008) and in pancreatic carcinoma (Yang et 
al. 2006). 
At the end of EMT the cells can express several mesenchymal markers (Kalluri & 
Weinberg 2009) (such as α-SMA, FSP1, vimentin and desmin). Nevertheless, full 
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EMT completion is rarely observed in cancer (Brabletz et al. 2018), so the 
expression of all of these end-stage markers is often not observed. PNT2-C2 and 
PC3 cells treated with TGF-β did not show changed in end-stage marker vimentin, 
nonetheless, it presented a considerable loss of E-Cadherin expression and an 
increase in cell motility, which indicates a loss of epithelial phenotype. Cells which 
lose surface E-cadherin expression are more susceptible to various EMT inducers, 
additionally it is well established that E-cadherin expression is lost on cells that 
undergo EMT (Heldin et al. 2012b; Brabletz et al. 2018; Gupta & Maitra 2016; Krebs 
et al. 2017; Puisieux et al. 2014). The expression of E-cadherin in vitro is directly 
correlated to the epithelial phenotype, and the simple perturbation of the E-Cadherin 
mediated tight cell-cell bond using monoclonal antibodies is enough induce a 
mesenchymal phenotype in MDCK cells (Imhof et al. 1983). In general, a negative 
correlation is observed between E-Cadherin expression and cancer grade 
(Birchmeier & Behrens 1994), which agrees with the demonstration, in several cell 
lines models, that cells with low E-cadherin expression present higher tumour growth 
and metastasis when injected in nude-mice (Thiery 2002). Interestingly, nuclear 
expression β-catenin is correlated to loss of E-cadherin protein expression (Tian et 
al. 2011), therefore, an analysis of the subcellular localization of β-catenin could 
reveal an involvement of this protein on TGF-β induced EMT in prostate cells. 
The TGF-β treatment also increased the migration of both PC3 and PNT2-C2 cells. 
Which is consistent with EMT, since cells that undergo EMT acquire higher migration 
ability (Heldin et al. 2012). It is interesting that PNT2-C2 presented a higher 
background migration when compared with PC3 cells. It was expected that PC3 
might have a higher basal migration ability (Lang et al 1999). However, the 
chemotaxis assay only detects cells that stay attached to the bottom of the Boyden 
chamber membrane, and a possible explanation is that PC3 cells detach from the 
bottom of the membrane quicker than PNT2-C2 cells and some signal was lost, 
nonetheless, a significant difference was observed between the vehicle and the 
TGF-β treatments. 
To add another layer on the complexity of EMT regulation, EMT is also promoted by 
several other stimuli that trigger the event via different pathways. However, these 
pathways often cross talk and compensate each other in a context-dependent 
manner. For example, in cultured rat lens epithelial explants the inhibition of β-
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catenin/CBP interactions decreased TGF-β-induced EMT (Taiyab et al. 2016). In 
endothelial cells, Notch1, Notch4 and TGF-β synergistically up regulate Snail during 
the EMT to forms the cardiac cushion morphogenesis (Niessen et al. 2008). In sight 
of the complexity of the cellular signalling that regulates EMT, more contextual 
knowledge is needed before they can be helpful in the cancer treatment. The 
following chapters will evaluate PRH, a novel EMT-TF that communicates with the 
TGF-β pathway, analysing it importance in clinical prostate cancer, its effects on 














Chapter 4: PRH represses EMT and 






PRH/HHEX is a homeodomain protein which act as transcription factor and regulates 
the proliferation and differentiation of multiple cell types. Disruption of PRH activity is 
associated with a variety of cancers including breast cancer, thyroid cancer and liver 
cancer (reviewed by  (Gaston et al. 2016)). PRH/HHEX knock-down can trigger 
downregulation of E-cadherin and mRNA protein in PNT2-C2 cells, and its 
overexpression reduced cell migration in prostate cancer cells (Siddiqui et al. 2017). 
PRH regulates the TGF-β pathway through the regulation of Endoglin (Kershaw et al. 
2014b), a TGF-β co-receptor that reduces TGF-β subcellular signalling. Hence the 
need for a more detailed evaluation of the role of PRH in EMT during prostate cancer 
development. 
The aims of this chapter are to investigate the expression of PRH in prostate cancer 
samples and to examine the relationship between PRH and EMT in prostate cancer 
cells. In this chapter I use online databases to assess the expression of PRH in 
prostate tumours from patients. I will examine the correlation between PRH 
expression and prostate adenocarcinoma differentiation through 
immunohistochemistry staining of a large number of prostate tumour samples. 
Furthermore, I will use microarrays to find possible PRH targets genes and further 
test some of those targets using western blotting, qRT-PCR and ChIP-qPCR. 
Results 
The PRH gene is altered in prostate adenocarcinoma 
To examine the relevance of PRH to prostate adenocarcinoma in more detail, two 
online cancer sequencing databases were used to generate statistics on PRH. 
cBioportal was used to analyse PRH gene alterations in prostate adenocarcinomas. 
Data from four different studies were analysed giving a total of 1627 patients (figure 
4.1). PRH was altered in 5% of the prostate samples sequenced (figure 4.1 A). The 
majority of alterations were deep deletions of the gene. The studies presented 
percentages of alterations, the highest percentage of alterations was observed in the 
study ‘Prostate (MICH)’, which detected alterations in 10% of their samples, 8% of 
117 
 
them being deep deletions of the gene (Figure 4.1 B). The difference in percentage 
observed in the different studies is probably due to different numbers of samples. 
Figure 4.1 C, D and E shows the samples for the 4 studies that presented PRH deep 
deletion. In C the samples were grouped based on whether patients received ADT 
treatment prior to the sample collection or not. 40% of the samples that presented 
PRH deep deletion came from patients that did not receiver ADT. In D samples that 
presented PRH deep deletion were grouped on co-alterations in the PTEN gene. 
66% of the sample that presented PRH deletion also presented alterations in PTEN. 
Finally, E shows frequency of each Gleason’s score observed in samples that 
presented PRH deep deletion. Most of the samples presented Gleason’s score 





Figure 4.1. PRH alterations in prostate adenocarcinoma. Data obtained from cBioportal. Compiling data 
from four different studies with a total of 1627 sequenced cases. (A) each bar represents a patient, 5% of the 
patients presented alterations in PRH, the majority of alterations were deep deletions. (B) shows a bar graph 
with the detailed results for each study. The highest incidence of PRH deep deletion was just over 8%, and the 
lowest was about 3%. (C) The table shows the stratification of prostate tumours that presented PRH deletion. 
Samples were grouped based on whether patients received ADT treatment prior to the sample collection or 
not. (D) The table shows the number of prostate tumours that presented PRH deletion and PTEN alterations 
in the same sample. (E) The table shows the frequency of each Gleason score on the samples that presented 
PRH deletion on cBioportal. 
118 
 
cBioportal was also used to analyse the disease-free survival rate of patients with 
prostate adenocarcinoma after their surgical treatment, comparing the rates for 
patients with HHEX alterations to patients that did not present them (Figure 4.2). The 
survival curves were not statistically significance, however, there is a trend for higher 








Figure 4.2. Disease-free survival of patients with prostate adenocarcinoma. Data obtained from 
cBioportal. Compiling data from four different studies with a total of 1627 sequenced cases. Kaplan-Meier plot 
was traced for the patients with and without HHEX alterations. 
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CpG methylation of the PRH gene 
Gene expression can be silenced by CpG methylation and this process is known to 
be important in the down-regulation of tumour suppressor genes in multiple cancer 
types including the RB gene in Retinoblastoma (Greger et al. 1989) and p16/CDKN2 
gene in bladder (Gonzalez-Zulueta et al. 1995), breast, prostate, renal, and colon 
cancers (Herman et al. 1995). MethHC database was used to compare PRH gene 
methylation in prostate adenocarcinoma with normal prostate samples. The 
database also provides a correlation of methylation in the PRH gene body with PRH 
mRNA expression in prostate samples (figure 4.3). Methylation in the PRH gene 
body was correlated with low PRH mRNA expression levels. A moderate correlation 
(R= -0.389) between the two variables was observed (figure 4.3 A). Meanwhile the 
β-value, which is the average ratio of methylated: unmethylated amplification signal, 
in prostate tumour samples was higher than in normal samples (figure 4.3 B) 
(p<0.005). The majority of tumour samples presented β-values higher then 0.6, this 
indicates that at least 60% of the CpG sites in the sample were methylated. Thus 
there is increased CpG methylation of the PRH gene in the prostate cancer samples 






Figure 4.3. PRH gene is methylated in prostate adenocarcinoma. Data obtained from MethHC. (A) 
correlation between PRH gene body methylation and PRH expression detected by RNAseq. A moderate 
negative correlation was found between the two variables. (B) Graph showing a comparison of methylation β-
values between tumour samples and normal samples. Prostate tumour samples presented statistically higher 
methylation in the PRH gene body when compared to normal prostate samples. 
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PRH expression in prostate cancer. 
To assess PRH protein expression in prostate adenocarcinoma 96 prostate 
adenocarcinoma samples obtained from needle biopsies from Abcam were stained 
by immunohistochemistry for total PRH using M6 antibody. After a histology grading 
training session with the pathologist, each sample was initially scored using 
Gleason’s scoring system (see section 2.11.3) to determine the differentiation 
degree of the glands in the histological view, and separately, they were blindly 
analysed to assess PRH immunostaining intensity and frequency of staining in the 
nucleus and cytoplasm. The numbers from the two analyses were compiled in a 
scatter plot and Pearson’s correlation test was used to determine whether there is a 











Figure 4.4. Gleason's grade is negatively correlated to cytoplasmic PRH expression in prostate 
adenocarcinomas. 96 specimens from patients with various degrees of prostate neoplasia, from benign prostatic 
hyperplasia to prostate adenocarcinoma were stained for PRH and scored for correlation analysis. (A) shows the 
correlation between cytoplasmic PRH immunostaining with Gleason’s score. The correlation method used was 
Pearson’s correlation with assumption that the data distributes as a Gaussian curve. The ‘R’ value found indicates 
a strong negative correlation, with the Gleason’s score explaining 59.51% of the variability in PRH expression. (B) 
on the left is ‘scene 50’ the sample presented a good number of normal glands with some areas where there was 
more stroma space within the glands. The PRH staining is moderately strong and highly frequent in this specimen 
epithelium’s cytoplasm. Nuclear staining, besides being strong, was not as frequent. On the right is ‘scene 40’, 
presented a large area of compact glans with marginal infiltration and an area with poor distinction between 











Figure 4.5. Gleason's grade is negatively correlated to nuclear PRH expression in prostate 
adenocarcinomas. 96 specimens from patients with various degrees of prostate neoplasia, from benign prostatic 
hyperplasia to prostate adenocarcinoma were stained for PRH and scored for correlation analysis. (A) shows the 
correlation between nuclear PRH immunostaining with Gleason’s score. The correlation method used was 
Pearson’s correlation with assumption that the data distributes as a Gaussian curve. The ‘R’ value found indicates 
a moderate negative correlation, with the Gleason’s score explaining 47.04% of the variability in PRH expression. 
(B) on the left is ‘scene 65’, the sample presented large areas of glands with enlarged stroma and several normal 
glands. The PRH staining is assigned strong and highly frequent in the nuclei of epithelial cells. Cytoplasmic strain 
was similarly frequent with a moderate intensity. On the right is ‘scene 70’, this showed large areas of 
indistinguishable cell mass and no clear glandular formation. Its nuclear PRH staining was weak and in low 
frequency, while a considerable number of cells have a moderate PRH expression in the cytoplasm. 
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The fitted data comparing cytoplasmic PRH stain with Gleason’s score shows a 
strong negative correlation between these two variables as the Pearson’s R= -0.771. 
This means that 59.51% of the variance in cytoplasm PRH staining was explained by 
the Gleason’s score. The representative photomicrography (Figure 4.4 B) of a 
benign prostate hyperplasia (on the left) stained for PRH, is a picture cropped from 
‘scene 50’ of the microscope scan. The specimen had mainly hyperplastic glands 
with more stroma space and occasional normal glands, being graded 1 for both, 
main finds and secondary finds, giving the sample a total score of 2 on the Gleason’s 
scoring system. The same sample was scored for PRH staining in the cytoplasm and 
nucleus. The PRH staining scoring took into account intensity and frequency of the 
prostate epithelium coloration. The specimen in scene 50 (Figure 4.4 B left) shows a 
moderate cytoplasmic colour (intensity 2) with 90% of the epithelium, being scored a 
stain factor of 180 (as in 2x90). 
Figure 4.4 B right, shows a representative photomicrography of a prostate 
adenocarcinoma scored 4, cropped from ‘scene 40’ of the tissue array scan. The 
largest area of the tumour showed infiltration of gland cells (grade 3), while the 
second bigger distinctive area of the tumour showed poor distinction of gland with 
irregular masses of tumorigenic tissue (grade 4). The cytoplasmic stain for PRH was 
weak (intensity 1) and not frequent (observed in 5% of the epithelial cells), giving a 
total stain score of 5. 
Figure 4.5 shows a similar result, the correlation between differentiation degree of 
the gland (i.e. Gleason’s score) and the nuclear PRH staining was negative 
moderate. The scatterplot of Gleason’s score versus PRH nuclear staining in 
patient’s prostates samples showed R=-0.6834, therefore, Gleason’s score 
explained 47.04% of the variance in PRH staining. Figure 4.5 B shows 
photomicrographs of two of those specimens used on the analysis. On the left, a 
cropped area from ‘scene 65’, the sample was score 2 in total regarding the 
Gleason’s scoring system, due to a large area with hyperplasic stroma and the 
presence of normal looking glands (Grade 1). Nuclear PRH staining was considered 
strong (intensity 3) and highly frequent (90% of the epithelium nuclei) in this sample 
(total colour score 270). On the right, there is a cropped area from ‘scene 70’. The 
sample in scene 70 shows a large area of poor differentiation with indistinguishable 
epithelium (grade 5), on a marginal area another in indistinguishable mass of cells 
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presented a glandular structure (grade 4), this sample was given a Gleason’s score 
9. Although there was some staining for PRH in this sample, it was not frequent. 
Some few cells (10%) retained a high intensity (intensity 3) PRH stain in the nucleus, 
giving a total colour score of 30. These results show that PRH is more frequently 




Microarray analysis shows that PRH regulates TGF-β signalling 
genes. 
Aiming to unveil PRH targets in prostate cell lines I took a genome-wide approach 
using microarrays. The microarray data was kindly provided by Dr Rachel Kershaw 
and Dr Sheela Jayaraman (University of Birmingham). The data were extracted from 
PNT2-C2 cells infected with either an adenovirus containing myc-PRH downstream 
of the CMV promoter (Soufi et al. 2006) or the control empty virus. mRNA from 3 
different experiments were taken and used in a microarray assay. A total of 6094 
genes were significantly up-regulated and 2373 genes down-regulated between PRH 
over-expressing cells and the control cells (fold change >1.5). Gene ontology was 
then performed using Gene Set Enrichment Analysis (for genes with FDR adjusted 
p>0.01) using the Hallmark gene sets. Figure 4.6 shows the significantly enriched 
gene sets. Figure 4.7 shows a heat map with data from the three PNT2-C2 Myc-PRH 
expressing and empty virus controls for the TGF-β gene cluster. 
TGF-β was detected by the gene ontology as a gene group significantly (p<0.01) 
altered by the Myc-PRH expressing virus. In the TGF-β gene cluster TGFB2 (x0.36) 
and TGFBR2 (x0.34) were down regulated. On the other hand SMAD6 (x2.56), ENG 

















Figure 4.6. PNT2-C2 PRH overexpression gene ontology. The gene sets with the most significant 
alterations were genes involved in EMT and Estrogen response. Other significantly altered gene sets 
includes p53 pathway and TGF-β signalling. 















Figure 4.7. TGF-β signalling altered genes in PNT2-C2 PRH overexpression microarray. The numbers 
used in the heat map are the relative expression of each gene detected by micro array. The mRNA extracted 
from PNT2-C2 PRH overexpression (OE) or empty virus control (EV) were used in the microarray to detect 
gene expression alteration in an unbiased fashion. The heat map shows the main TGF-β signalling altered 




PRH ChIP sequencing 
Using the same adenovirus (Soufi et al. 2006), a colleague performed a ChIPseq 
analysis and allowed me to analyse the myc-PRH trace sequence aligned to the 
whole human genome. I analysed peaks near the TGF-β genes detected by 
microarray. Figure 4.8 shows ChIP-seq traces aligned with a portion of the human 
genome (Human Feb. 2009 (GRCh37/hg19) Assembly) in the UCSC Genome 
Browser. The upper represents accumulation of H3K27Ac and was provided by 
UCSC Genome Browser. H3K27Ac is a marker is often found in active regulatory 
sites. The bottom trace shows IgG ChIP representing the background. The four 
genes observed in the images were chosen because they are important to the TGF-β 
signalling and they were among the biggest alterations in the TGF-β family altered 
genes in the microarray screening. The genome region aligned with the ChIP peaks 













































































Figure 4.8. ChIP sequencing trace. The ChIP-seq trace was aligned with whole human genome version ‘Human Feb. 2009 (GRCh37/hg19) Assembly’ using UCSC Genome 
Browser. In each picture the H3K27Ac marker (upper trace) was provided by UCSC Genome Browser. The yellow arrows show the peaks from where the DNA sequence was 
used to design the PCR primers. (A) CDH1 gene had two relatively small equidistant peaks, the sequences of the regions were used to design the PCR primers. The first peak 
is located on the promoter region of CDH1, and the second at an equidistant region in the first intron. Both peaks were in regions where H3K27Ac marker was present. (B) 
TGFB2 gene showed several high peaks, the highest one was chosen as region of interest. The region had H3K27Ac marker and is located in the second intron. (C) TGFBR2 
gene showed a peak at the promoter region, the peak also aligned with the presence of H3K27Ac marker. (D) TGFBR1 gene showed a peak in the third intron, the peak was not 
aligned with H3K27Ac markers. ChIP-seq was performend by Dr Philip Kitchen at University of Birmingham. 
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PRH seems to be an important regulator of TGF-β signalling since TGF-β signalling 
genes were alerted in microarray. One of the more dramatic alterations was 
observed in the genes TGFB2 and TGFBR2. The myc-PRH ChIP-seq traces showed 













PRH overexpression downregulates TGF-β genes and upregulates 
E-cadherin gene expression 
To confirm that multiple TGF-β signalling genes are regulated by PRH, I 
overexpressed PRH in PC3 cells. The choice of an adenovirus vector containing 
myc-PRH downstream of the CMV promoter (Soufi et al. 2006), was made based on 
the high efficiently of infection with this method. The cells were infected with the myc-
PRH (PRH) or empty virus (ΔE1) and left to grow for 48h post infection (as explained 
in section 2.7.2.1.1). mRNA extracts were used in qPCR (Figure 4.9), for the genes 
flagged in the microarray analysis (TGFB2 and TGFBR2). HHEX qPCR was used to 
show successful over-expression of PRH and CDH1 (E-cadherin) was used as an 
epithelial marker. The same infection protocol was used to extract cross-linked cell 
nuclei and they were used in a ChIP-qPCR assay (figure 4.10), to confirm if PRH 
binds to the genes flagged (CDH1, TGFB2, TGFBR1 and TGFBR2). PC3 cells were 
infected with E1 or PRH virus, cross-linked and the nuclei were extracted. The DNA 
was shredded and ChIPed using either Myc-tag or normal rabbit IGG antibody. The 
purified DNA was used in qPCR detection. Primers were produced to amplify regions 


























qRT-PCR shows the mRNA levels of the TGF-β signalling genes tested, TGFB2 and 
TGFBR2 were downregulated (p<0.05) in the PRH group when compared to the ΔE1 
group. HHEX upregulation (p<0.05) was used to show successful over-expression of 
PRH. CDH1 (E-cadherin) was used as an epithelial marker and was found to be up-
regulated with PRH expression when compared to E1. 
In the ChIP-qPCR, two primers were used to detect E-cadherin gene (CDH1) one 
probing the region - 4500bp and the other to the + 4500bp of the gene, a 3-fold 
Figure 4.9. PRH regulates epithelial marker gene CDH1 and TGF-β signalling genes. Two adenoviruses 
were used to infect PC3 cells. ΔE1= empty virus control, PRH= wild type myc-tagged PRH. qRT-PCR of the 
mRNA extracted from the infected cells. HHEX was used to show successful over-expression. CDH1 was up-
regulated in PRH when compared to ΔE1. TGFB2 and TGFBR2 were both downregulated. No detectable 
quantities of TGFBR1 were found. Statistical analysis: one-sample t test with hypothetical value 1. *different 


























































































Figure 4.10. PRH regulates EMT/MET genes and TGF-β signalling genes. Two adviruses were used to 
infect PC3 cells. ΔE1= empty virus control, PRH= wild type myc-tagged PRH. Myc-tag ChIP-qPCR of PC3. 
Myc-PRH bind to E-cadherin gene (CDH1) in the regions -4500bp (3-fold increase) and +4500bp (6-fold 
increase). It also binds to +54000bp region of the gene TGFB2 (5-fold increase), -11000bp region of the gene 
TGFBR2 (3-fold increase) and +30000bp region of the gene TGFBR1 (5-fold increase). Statistical analysis: 




increased binding of myc-PRH above the background was found in the - 4500bp 
region and a 6-fold increase in the + 4500bp region. The + 54000bp region of 
TGFB2 presented a 5-fold PRH binding increase above the background. In the 
TGFBR2 gene the primers detected the region - 11000bp, and showed a 3-fold 
above the background PRH binding. The + 30000bp region of TGFBR1 presented a 
5-fold increase in the Myc-PRH (Myc-tag ChIP). These findings suggest that PRH 
overexpression can trigger partial MET in PC3 cells rescuing the epithelial status of 
these cells by directly regulating the expression of E-cadherin while downregulating 
the expression of TGF-β signalling genes. 
To test whether PRH also interfered with the migration of PC3 cells I performed a 
chemotaxis assay using Boyden chambers. Initially, the adenovirus carrying PRH 
overexpression (PRH) plasmids or empty vectors (ΔE1) plasmids were used to infect 
the cells and analyse the effects of PRH on cell migration. Unfortunately, the virus 
infection itself interfered with the cell migration (figure 4.11 A): the E1 virus reduced 
cell migration as much as the PRH overexpression virus. Nonetheless, we still 
observed an apparent morphological change in the PRH overexpression adenovirus 
infected cells, which was not observed in the empty virus treated cells. As seen in 
figure 4.11 B, the PRH adeno-virus infected cells showed smaller surface coverage, 
and the cells looked more rounded. To avoid this viral effect on migration, a plasmid 
transfection using lipofectamine was used to evaluate the effect of PRH expression 
on PC3 cell migration. The transfection efficiency was relatively low, so PRH plasmid 
was co-transfected with a plasmid expressing GFP, and GFP alone was used as a 
control. From the migrated cells only green ones, the cells expressing GFP, were 
considered. Figure 4.11 C shows that PRH overexpression significantly (p<0.05) 





















The use of adenovirus provided a good PRH overexpression in a high percentage of 
the cells, therefore, although not being useful in migration assays, it produced an 
excellent model to study the molecular alterations caused by PRH overexpression. 
Four different adenoviruses were used to infect PC3 cells. The same ΔE1 was used 
as an empty virus control, and PRH virus to express myc-tagged wild type PRH. 
However, two other myc-tagged PRH viruses containing mutations were also used, 
PRHCC is a myc-PRH with mutations that prevent phosphorylation by CK2 and 
PRHM1 is a myc-PRH mutant that cannot bind to DNA (Soufi et al 2006). A no viral 
infection control was used as a comparison (figure 4.12). Following infection, the 
cells in each group were divided in two, half of the cells were treated with TGF-β and 
the other half treated with vehicle for 48h. As shown in figure 4.11 whole protein 
extracts from these treatments were used in western blot analysis (as explained in 
section 2.9.1). To assess successful overexpression of the PRH and its variants, a 
myc-tag western blot was performed. To assess epithelial status of the cells, the 
Figure 4.11. The effects of PRH overexpression on cell migration. (A) PRH over expression in PC3 cells using 
adenovirus, the viral infection showed interference with the cell migration and proved itself unsuitable for this 
analysis. (B) Photomicrography of PC3 cells infected with no virus (NV), empty virus (E1) or PRH virus. PRH 
virus infected cells showed reduced surface coverage at this time point and altered morphology when compared 
to NV and E1 controls. (C) Migration assay to analyse the effect of PRH overexpression on PC3 cell migration 
using lipofectamine transfection. PRH was co-transfected with GFP and GFP alone used as the control. PRH 
transfected group showed a reduced number GFP expressing migrated cells when compared to GFP only group. 
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epithelial marker E-cadherin was evaluated by western blot using a low exposure 












The PRH wildtype group showed a significantly (p<0.05) stronger E-cadherin 
expression when treated with vehicle. TGF-β treatment significantly (p<0.05) 
reduced the expression of E-cadherin in the presence of PRH overexpression. 
PRHCC also showed a significant (P<0.05) upregulation in E-Cadherin expression, 
although the band was less intense than the PRH band. TGF-β treatment rescued 
the low expression status of E-Cadherin but the reduction was not statistically 
significantly. None of the other treatments showed E-cadherin expression in short 
exposure times. I conclude that PRH up-regulates E-Cadherin in PC3 cells inducing 
a partial MET. TGF treatment blocks the up-regulation of E-Cadherin by PRH, 
despite the fact that PRH expression is not driven by the PRH promoter in this 
experiment. This suggests that TGF treatment reduces PRH mRNA levels or 
otherwise blocks PRH action without regulating the activity of the PRH promoter. 
  
Figure 4.12. PRH induces MET in PC3 cells. Different adenoviruses were used to infect PC3 cells. NV= no 
virus control, ΔE1= empty virus control, PRH= wild type myc-tagged PRH, PRHCC= myc-tagged PRH mutant 
that cannot be phosphorylated and PRHM1= myc-tagged PRH mutant that cannot bind to DNA, T= TGF-β 
treated and V=vehicle treated (V). (A) Representative western blot images. E-cadherin, β-actin, Lamin A/C and 
Myc-tag with different virus infections and TGF-β or vehicle treatment. (B) PRH expression increased E-
cadherin expression and the TGF-β treatment abolished the effect of PRH on E-cadherin. Densitometry of 
three independents short-exposure E-cadherin western blot, bands normalised to β-actin. E-cadherin up-
regulation was observed in PRH and PRHCC groups, TGF-β treatment partially rescued PRH effect on E-
cadherin in both treatments. No other treatment increased E-cadherin expression. Statistical analysis: one-
sample t test with hypothetical value 1. *different from NV V with p<0.05 #different from PRH V with p<0.05.  
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Inducible PRH overexpression in PC3 cells 
The results described thus far in this chapter suggest that PRH regulates the 
expression of multiple TGF-β signalling multiple genes and that PRH overexpression 
represses cell migration. However the adenovirus infection interfere with cell 
migration. Stable cell line models are important in the study of gene function in 
mammalian cells, as they are genetically homogeneous in culture, and because the 
DNA is integrated into the genome of the cells and, even subsequent generations 
will carry the transgene. Here I describe the creation of a doxycycline inducible PRH 
overexpression system based on the PC3 cell line. The model will offer the 
opportunity to study the effects of PRH on proliferation over a longer time in a 
system where all of the cells will carry the PRH gene. This system could enhance the 
reproducibility of PRH overexpression. Moreover, the use of a second 
overexpression system will confirm that the results obtained using the adenoviral 
expression system are robust and reliable. 
Cell line production and doxycycline dose response 
To create a doxycycline inducible PRH overexpression stable cell line, PC3 cells 
were transduced with lentivirus particles carrying a myc-tagged PRH cDNA 
downstream of a doxycycline inducible promoter (as described in section 2.4.2). The 
lentivirus also carries constitutively expressed genes to conferred gentamicin 
resistance and GFP expression to the transduced cells. The antibiotic resistance is 
important to select the transduced cells. The GFP tag will allow the observation of 
the cells using a fluorescence microscope. Figure 4.13 shows images of the 
transduced cells before and after selection. 
The initial incubation with the lentiviral particles transduced approximately 50% of the 
PC3 cells. The selection with G148 killed all of the uninfected cells, while the other 
ones proliferated, resulting in approximately 100% of the cells in the well expressing 
GFP. The cells were named PC3 PRH LV and expanded still in selection media for 
another two passages. When the number of cells was sufficient in number to keep 
stocks and conduct experiments, the cell stocks were frozen in freezing media and 
kept in liquid nitrogen until needed. 
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Is important to mention that the PC3 PRH LV cell line is polyclonal. Alternatively, a 
stable cell line can be made by selecting clones that efficiently express the inserted 
gene and by growing the cell line from a single starter cell. Both methods have merit 
but the choice to use a polyclonal lineage was made to account for the 
heterogenicity observed in prostate tumours. Additionally, polyclonal cell lines 








Figure 4.13. Establishment of a PC3 PRH overexpression cell line. Constitutively expressed 
GFP showed successful transduction of the vector carrying the inducible PRH overexpressing 
lentivirus. Photomicrography taken in a Leica DMI 6000 B microscope shows an approximate rate 
of 50% GFP expressing cells. The lentivirus particle used also carry a constitutively resistance to 
gentamicin, the section ‘After selection’ shows pictures of PC3 with PRH lentivirus after being 




To assess the doxycycline dose to be used in the PRH overexpression analysis, a 
doxycycline dose-response experiment was performed. The PC3 PRH LV cells were 
seeded in 6 well plates and treated with vehicle or various doses of doxycycline (as 
explained in section 2.7.2.1.2). After seven days of treatment, whole cell protein 
extract was used in a myc-tag western blot to examine overexpression of myc-PRH 
(Figure 4.14). Although there was a variation in lower doses, PRH overexpression 
behaved in a dose-dependent fashion, in that, the highest doxycycline dose (1.5 
ug/mL) showed the most intense myc-tag band. Photomicrographs were also taken 
to analyse the cell morphology and confluence changes caused by the treatment 








Figure 4.14. Doxycycline induced Myc-PRH expression in PC3 PRH LV. Western blot image of 
PC3 PRH LV cells treated with vehicle or increasing doses of doxycycline. Myc-tag western showed 














Figure 4.15. Doxycycline reduced PC3 PRH LV confluence. Photomicrography taken in a Leica 
DMI 6000 B microscope. Equal amounts of cells were seeded in 6-well plates and treated with 
different amounts of doxycycline or vehicle for seven days. An apparent increase in the frequency 
of rounded cells was also observed in all the doxycycline doses from 1.2 ug/mL and higher. 
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Doxycycline treatment reduced the PC3 PRH LV cell confluence in a dose-
dependent fashion; the cell confluence went from approximately 100% in vehicle to 
approximately 90% in 0.3 ug/mL doxycycline, 50% in 1.2 and 1.5 ug/mL doxycycline 
confluence was between 50% and 40% (Figure 4.15). This finding suggests that the 
cell proliferation was reduced with the doxycycline treatment. Furthermore, the 
treatment seemed to reduce the presence of elongated cells in a dose-dependent 
manner. Although the appropriate cell measurements were not made, observations 
suggested that doxycycline treatment presented a higher frequency of rounded cells, 
clearly observed in figure 4.15 (0.6, 0.9, 1.2 and 1.5 ug/mL doxycycline). 
Figure 4.16 A shows an MTT assay performed in PC3 cells to assess toxicity of 
Doxycycline to PC3 cells. To assess the effects of PRH overexpression on cell 
viability, the cells were treated with either vehicle or increasing doses of doxycycline 
for seven days. On the seventh day, MTT assays were performed as explained in 
section 2.12 (figure 4.16 B). Concomitantly, cells were seeded in a 6-well plate and 
treated with vehicle or doxycycline 1.5 ug/mL. Over eighteen days, cells were 
trypsinised, counted and reseeded in a known dilution every 2 days. The total 
number of cells on each day was determined and normalised to the dilution factor. 
The results were plotted in a growth curve graph (figure 4.16 C). To evaluate if the 
cells were dividing slower, cells were treated with doxycycline 1.5 ug/mL or vehicle, 
and on the seventh day, cells were trypsinised, seeded in equal numbers in a 96 well 
plate and left to recover overnight. An EdU incorporation assay was then performed 
to determine the number of cells transitioning through S-phase (as explained in 






















The MTT assay showed that doxycycline only induced statistically significant 
changes in the number of viable cells at doses higher than 7 ug/mL, however, dosed 
higher than 1 ug/mL, reduced the number of viable PC3 PRH LV cells after seven 
days of treatment. The growth curve showed that PC3 PRH LV cells treated with 
doxycycline (1.5 ug/mL) reduced the proliferation rate observed (p<0.05). Cell growth 
was observed for eighteen days, but the trend observed indicates a widening in the 
difference between the vehicle treated cell proliferation curve and the doxycycline 
treated PC3 PRH LV cell proliferation curve. EdU is incorporated into the DNA of 
dividing cells, making its measurement a reflection of the cell division rate. The data 
show a reduced EdU incorporation in doxycycline treated PC3 PRH LV cells when 
compared to vehicle treatment (p<0.05). Thus, the low number in the doxycycline 
treated PC3 PRH LV cells observed is likely due to a reduced cell division rate. 
Figure 4.16. Doxycycline reduced PC3 PRH LV cell growth. (A) The graph shows the average 
formazan salt formation measured using a spectrophotometer (viability assay) in doxycycline and 
vehicle treated cells with 8 technical replicates. Statistical analysis: One-way ANOVA followed by 
Bonferroni post-test, p<0.05. (B) The graph shows viability assay in PC3 PRH LV cells treated with 
vehicle or increasing doses of doxycycline. (C) The graph shows total number of PC3 PRH LV cells 
in several time points over eighteen days, doxycycline (1.5 ug/mL) or vehicle. Statistical analyses: 
two-way ANOVA with Bonferroni post-test to compare the treatments in each time point, p<0.05. 
(D) The graph shows EdU incorporation in PC3 PRH LV cells treated with 1.5 ug/mL of doxycycline 
or vehicle for seven days. The incorporated EdU was measured by colorimetric assay using 
spectrophotometer. Statistical analysis: two tailed unpaired t-test, p<0.05 
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The reduction in cell number could also be a result of increased cell death caused by 
antibiotic toxicity. To assess if the doxycycline treatment is toxic and killing the PC3 
PRH LV cells, I performed propidium iodide staining. Propidium iodide is a 
fluorescent DNA intercalating dye that cannot cross the cell membrane, and it is 
useful to stain dead cells. Three conditions were used: as a positive control, an 
excessive dose of the antibiotic G148 (9 mg/mL), as a negative control doxycycline 


























Doxycycline treatment is not toxic to the PC3 PRH LV cells since no propidium 
iodide stained cells were present in doxycycline treated cells. The positive control 
presented an average of 15 propidium iodide stained cells per counted field from a 
total of 10 fields (n=1). 
  
Figure 4.17. 1.5 ug/mL of Doxycycline does not kill PC3 PRH LV cells. Photomicrography taken 
in a Leica DMI 6000 B microscope shows PC3 PRH LV cells treated with 1.5 ug/mL of doxycycline 
for 7 days do not stain with propidium iodide. The positive control presented an average of 15 
cells/field stained with propidium iodide. 
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PC3 PRH LV characterisation 
To assess whether doxycycline treatment would affect the migration of PC3 PRH LV 
cells, the cells were treated with vehicle or increasing doses doxycycline for 7 days 
before being used in a chemotaxis assay (as explained in section 2.8) (figure 4.18 
A). Only one repetition of this migration dose-response was made, but migration in 
PC3 PRH LV cell is reduced in a dose-dependent fashion. Therefore, the most 
efficient migration inhibition, observed with 1.5 ug/mL of doxycycline was chosen to 
confirm the effects on migration. To confirm reproducibility, cells in three 
independent experiments were treated with 1.5 ug/mL of doxycycline or vehicle, 
these cells were used in chemotaxis assays (figure 4.18 B). Doxycycline 1.5 ug/mL 
significantly reduced PC3 PRH LV cell migration when compared to vehicle 
treatment (p<0.05), Hydroxyurea was used in all of the chemotaxis assays to inhibit 
cellular proliferation. 
A reduced migration ability is a characteristic of epithelial cells in comparison to 
mesenchymal cells. Earlier I showed that transient PRH overexpression reduced cell 
migration and recovered an epithelial phenotype in PC3 cells. Therefore, the 
reduced in migration observed here could be a reflection of reactivation of epithelial 
phenotype in doxycycline treated PC3 PRH LV cells. To evaluate cell morphology 
changes, the cells were treated with doxycycline or vehicle for seven days. 
Microscope photographs were used to analyse cell morphology (figure 4.18 C). The 
cells treated with 1.5 ug/mL of doxycycline presented an apparent lower frequency of 
elongated cells. Detailed manual observation of the cell morphology revealed the 
existence of cell arrangements in clusters, characteristic of epithelial cells, in 
doxycycline treated PC3 PRH LV cells. An example of doxycycline treated PC3 PRH 






















The reduction in migration plus the morphology changes showed by microscope 
observation indicates a possible reactivation of an epithelial phenotype in PC3 PRH 
LV cells. However, epithelial marker protein expression is the best way to 
demonstrate epithelial phenotype. To assess if the PRH overexpression induced by 
doxycycline in PC3 PRH LV cells can recover an epithelial phenotype, the cells were 
treated with doxycycline or vehicle for seven days. Whole cell mRNA extract was 
then used in qRT-PCR (as explained in section 2.10.1) to measure the expression 
levels of epithelial markers and TGF-β signalling genes, HHEX qRT-PCR was used 
to confirm PRH mRNA overexpression (figure 4.19 A). Doxycycline induced PRH 
Figure 4.18. Doxycycline reduces PC3 PRH LV cell migration in chemotaxis assays. (A) The 
graph shows the percentage of migrated PC3 PRH LV cells (18h) after treatment with vehicle or 
increasing doses of doxycycline (n=1) for 7 days. (B) The graph shows the percentage of migrated 
cells in 3 independent experiments where PC3 PRH LV cells were treated with vehicle or 1.5 ug/mL 
of doxycycline for 7 days. Statistical analyses: two tailed unpaired t-test, p<0.05. (C) 
Photomicrographs of PC3 PRH LV in culture treated with vehicle or 1.5 ug/mL of doxycycline for 7 
days. Doxycycline treated cells showed an apparent lower average of elongated cells and some 
cases where the cells grew in clusters (characteristic of epithelial cells) were observed, as seen in 
the picture of the doxycycline treated cells. 
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mRNA overexpression when compared to vehicle treated cells (p<0.05). PRH 
overexpression significantly upregulated E-cadherin mRNA (CDH1) expression 
(p<0.05), while significantly downregulated TGF-β pathway genes (TGFB2 and 
TGFBR2) (p<0.05). 
Whole cell protein extract was also used to assess epithelial protein phenotype. Myc-
tag western blotting was used to confirm overexpression (figure 4.19 B). Myc-tag 
western blot showed myc-PRH being detected only in PC3 PRH LV treated with 
doxycycline. Lamin A/C shows equal protein loading. E-cadherin western blot 














Figure 4.19. Doxycycline reactivates epithelial phenotype in PC3 PRH LV. (A) The graph shows the 
relative mRNA expression of various genes in PC3 PRH LV cells treated with vehicle or 1.5 ug/mL of 
doxycycline. HHEX mRNA upregulation shows successful PRH mRNA overexpression. All statistical 
comparisons made were between doxycycline 1.5 ug/mL and vehicle treatment. Statistical analyses: one-
sample t-test with hypothetical value set to ‘1’, p<0.05, n=3. (B) Western blot images of PC3 PRH LV protein 
extract probed with myc-tag antibody show PRH overexpression. E-cadherin western blot was used as an 




It was previously shown that PRH mis localisation is observed in breast cancer 
(Puppin et al. 2006). Also, the hyper-phosphorylation of PRH and its subsequent 
degradation by the proteasome is correlated to increased cell migration and 
proliferation in prostate cancer cells (Noy et al. 2012; Siddiqui et al. 2017). These 
reports suggest that PRH plays a role in cancer progression. Here I showed that 
HHEX is altered in 4% of the sequenced patients with prostate adenocarcinoma, and 
that the majority of the alterations were deep deletions. The loss PRH /HHEX gene 
in prostate cancer suggests that this gene is a potential tumour suppression gene. 
Interestingly, using the same database showed that HHEX gene deletion co-
occurrence with PTEN gene deletion is statistically significant. PTEN is a tumour 
suppressor gene commonly deleted in many cancers, (as reviewed by Chu & 
Tarnawski 2004). PTEN and HHEX are both located at chromosome 10 in the region 
10q23, this region presents loss of heterozygosity in approximately 50% of prostate 
cancers (Feilotter et al. 1998). Epigenetic regulation of PRH in prostate 
adenocarcinoma may also play a role in prostate cancer progression. The data 
obtained from the MethHC database compares the β-value of prostate 
adenocarcinoma samples to normal prostate samples. The methylation test is made 
by enquiring the CpG site with a methylated-specific probe and an un-methylated-
specific probe, the β-value is the ratio of methylated probe intensity (Du et al. 2010). 
Here I showed that the average β-value of prostate adenocarcinoma in the HHEX 
gene body is higher than in normal prostate samples. CpG methylation is usually 
associated with gene silencing. My analysis shows that the increase in CpG 
methylation correlates with reduced PRH mRNA expression. This adds further 
weight to the suggestion that PRH is a tumour suppressor protein in prostate cancer. 
The PRH immunostaining in a large number of prostate adenocarcinoma tissues 
also further illustrates the importance of PRH in prostate cancer progression. The 
Gleason’s score (GS) description used here was described by the 2005 International 
Society of Urological Pathology (ISUP) Consensus Conference, with some 
modifications (Epstein et al. 2005). This newer system does not score tumours that 
would be originally scored GS 2–5 on a needle biopsy. The reason for this change is 
that the progression of the disease will depend on the most dedifferentiated part of 
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the tumour, with scoring being assigned to those areas. A needle biopsy can 
randomly pick a relatively well differentiated part of the tumour and mislead the 
prognosis prediction (Epstein et al. 2005). Because in this work we aimed to assess 
the correlation between PRH expression and differentiation degree of the gland, a 
scoring of each gland specifically would be more suitable, so the implementation of a 
narrower view of the prostate tissue could offer a more consistent population of 
glands on the histological section. Furthermore, I needed to score all the samples 
with the same criteria. Therefore, tumours that would be normally not be graded by 
needle biopsies due to low GS, here were still graded with the low scores of the 
original system, that way numeric variables could be used to compare the samples in 
the correlation test. 
The PRH immunohistochemistry showed that PRH staining in the cytoplasm and 
nucleus of prostate cancer samples were negatively correlated to the differentiation 
degree of the tumours, expressed in the form of Gleason score. Interestingly, the 
results found in the correlation test were somewhat different from the ones published 
by Siddiqui and co-workers (Siddiqui et al 2017). This work showed that total 
cytoplasmic PRH appears to be elevated in these BPH and in a small number of 
prostate adenocarcinomas. However, the sample size in this work did not allowed a 
proper statistical evaluation, so a larger scale test, such as the one presented here, 
was still needed. The most consistent finding in the histopathology work in Siddiqui 
et al 2017 paper was the hyper-phosphorylation of nuclear PRH in BPH. The 
phosphorylation of PRH leads to PRH degradation, as shown by Noy et al 2012. This 
early stage phosphorylation, potentially, could lead to down-regulation of total PRH, 
via degradation of PRH by proteasome. Additionally, from the 9 adenocarcinoma 
(AC) samples presented, four samples were graded with GS >9 and presented 
moderate staining intensity. While from the 5 samples graded with GS =9, three 
presented low intensity staining, the sample size was too small to predict this 
correlation, but the trend agrees with my findings. 
Another difference between the two reports is the sample type. Here the samples 
were obtained in needle biopsies, while the samples in Siddiqui et al 2017 paper 
were from a total prostate examination. The total prostate examination allows a 
whole tumour Gleason grading, which is important for the treatment and prognosis of 
the patient. However, the expression levels of neoplastic driving factors is known to 
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change in different parts of the tumour (Zieglschmid et al. 2007; Hu et al. 2013; 
Norton et al. 2016). The complex microenvironment can create different levels of 
differentiation within the same tumour and an equivalent difference in the expression 
levels of some proteins. Therefore, within the same tumour, it is possible to find 
areas expressing more or less PRH. This created a necessity to grade each gland 
separately in order to obtain a realistic comparison between PRH expression and 
gland differentiation, as discussed above. Finally, it is important to note that these 
samples should be re-scored by a pathologist before publication.  
The results obtained in vitro also corroborate the correlation between PRH 
expression and tumour cell differentiation. The PC3 cell line was established in 1979 
from a bone metastasis of a prostate adenocarcinoma. Morphological studies of PC3 
showed that it is compatible with poorly differentiated adenocarcinoma. It presents a 
high metastatic and high tumour forming capability. The overexpression of PRH in 
PC3 cells reduced the migratory ability of PC3 cells and altered cell morphology. The 
expression of the epithelial marker E-cadherin was also affected. A clear E-cadherin 
up regulation was observed by western blot and by qPCR when PRH is over-
expressed. As discussed on the previous chapter, E-cadherin expression is 
correlated with epithelial phenotype and better prognosis in cancer, including 
prostate cancer (Wade & Kyprianou 2018). 
The ChIP data showed a possible direct regulation of the CDH1 gene by PRH. ChIP-
qPCR confirmed binding of Myc-PRH on both CDH1 sites tested. Additionally, PRH 
seems to bind to multiple sites on the CDH1 gene, as shown on the ChIP-seq trace. 
the PRH. The binding of PRH in different sites of the same gene could suggest the 
activation of expression via enhancer cooperation. A transcription factor can change 
the shape of the DNA in order to move from one binding site to another, forming a 
DNA loop in the process, reviewed by (Yesudhas et al. 2017). By forming a loop, a 
transcription factor can also serve as a protein bridge on the DNA, recruiting a 
distant enhancer to increase gene expression (Matthews 1992). For example, a 
DNA-loop activating an enhancer cooperation was demonstrated during the MET in 
non-tumorigenic mouse mammary gland cells. The DNA-loop was able to activated 
re-expression of E-cadherin by bringing two enhancers together (Alotaibi et al. 
2015). The presence of enhancers on both regions identified by ChIP-qPCR 
(enhancer ID GH16J068731 and GH16J068736) opens the interesting possibility of 
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a future study to evaluate reactivation of E-cadherin expression by a similar 
mechanism in prostate adenocarcinoma cells. However, the possibility that PRH can 
activate E-cadherin expression simply by initiating the transcription is not discarded, 
Chromatin Conformation Capture (3C) studies could help elucidate this question, 
since 3C provided information on 3D chromatin structures that occur in living cells. 
Another important alteration that PRH over-expression brought about was the 
regulation of TGF-β pathway proteins. The microarray data showed that the PRH 
over expression down-regulated the expression of TGFB2 and TGFBR2 mRNA. 
Additionally, the ChIP seq showed peaks at theTGF2, TGFBR2 and TGFBR1 genes, 
all confirmed by ChIP-qPCR. TGF-β signalling is important in prostate cancer 
progression. The blockage of TGF-β signalling by overexpressing a dominant-
negative TGFBR2 supressed tumour formation by PC3MM2 cells injected into nude 
mice (Zhang et al. 2005). Moreover, TGF-β has been shown to have a context-
dependent effect on prostate cancer. Initially, TGF-β presents a tumour suppressor 
activity, but in advanced prostate tumours, it shows a pro-proliferative effect (Wade & 
Kyprianou 2018; Massagué 2008a). Mice expressing dominant negative TGFBR2 
showed higher metastatic activity than the controls (Tu et al. 2003). As shown here, 
PRH overexpression in PNT2-C2 cells caused down-regulation of TGF-β signalling 
genes (TGFB2 and TGFBR2), while the over-expression of PRH in PC3 cells down-
regulated the TGF-β signalling genes (TGF2 and TGFBR2) and repressed cell 
migration. TGFBR1 expression was not detected here, data from the cancer cell line 
encyclopaedia (CCLE) shows that TGBR1 expression in PC3 cells is lower than 
TGF2 and TGFBR2 but is detectable by RNAseq. The fact that TGFBR1 was not 
detected here might be due to low mRNA concentration, or low primer quality. 
Therefore, the repetition of the qPCR should be done using a different primer pair to 
clarify this question. Nevertheless, the downregulation of TGFB2 and TGFBR2 is an 
important modification to the TGF-β pathway and it is likely to be effective in 
triggering MET in PC3 cells. Moreover PRH directly activates the expression of 
Endoglin, a TGF-β co-receptor that down-regulates TGF-β signalling (Siddiqui et al. 
2017). 
The establishment of a stable inducible PRH overexpressing cell line base on PC3 
cells was successful. The dose-dependent response observed in PRH 
overexpression with doxycycline treatment showed that the overexpression could be 
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regulated by adjusting the dose of doxycycline. Moreover, even the highest dose of 
doxycycline tested does not seem to be cause direct toxicity. There was a reduction 
in the number of viable cells at the highest doxycycline dose tested, however, the 
reduction in the number of viable cells is a reflection of the reduction of cell 
proliferation rate, observed by the EdU incorporation assay.  
MTT is a popular method to determine the number of viable cells due to its low cost 
and easy execution. It is based on the metabolisation of tetrazolium salt by the 
mitochondria of living cells (Sylvester 2011). The metabolite product (formazan blue) 
is coloured and can be measured using a spectrophotometer. In the assay executed 
here, the same number of cells were seeded in each well of a 96-well plate. 
However, the cells were incubated after seeding for 48 hours. That gives time for the 
cells to proliferate, therefore cells presenting a lower proliferation rate would display 
a lower quantity of formazan blue formed after the addition of MTT salt. The reduced 
incorporation of EdU and reduced growth rate support the theory that the lower 
number of viable cells is a reflection of the lower number of cells rather than a toxic 
effect of doxycycline. Furthermore, the propidium iodide staining shows no difference 
in the number of dead cells between the vehicle treatment and the highest dose of 
doxycycline tested. 
Published data shows that PRH overexpression reduced the cell migration in 
prostate and breast cells (Kershaw et al. 2014b). Lower migratory ability is a 
characteristic of cells displaying an epithelial phenotype (Thompson et al. 2005). 
Epithelial cells are closely attached to their neighbouring cells by adhesion proteins 
such as E-cadherin. In some cases, they are also attached to a basal membrane 
where they remain indefinitely (Gartner et al. 2011). Actually, the detaching of 
epithelial cells from their basal membrane is one of the last stages of EMT (Kalluri & 
Weinberg 2009). In culture, epithelial cells are normally strongly attached to their 
neighbouring cells, growing in clusters and presenting low migratory ability (Lang et 
al. 2001). In PC3 PRH LV cells treated with doxycycline, I observed a reduction of 
migration and in culture, a cluster growth pattern was occasionally seen. Additionally, 
the expression of the main epithelial phenotype marker, E-cadherin, was found 
upregulated in PC3 PRH LV cells when they were treated with doxycycline. 
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The demonstration of similar effects of PRH overexpression in PC3 cells in a second 
model shows the robustness of the data. Stable cell line models have the advantage 
of a more homogenous overexpression, which can increase reproducibility (Savage 
et al. 2013; Büssow 2015). The qRT-PCR from the stable overexpression showed 
less variability than the adenoviral overexpression. However, they show the same 
results regarding the expression of epithelial markers and TGF-β signalling genes. 
With this, it possible to speculate that the expression of PRH can influence TGF-β 
signalling in prostate cancer. I showed that PRH protein expression is often down-
regulated in advanced prostate adenocarcinoma, that PRH directly regulates TGF-β 
signalling genes TGFB2 and TGFBR2, and that the overexpression of PRH can re-
activate epithelial markers expression in PC3 cells. So, it is secure to say that PRH 
could regulate EMT in prostate adenocarcinoma cells by downregulating some of the 
proteins in the TGF-β signalling pathway. 
The use of a TGF-β inhibitor to treat prostate cancer treatment had been discussed 
previously (Jones et al. 2009). In general, most of the data available comes from pre-
clinical research. The inhibition of TGF-β pathway using antibodies prevented the 
appearance of lung metastasis caused by breast cancer (Biswas et al. 2007). 
However, as there are a number of contradictory publications and a much greater 
contextual understanding of TGF-β signalling is necessary. As TGF-β and PRH both 
regulate EMT in prostate cancer cells, and PRH seems to regulate the TGF-β 
pathway, PRH expression is likely to be important to TGF-β signalling during 
prostate cancer progression. With a better understanding of this process, we may be 
able to make more educated decisions regarding the treatment of earlier stages of 
















Chapter 5: TGF-β regulates PRH 









An association between TGF-β signalling and PRH expression has been shown 
before. Published data showed that Smad3 and Smad2 regulates PRH expression in 
mice embryos, since animals that were heterozygous for a deletion of both genes 
presented PRH down-regulation accompanied by craniofacial axis, liver and thyroid 
malformations (Liu et al. 2004). However, in vitro experiments with HHEX promoter 
fragments cloned upstream from a luciferase gene suggested that Smad3 and 
Smad2 did not bind to the region studied (Zhang et al. 2002). Therefore, it remains to 
be clarified how TGF-β signalling regulates PRH expression and whether it does so 
in prostate cells. Here I use qRT-PCR and western blotting to examine the effects of 
TGF-β treatment on PRH expression and PRH phosphorylation in prostate cell lines. 
To examine the mechanism by which TGF-β regulates PRH activity, I also use 
phosphorylation inhibitors to examine whether the PRH phosphorylation is 
responsible for the effects of TGF-β on PRH expression in prostate cells. In parallel, I 
assess whether the HHEX promoter region is enriched following TGF treatment, 
meaning that pSmad3 binds to HHEX gene. 
Results 
TGF-β treatment down-regulates PRH expression 
PC3 cells were treated with TGF-β or vehicle for 48 hours. After harvesting, whole 
cell protein extracts were used in PRH western blotting (as described in section 
2.9.1) (Figure 5.1 A), and Lamin A/C was used as a loading control. The western blot 
images were analysed in ImageQuant to obtain densitometry of each band. PRH 
densitometry was normalised by Lamin A/C densitometry in three independent 
experiments for statistical analysis (Figure 5.1 B). As can be seen in the Figure, 
TGF-β treatment brings about a 50% reduction in PRH protein levels in PC3 cells. 
TGF-β treatment also down-regulates PRH protein expression in PNT2-C2 cells 
(Figure 5.2 A). The 50% decrease in protein expression found in PNT2-C2 cells was 


















Figure 5.1. TGF-β down regulates PRH protein levels in PC3 cells. PC3 cells were treated with TGF-β or 
vehicle for 48h, whole cells lysates were used to protein to be used in western blotting. (A) Representative 
western blot images of PC3 protein extract probed with PRH and Lamin A/C antibodies. (B) The graph shows 
the results of densitometry of three independent PRH western blots normalised to the loading control Lamin 
A/C.  Statistical comparisons made were between TGF-β and vehicle groups. Statistical analyses: one-sample 
t-test with hypothetical value set to ‘1’, n=3, p<0.05. 
Figure 5.2. TGF-β down regulates PRH protein levels in PNT2-C2 cells. PNT2-C2 cells were treated with 
TGF-β or vehicle for 48h, whole cells lysates used in western blotting. (C) Representative western blot images 
of PNT2-C2 protein extract probed with PRH and Lamin A/C antibodies. (B) The graph shows the results of 
densitometry of three independent PRH western blots normalised to the loading control Lamin A/C. Statistical 
comparisons made were between TGF-β and vehicle groups. Statistical analyses: one-sample t-test with 
hypothetical value set to ‘1’, n=3, p<0.05. 
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TGF-β treatment increases PRH phosphorylation through protein 
kinase CK2 
Published data shows that protein kinase CK2 phosphorylates PRH (Noy et al. 
2012). Phosphorylated PRH (pPRH) is unable to bind DNA and is a substrate for 
proteasomal processing. It is also known that TGF-β stimulation activates CK2 
during EMT (Kim et al. 2018). To assess whether TGF-β treatment alters PRH 
phosphorylation in PNT2-C2 and PC3 cells, these cells were treated with 5 ng/mL of 
TGF-β for 48h. Whole cell extracts were used for pPRH western blotting, and Lamin 
A/C was used as a loading control (figure 5.3). Western blotting images showed a 
small increase in the pPRH signal. Repetitions of the experiment showed the 
consistency of the increase. To quantify and compare the signal in each condition, 
the images were used in densitometry analyses using ImageQuant and the 
densitometry values for pPRH were normalised to Lamin A/C densitometry values. 
Statistical analysis showed significance, confirming that the expression of pPRH in 























To determine whether CK2 is responsible for the TGF-β induced phosphorylation of 
PRH, PC3 and PNT2-C2 cells were treated with either vehicle, 5 ng/mL of TGF-β, 5 
ng/mL of TGF-β plus 10 uM of the well characterised CK2 inhibitor TBB or 10uM 
TBB alone. Whole cell protein extract was used in pPRH western blot, and Lamin 
A/C was used as a loading control (Figure 5.4). TGF-β significantly augmented the 
pPRH signal while co-treatment with TGF-β plus TBB abolished the increase in 
pPRH in both PNT2-C2 and PC3 cells. 
  
Figure 5.3. TGF-β induces PRH phosphorylation in prostate cell lines. PNT2-C2 and PC3 cells were 
treated with TGF-β or vehicle for 48h, whole cells lysates were used in western blot experiments. (A) 
Representative western blot images of PC3 protein extract probed with pPRH and Lamin A/C antibodies. (B) 
The graph shows the results of densitometry of three independent pPRH western blots normalised to the 
loading control Lamin A/C. All statistical comparisons made were between TGF-β and vehicle groups. 
Statistical analyses: one-sample t-test with hypothetical value set to ‘1’, n=3, p<0.05. (C) Representative 
western blot images of PNT2-C2 protein extracts probed with pPRH and Lamin A/C antibodies. (D) The graph 
shows the results of densitometry of three independent pPRH western blots normalised to the loading control 
Lamin A/C in PNT2-C2 cells. Statistical comparisons made were between TGF-β and vehicle groups. Statistical 






















Figure 5.4. TBB prevents TGF-β induced PRH phosphorylation in prostate cell lines. PNT2-C2 and PC3 
cells were treated with vehicle, TGF-β, TGF-β+TBB or TBB alone for 48h, whole cells lysates used in western 
blotting. (A) Representative western blot images of PC3 protein extract probed with pPRH and Lamin A/C 
antibodies. (B) The graph shows the densitometry of three independent pPRH western blots normalised to the 
loading control Lamin A/C in PC3 cells. Statistical analyses: one-way ANOVA followed by Bonferroni test for 
multiple column comparison, n=3, p<0.05. (C) Representative western blot images of PNT2-C2 protein extract 
probed with pPRH and Lamin A/C antibodies. (D) The graph shows the densitometry of three independent 
pPRH western blots normalised to the loading control Lamin A/C in PNT2-C2 cells. Statistical analyses: one-
way ANOVA followed by Bonferroni test for multiple column comparison, n=3, p<0.05. 
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CK2 inhibition does not block the effects of TGF-β on cell migration 
To determine if TGF-β induced phosphorylation of PRH by CK2 was required for 
TGF-β induced cell migration, PC3 and PNT2-C2 cells were treated with either 
vehicle, 5 ng/mL of TGF-β, 5 ng/mL of TGF-β plus 10 uM of TBB or 10uM of TBB 
alone. After 48h, the cells were harvested and counted. Equal amounts of cells were 
then used in a chemotaxis assay (as explained in section 2.8) (figure 5.5). TGF-β 
treatment significantly increased the percentage of migrated cells in both PC3 and 
PNT2-C2 in three independent experiments. TBB treatment did not reduce cell 
migration back to basal levels in either of the cell lines tested. TBB treated cells did 
not show any difference in migration when compared to vehicle group in both cell 
lines. I conclude that phosphorylation of PRH is not required for the effect of TGF-β 










Figure 5.5. TBB does not prevent TGF-β induced prostate cell migration in chemotaxis assays. PNT2-
C2 and PC3 cells were treated with vehicle, TGF-β, TGF-β+TBB or TBB alone for 48h, cells were then 
harvested, and their concentration adjusted to be used in migration chemotaxis assays. The assays were 
performed after cell concentration adjustment were performed in the presence of hydroxyurea to compensate 
for effects on cell proliferation the cell growth component on the number of migrated cells to be detected. (A) 
The graph shows the average percentage of migrated PC3 cells in three independent experiment submitted to 
chemotaxis assay. Statistical analyses: one-way ANOVA followed by Bonferroni test for multiple column 
comparison, n=3, p<0.05. (B) The graph shows the average percentage of migrated PNT2-C2 cells in three 
independent experiment submitted to chemotaxis assay. Statistical analyses: one-way ANOVA followed by 
Bonferroni test for multiple column comparison, n=3, p<0.05. 
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TGF-β regulates PRH mRNA expression possibly by a direct effect 
of pSmad3 
To evaluate the effects of TGF-β treatment on PRH mRNA expression, PNT2-C2 
and PC3 cells were treated with TGF-β or vehicle for 48h. Whole cell mRNA extract 
was then purified and used in qRT-PCR. HHEX (PRH) mRNA expression was 
measured relative to GAPDH and β-Actin expression (PNT2-C2- Figure 5.6 A PC3 – 
Figure 5.6 B). TGF-β treatment significantly down-regulated the relative expression 
of PRH mRNA when compared to the vehicle treatment (p<0.05) in both PNT2-C2 













Figure 5.6. TGF-β down- regulates PRH mRNA expression in prostate cells. PNT2-C2 and PC3 cells were 
treated with TGF-β or vehicle for 48h. Whole cell mRNA extract was then used in qRT-PCR experiments. (A) 
The graph shows the relative expression of HHEX mRNA in PNT2-C2 cells treated with vehicle or 5 ng/mL of 
TGF-β. Statistical comparisons made were between TGF-β and vehicle groups. Statistical analyses: one-
sample t-test with hypothetical value set to ‘1’, n=3, p<0.05. (B) The graph shows the relative expression of 
HHEX mRNA in PC3 cells treated with vehicle or TGF-β. Statistical comparisons made were between TGF-β 
and vehicle groups. Statistical analyses: one-sample t-test with hypothetical value set to ‘1’, n=3, p<0.05. 
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To determine whether TGF-β signalling could directly regulate PRH expression 
through activation of the transcription factor pSmad3, PC3 cells were treated with 
TGF-β or vehicle and used for pSmad3 ChIP experiments. After 48 hours, protein-
DNA complexes in the cells were cross-linked using methanol free formaldehyde. 
Chromatin was then extracted and used in pSmad3 ChIP-qPCR. ChIP-qPCR with 
rabbit IgG was used as a control for background. Primers specific for Chromosome 
18 sequences were used as a negative control and the Smad7 gene was used as a 
positive control (as explained in section 2.10.2) (figure 5.7). ChIP-qPCR shows that 
pSmad3 presented a 3.5-fold enrichment of HHEX promoter chromatin 
immunoprecipitation above the background with TGF-β treated PC3 cells. The 
vehicle treatment did not enrich HHEX promoter gene ChIP above the background. 
The positive control Smad7 was significantly enriched on both vehicle and TGF-β 
treatment. However the negative control CH18 did not present any enrichment above 


























* Different from Vehicle (IgG ChIP) p<0.05 
# Different from Vehicle (pSmad3 ChIP) p<0.05 
Figure 5.7. HHEX promoter enrichment in pSmad3 ChIP-qPCR in TGF-β treated PC3 cells. PC3 cells 
were treated with vehicle or TGF-β for 48hand used in a ChIP assay using pSma3 or normal rabbit IgG 
antibodies.10% of the extracts were separated to be used to quantify the input. After the ChIP, DNA was 
purified and used in qPCR to detect regions of the HHEX gene and HHEX promoter. CH18 primers were used 
as a negative control and Smad7 primers used as a positive control. The levels of amplicon were normalised 
by the input expression and calculated as percentage of input. The graph shows the average percentage of 
input detected by ChIP-qPCR using PC3 cells in three independent experiment. Statistical comparisons were 
made between the results for each primer on the IgG ChIP (background) versus the pSmad3 ChIP. Statistical 
analyses: two-way ANOVA followed by Bonferroni test for multiple column comparison, * different from IgG 
vehicle. # different from pSmad3 vehicle, n=3, p<0.05. 
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TGF-β effects in DU145 cells: Context is important in PRH-TGF-β 
crosstalk in prostate cancer cells 
It is known that TGF-β effects are dependent on the context in which it is activated 
(Massagué 2012). For example, TGF-β can induce cell death or cancer progression 
depending on whether Smad4 is expressed or not in pancreatic ductal 
adenocarcinoma (PDA) cells (David et al. 2016). To investigate and compare the 
effects of TGF-β in EMT and PRH regulation in another prostate cancer cell line, I 
used prostate cancer cell line DU145 and repeated the TGF-β treatment previously 
performed in PC3 and PNT2-C2 cells. 
TGF-β induced EMT markers in DU145 cells 
To screen for TGF-β markers, DU145 cells were treated with 5 ng/mL of TGF-β for 
48 hours (as described in section 2.7.1). Whole cell protein extract was then used in 
western blot assays with EMT marker antibodies (Figure 5.8 A). mRNA cell extract 
was also used in qRT-PCR to assess the mRNA expression of EMT markers that 













Figure 5.8. EMT markers screening in DU145 cells. (A) Photoradiography of seven EMT markers analysed 
by western blotting in DU145 whole cell protein extracts. In the left column, protein extracted from DU145 cells 
treated with vehicle. In the right column, protein extracted from DU145 cells treated with TGF-β (5ng/mL) for 
48h. The expression of each EMT marker was compared to the expression of a housekeeping protein (β-Actin 
or Lamin A/C). (B) The graph shows the relative expression of CDH1 mRNA in DU145 cells treated with vehicle 
or 5 ng/mL of TGF-β. Statistical comparisons made were between TGF-β and vehicle groups. Statistical 
analyses: one-sample t-test with hypothetical value set to ‘1’, n=3, p<0.05. (C) The graph shows the relative 
expression of Snail mRNA in DU145 cells treated with vehicle or TGF-β. Statistical comparisons made were 




The EMT markers western blot screening showed that TGF-β caused changes in the 
expression of four proteins. E-cadherin was found to be down-regulated when 
DU145 cells were treated with TGF-β, in comparison to vehicle treated cells. β-actin 
western blot in the same membrane was used to show equal protein loading. Snail 
was found up-regulated in TGF-β treated DU145 cells when compared to vehicle 
treated DU145 cells. Lamin A/C western blot in the same membrane shows equal 
loading. ZO-1 was found down-regulated in DU145 cells treated with TGF-β in 
comparison to vehicle with Lamin A/C as a control. β-catenin was found up-regulated 
in TGF-β treated DU145 cells in comparison with vehicle treated DU145 with β-Actin 
as a control. 
qRT-PCR for E-cadherin and Snail expression agreed with the western blot results. 
E-cadherin mRNA levels normalised to GAPDH mRNA levels, were found 
significantly down-regulated after TGF-β treated DU145 when compared to vehicle. 
Conversely, Snail mRNA, also normalised to GAPDH mRNA expression, was up-




Increased stability of PRH protein in DU145 cells 
To evaluate TGF-β regulation of PRH expression in DU145 cells, the cells were 
treated with TGF-β for 48 hours (as described in section 2.7.1). To evaluate PRH 
protein expression and its phosphorylation, whole cell protein extract was used in 
PRH and pPRH western blots (figure 5.9 A) in four independent experiments. The 
western blot analysis showed that TGF-β treatment did not reduce PRH protein 
expression over this time scale in DU145 cells when compared with the vehicle 
treatment. Another interesting finding was that TGF-β treatment did not augmented 
PRH phosphorylation in DU145 cell when compared to vehicle treatment. Lamin A/C 
western blots were used to show equal loading. 
TGF-β or vehicle treated DU145 whole cell mRNA extract was then used in qRT-
PCR to evaluate HHEX mRNA expression (Figure 5.9 B) in three independent 
experiments. The PRH mRNA levels were normalised to GAPDH mRNA levels. PRH 
mRNA relative expression was down-regulated in TGF-β treated DU145 cells when 
compared to vehicle treated cells. Thus TGF-β treatment reduces PRH mRNA levels 









  Figure 5.9. TGF-β effects on PRH expression in DU145 cells. (A) Western blotting images of TGF-β or 
vehicle treated DU145 cells. Whole cell protein extract was used in western blot analysis, the membranes were 
probed with PRH or pPRH antibodies. Lamin A/C was used to show equal loading. (B) The graph shows the 
relative expression of HHEX mRNA in DU145 cells treated with vehicle or 5 ng/mL of TGF-β. All statistical 
comparisons made were between TGF-β and vehicle groups. Statistical analyses: one-sample t-test with 
hypothetical value set to ‘1’, n=3, p<0.05. 
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Blood platelets stimulate prostate cell migration and extravasation 
through TGFβ-mediated down-regulation of PRH/HHEX. 
Extravasated blood platelets can influence the tumour microenvironment through the 
release of cytokines including PDGF, VEGF and TGF-β (Blakytny et al. 2004; 
Haemmerle et al. 2016). Blood platelets release TGF-β and induce EMT-like 
changes in cancer cells and the simple inhibition of TGF-β signalling in platelets of 
mice protected then against lung metastasis (Labelle et al. 2011). This shows the 
important role that platelets can play in providing TGF-β at the tumour site and to 
circulating tumour cells, facilitating the emergence of a malignant phenotype. As 
TGF-β is known to be important to the progression of prostate cancer I examined the 
effect of blood platelets on prostate cells and PRH expression.  
Platelets induce cell migration and extravasation by activating the TGF-β 
pathway 
Dr Yusra Siddiqui kindly ceded some preliminary data from experiments conducted 
in our laboratory. To assess if blood platelets could increase extravasation by PNT2-
C2 cells, plasmid expressing PRH shRNA or empty vector (SVC) shRNA were 
transfected into PNT2-C2, the cells were then selected and treated with platelets or 
vehicle and used in in vitro extravasation assays (figure 5.10 A). To test if the 
extravasation induced was related to activation of TGF-β, the pathway, PRH 
knockdown (KD) and control PNT2-C2 cells were treated with blood platelets plus or 
minus SB431542 (a TGFβR1 inhibitor) (figure 5.10 B). A diagram of the 









Figure 5.10. Blood platelets released TGF-β induces prostate cell migration and extravasation. (A) PRH 
shRNA KD (KD) or vector control (SVC) were transfected into PNT2-C2 cells. After 10 days in selection 
transfected cells were treated with platelets or vehicle before being used in extravasation assays. The graph 
shows the average number of extravasated cells in three independent experiments performed in the presence 
of hydroxyurea. Statistical analyses: one-way ANOVA followed by Bonferroni test for multiple column 
comparison, n=3, p<0.05. (B) SB431542 is an established inhibitor of TGF-β signalling. KD and SVC PNT2-
C2 cells were treated with vehicle, vehicle + platelets or SB431542 + platelets and used in extravasation assays 
as above.  Statistical analyses: one-way ANOVA followed by Bonferroni test for multiple column comparison, 
n=3, p<0.05. all the extravasation assays showed here were performed by Dr Yusra Hasan Siddiqui and used 
here with authorisation. (C) PNT2-C2 and PC3 cells were treated with platelets or vehicle before being used in 
chemotaxis assays. Statistical analyses: two-tailed unpaired t-test, n=3, p<0.05. (D) The cells used in the 
migration assays showed in ‘C’ were used to make whole cell protein extracts. The protein extracts were used 
in pSmad3 western blotting analysis to show activation of TGF-β signalling pathway. 
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The data in Figure 6.1 A shows that PRH knockdown significantly increased PNT2-
C2 extravasation when compared to SVC transfected PNT2-C2 cells. Platelets alone 
were not able to increase PNT2-C2 extravasation, but platelet treatment significantly 
increased the migration of PHR KD cells when compared to vehicle treated PRH KD 
PNT2-C2 cells. Furthermore, when PRH KD PNT2-C2 cells were treated with 
platelets and SB431542, there was statistically significant reduction in extravasation 
(Figure 5.10 B). Treatment with SB431542 did not affect cell migration induced by 
PRH KD alone. To assay the effect of platelets on cell migration, I treated PC3 and 
PNT2-C2 cells with blood platelets for 48 hours and performed cell migration assays 
(Figure 5.10 C). To confirm the activation of TGF-β pathway, the leftover cells from 
the migration assay were used in pSmad3 western blotting experiments (figure 5.10 
D). The migration assay showed that platelet treatment augmented the migration of 
both PNT2-C2 and PC3 cells when compared to vehicle treatment. The pSmad3 
western blot showed TGF-β activation in both PNT2-C2 and PC3 cells treated with 




Platelets treatment presents the same alterations as TGF-β treatment 
To assess if platelet treatment would produce the same changes in PRH levels as 
TGF-β, PNT2-C2 and PC3 cells were treated with either TGF-β, platelets or vehicle 
controls (as described in section 2.7.1). Whole cell protein extracts were used in 
PRH and pPRH western blots (figure 5.11) with Lamin A/C to show equal loading. 
Platelet treatment down-regulated PRH protein levels and augmented pPRH levels 
in both prostate cell lines. As previously shown, TGF-β treatment down-regulated 












Figure 5.11. Platelets regulation of PRH expression. The western blot images compare the effects of 
platelets and TGF-β treatments on PRH expression in PC3 and PNT2-C2 cells. Lamin A/C was used to show 
equal loading. (A) Photoradiography of PRH and pPRH expression analysed by western blot from PC3 whole 
cell protein extract. On the left, cells treated with vehicle or TGF-β. On the right, cells treated with platelets or 
vehicle. (B) Photoradiography of PRH and pPRH expression analysed by western blot from PNT2-C2 whole 




To assess if platelet treatment could induce an epithelial phenotype, PC3 cells were 
treated with platelets or vehicle for 48 hours on two independent occasions. Whole 
cell mRNA extract was then used in CHD1 (E-cadherin) qPCR. CDH1 expression 
levels were normalised to GAPDH levels (figure 5.12 A). Treated cells were also 
used to produce whole cell extracts used in E-cadherin and β-actin western blots. 
Platelet treatment reduced CDH1 mRNA levels in two independent experiments, 
when compared to vehicle treatment. Platelet treatment also reduced E-cadherin 














Figure 5.12. The effects of platelet treatment on the epithelial marker E-cadherin. PC3 cells were treated 
with platelets or vehicle for 48 hours before being harvested and lysed to be used in qRT-PCR and western 
blotting assays. (A) The graph shows the relative CDH1 mRNA expression in two independent experiments 




PRH binds to the IL-6 promoter 
Platelets are reported to aid cancer cells through direct interaction, triggering EMT, 
extravasation and immune system evasion (Haemmerle et al. 2016; Carr et al. 2014; 
Labelle et al. 2011). IL-6 is a cytokine known to induce platelet production (Stahl et 
al. 1991) and to be up-regulated in prostate cancer (Nguyen et al. 2014). Evaluation 
of ChIP-seq data showed that myc-PRH binding is enriched in the IL-6 gene region 
(Figure 5.13). Several locations within the gene were detected in the sequencing and 
one of the most frequently detected regions was at the promoter, close to the 
transcription initiation site. The promoter regions detected in the sequencing also 



































Figure 5.13. PRH occupation on IL-6 gene. ChIP-seq trace aligned with whole genome version ‘Human Feb. 2009 (GRCh37/hg19) Assembly’. The image is a screen shot 





TGF-β signalling is an important factor in prostate adenocarcinoma progression, 
(reviewed by (Derynck et al. 2001; Levy & Hill 2006). Promising new anti-TGF-β 
drugs were found to be effective in clinical trials. However, identifying predictive 
biomarkers to flag patients who would most likely benefit from these inhibitors is also 
an important issue to be overcome (reviewed by (de Gramont et al. 2017). 
PRH is a novel EMT-TF shown to regulate cell proliferation and migration in prostate 
cancer cell lines (Kershaw et al. 2014; Siddiqui et al. 2017). The previous chapters 
showed that PRH protein expression is correlated to gland differentiation in patients 
with prostate cancer. This chapter presents evidence that PRH directly regulates 
TGF-β signalling genes. As aforementioned, published data shows that the inhibition 
of TGF-β signalling by expression of a heterozygote dominate negative of Smad3 
and Smad2 down-regulated HHEX expression in embryos (Liu et al. 2004). 
However, this paper did not show the mechanism of how HHEX expression came to 
be down-regulated. This chapter studied the effects of TGF-β on PRH protein and 
mRNA expression in prostate cancer for the first time, and, proposed a mechanism 
that could explain how TGF-β regulates PRH expression. 
Interestingly, inhibition of TGF-β signalling activation by down-regulating the 
functions of Smad3 and Smad2 was shown to reduce PRH expression in mice 
embryos (Liu et al. 2004). Here, the activation of Smad3 by treatment with TGF-β in 
prostate cell lines down-regulated PRH expression at both the protein and mRNA 
levels. These conflicting results may be explained by the different models used in 
these experiments. While embryo models will most likely show primary functions of 
the TFs, in adenocarcinomas TFs are known to be dysregulated. Dysregulation and 
disrupted cooperation between transcription factors are reported to be a driving 
factor in cancer progression, (reviewed by (Ell & Kang 2013; Wang et al. 2016). 
Specifically, TGF-β in prostate cancer is known to be dysregulated, as the primary 
effect of TGF-β in prostate epithelium is anti-proliferative, but as the cancer 
progresses, TGF-β becomes an inducer of cell proliferation and migration, (reviewed 




Thus, the differences observed in the data here and from Liu’s et al could be a 
reflection of the contextual interactions that the TFs face in different cells. For 
example, the context in which TGF-β pathway is activated in pancreatic ductal 
adenocarcinoma was shown to regulate cell fate (David et al. 2016). The complex of 
r-Smads formed by Smad2/Samd3 activate transcription of the gene SOX4, together 
with SOX4, Klf5 (normally expressed in this cell line) promotes tumorigenesis. In the 
presence of the co-Smad Smad4, the r-Smads form a Smad2/Smad3/Smad4 
complex. The triple Smad complex can now activate the transcription of the gene 
encoding the EMT-TF Snail. Snail can associate with the Smad2/Smad3/Smad4 
complex forming a unit that inhibits the transcription of Klf5. However, 
Smad2/Smad3/Smad4 can still activate transcription of the gene SOX4. SOX4 alone 
without the presence of Klf5 drives a totally different cell fate; an apoptotic system is 
activated leading the majority of cells to death (David et al. 2016). 
The data here also show that treatment with TGF-β increases PRH phosphorylation 
by CK2. This corroborates published data which showed that CK2 causes hyper 
phosphorylation of the PRH protein and that PRH phosphorylated by CK2 can no 
longer bind to DNA and becomes a substrate for proteasome processing/cleavage 
(Noy et al. 2012). Conversely, TGF-β is reported to activate CK2 and this is essential 
for TGF-β induced EMT in a human non-small cell lung cancer cell line (A549) (Kim 
et al. 2018). Interestingly, inhibition of CK2 activity reduced the migration induced by 
TGF-β in A549 cells, but this effect was not observed here in prostate cells. 
However, there were some key differences in the migration experiments conducted 
here and the ones conducted by Kim and co-workers (Kim et al 2018). Here the CK2 
inhibition was achieved using TBB, an established CK2 inhibitor. Kim and co-workers 
inhibited CK2 activity by generating a stable CSNK2A1 knockdown in A549 cells. 
The CSNK2A1 gene encodes the subunit  of the protein CK2 (CK21), and its 
knockdown is reported to decrease cellular activity of CK2 (Ko et al. 2012). However, 
they did not knockdown CSNK2A2 which encodes CK2 ’ an alternative CK2 
catalytic subunit. Knockdown of both  and ’ is required to inhibit CK2 in some cells 
types (Wadey et al. 2017). Kim and co-workers made use of CK2 inhibitors in other 
experiments, but a migration assay using drug inhibition was not performed (Kim et 
al 2018). Perhaps the CK2 inhibition achieved with genetic modification was different 
from that achieved with the utilization of drugs. Here the CK2 inhibition using TBB in 
177 
 
the TGF-β treated cells was enough to reduce the pPRH western blot signal to the 
same levels seen in cells treated with only vehicle, but the TGF-β induced cell 
migration remained unaffected by the TBB treatment. The conflict observed between 
the two studies could also be a result of the cell line model in which they were 
performed. Here the studies were performed in two prostate cell lines, one 
immortalised and the other cancerous, while Kim and co-workers made use of a lung 
cancer cell line. Several proteins are reported to have different effects in different 
tissues. For example, the effect of Histone-lysine N-methyltransferase SETD7 
(SET7/9) in apoptosis (Gu et al. 2017). SET7/9 is protein that methylate histones and 
non-histones proteins and is important in epigenetic regulation of the genome. 
SET7/9 is reported to induce apoptosis in human acute myeloid leukaemia cells 
(AML) but in non-small-cell lung cancer (NSCLC) cells it inhibits apoptosis (Gu et al. 
2017). 
The possibility that TGF-β directly regulates PRH expression should also be 
considered. Here I have shown that pSmad3 can bind to the HHEX promoter region 
at the distance of around -1Kbp upstream of the transcription initiation site. 
Approximately 3.5-fold enrichment above the background was detected in a pSmad3 
Chip-qPCR assay. A paper published in 2002 reported the HHEX gene is regulated 
by a Smad-dependent pathway (Zhang et al. 2002). This paper showed an elegant 
experiment where several pieces of the PRH promoter were cloned upstream of a 
luciferase gene in plasmids. The plasmids were then transfected to stem cell line 
(C3H10T1/2) and embryo adenocarcinoma (P19) cells and the cells were treated 
with different TGF-β pathway activators including TGF-β2 and BMP2. The cells were 
also co-transfected with different Smad-expressing plasmids. Only the co-expression 
of Smad1 and Smad4 was able to increase luciferase activity with some of the 
constructs tested. Smad2 and Smad3 were not able to increase the luciferase 
activity in this model. These findings conflict with the data presented here. However, 
TGF-β is known to signal through Smad3 and Smad2 only (Ikushima & Miyazono 
2010), and a regulatory effect was observed on PRH gene expression when the cells 
were treated with TGF-β. The reason for the differences may relate to the promoter 
regions that were studied. Here a region approximately 1Kbp upstream from the 
transcription initiation site of the PRH gene showed enrichment for pSmad3 ChIP-
qPCR. In contrast in the study reported by Zhang et al the furthest region analysed 
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was 454bp upstream to the transcription initiation site (Zhang et al. 2002). Therefore, 
the reason for Smad3 not being able to regulate luciferase activity might be because 
a Smad3 regulatory main site in HHEX promoter was not cloned into any of the 
luciferase constructs (Zhang et al. 2002). Alternatively, TGF may regulate PRH 
through other pathways. The results shown in Chapter 4 showed that TGF-β blocks 
the effects of PRH on E-cadherin expression even when PRH is expressed from a 
heterologous promoter.  
Apart from the changes in E-cadherin and Snail, also observed in PC3 cells, TGF-β 
treated DU145 cells presented down-regulation of ZO-1. ZO-1 is a protein present in 
tight junctions, it is an epithelial marker and its down-regulation signals loss of 
epithelial phenotype (Zeisberg & Neilson 2009). Loss of ZO-1 expression is 
associated with cancer progression (Salvador et al. 2016). ZO-1 expression is down-
regulated in breast cancer (Hoover et al. 1998), and its expression in non-small cell 
lung cancer is associated with a good prognosis (Ni et al. 2013). Interestingly, ZO-1 
was reported to interact with β-catenin in migrating colorectal cancer cells (Hirakawa 
et al. 2009). During the migratory phase, ZO-1 interacts with β-catenin at tight 
junctions, but once cells are confluent and polarised, Cortactin replaces β-catenin for 
ZO-1 interactions at the tight junctions (Hirakawa et al. 2009). β-catenin is an 
adhesion protein that presents a second effect as a transcription factor and its role in 
prostate cancer is a controversial topic. Studies show conflicting results, but in 
general, the most likely influence of the β-catenin/Wnt signal pathway is during the 
emergence of castration-resistant tumours (Kypta & Waxman 2012). β-catenin also 
interacts with the TGF-β pathway. It was demonstrated that β-catenin knockdown in 
alveolar epithelial cells abrogates the EMT effects of TGF-β indicating a dependency 
on β-catenin for TGF-β effects in this cell model (Zhou et al. 2012). Here both β-
catenin and ZO-1 showed altered expression in DU145 cells treated with TGF-β, 
changes that were not observed in PC3 cells. This suggests that the differences in 
TGF-β effects observed here could be partially explained by the absence or 
presence of these proteins. 
Another interesting observation was the lack of down-regulation of PRH protein in 
DU145 cells with TGF-β treatment. In previous chapters it was shown that TGF-β 
treatment in PC3 cells down-regulated PRH at the protein and mRNA levels. 
Furthermore, it was found that pSmad3 binds to PRH promoter in TGF-β treated 
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PC3 cells. However, in DU145 cells TGF-β treatment did not down-regulate PRH 
protein levels. Perhaps, as discussed above, the different context in which TGF-β 
acts in each cell type modifies its effects on PRH expression. However, TGF-β did 
down-regulate PRH mRNA levels in DU145 cells. Down-regulation of mRNA levels 
that is not followed by a decrease in protein signal indicates a higher level of protein 
stability. TGF-β treatment did not increase pPRH signal in DU145 cells. As shown 
and discussed in previous chapters, TGF-β activates CK2 to phosphorylate PRH 
which becomes subject to proteasomal processing (Noy et al. 2012; Kim et al. 2018). 
Additionally, PRH turnover studies in K562 cells showed that the PRH protein has a 
very long half-life in these cells (Bess et al. 2003). Longer time course experiments 
may therefore be required to see down-regulation of PRH protein levels in DU145 
cells by TGF-β treatment. 
Experiments with a protein synthesis inhibitor such as cycloheximide to examine the 
PRH turnover in DU145 would also help to clarify these results. Future experiments 
comparing PRH stability in PC3 and DU145 cell lines facing TGF-β treatment would 
enhance our understanding of PRH/TGF-β interactions in prostate cancer. 
Platelets are known to be important in cancer metastasis through activation of TGF-β 
and other mechanisms of signalling (Haemmerle et al. 2016). Colon carcinoma cells 
treated with platelets formed more lung metastasis in a tail vein injection assay, while 
the same experiment done in mice with platelets that lack TGF-β showed reduced 
lung metastasis (Labelle et al. 2011). Platelets were also shown to aid cancer cell 
extravasation. TGF-β released by platelets can disrupt adhesion proteins at cell 
junctions opening spaces in the endothelium (Labelle et al. 2011). These reports are 
aligned with the findings reported here. Blood platelets induced cell migration and 
extravasation in PRH knockdown prostate cells. pSmad3 western blot showed 
activation of TGF-β signalling. Conversely, inhibition of TGF-β signal reduced 
platelet-induced extravasation. It is important to acknowledge that platelets are not 
the only possible source of TGF- in the tumour context, for example infiltrating T 
cells could account for part of the production of TGF- in the tumour (Donkor et al 
2011). 
Additionally, cells treated with platelets presented signs of EMT in published reports, 
for example, increased migration of hepatocellular cancer cells treated with platelets 
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(Carr et al. 2014) and EMT in murine colon adenocarcinoma cells treated with 
platelets (Labelle et al. 2011).  This corroborates my findings in prostate cancer cells, 
since here I showed that platelets induce a loss of epithelial phenotype, indicated by 
the down-regulation of E-cadherin and increased migratory ability. Additionally, TGF-
β released by platelets induced extravasation only in PNT2-C2 PRH knockdown 
cells. Together with the demonstration that platelets can down-regulate PRH 
expression as seen with TGF-β treatment, these results indicate that the TGF-β 
released by platelets could compromise PRH activity in relatively well-differentiated 
prostate cells in the early stages of the cancer triggering or potentiating the EMT 
which develops subsequently. 
Altogether these data indicate that platelets can be an important factor in prostate 
cancer, especially in early stages. Several reports show that late stage prostate 
cancer can be associated with a low platelet count (thrombocytopenia) (Betsch et al. 
2010). However, the thrombocytopenia associated with metastatic prostate cancer is 
thought to be a consequence of bone marrow dysfunction caused by bone marrow 
metastases. On the other hand, Interleukine-6 (IL-6) is reported to induce the 
production of platelets (thrombopoiesis) (Stahl et al. 1991) and is reported to 
correlate with poor prognosis when detected in early prostate cancer (Nguyen et al. 
2014). Patients with untreated metastatic prostate adenocarcinoma presented high 
serum levels of IL-6 (Nguyen et al., 2014). IL-6 overproduction mediates 
thrombopoiesis through the production of thrombopoietin in several cancers (Kaser 
et al., 2001). This information could help trace a hypothetical time line in the effects 
of platelets and PRH over prostate cancer progression (figure 5.14). Early stage 
cancer causes inflammation, augmenting the production of IL-6 (Culig, 2014). IL-6 
over-production triggers thrombopoiesis and later excessive quantities of platelets 
(thrombocytosis) (Kaser et al., 2001). Platelets can extravasate and interact with 
cancer cells activating TGF-β signalling (Haemmerle et al., 2016). TGF-β down-
regulates PRH facilitating EMT and metastasis. Cancer cells in the blood stream also 
interact with platelets and thereby evade the immune system, this interaction is also 
thought to facilitate extravasation. Prostate metastasis formed in the bone marrow 
would disrupt haematopoiesis and thrombopoiesis, causing thrombocytopenia. 
Interestingly, our ChIP-seq data showed a possible occupation of the IL-6 promoter 
by PRH, suggesting that PRH could have an effect on thrombopoiesis. This opens 
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This work explores the regulation of a novel EMT-TF, PRH, in prostate cancer cells. 
However, there is a general discussion on the roles and actual relevance of EMT-
TFs to cancer. This is mainly due the complexity of EMT regulation and use of sub-
optimal models (Brabletz et al. 2018) that can show conflicting results. EMT is not a 
uniform process limited by a unique pathway as different cell signalling programmes 
can initiate EMT-like changes in prostate cancer. Among them androgen receptor 
(AR) signalling, oestrogen signalling, TGF-β, IGF and EGF are commonly flagged as 
activators (as reviewed by Montanari et al 2017). Furthermore, there are several 
EMT-TFs, including Snail, Slug TWIST1 and ZEB (Jolly et al. 2015, Gasior et al 
2017) and inflammatory mediators such as NF-B that can be involved (Tong et al 
2018). Additionally, cancer cells need to adapt to different and severe environments, 
which creates a selection for constant change and adaptability (Brabletz et al. 2018). 
This is noticeable in tumours, where intermediate states of cell differentiation are 
observed. The microenvironment creates a dynamic system where cells can 
differentiate and de-differentiate according to environmental inputs (Jolly et al. 2015). 
Therefore, the arbitrary silencing of a marker and the use of end-stage classification 
systems in a plurally regulated process that is in constant modification can often 
mask its real relevance in cancer progression. Nonetheless, the use of simplistic 
models can still provide data on the plasticity of the EMT and give conclusions that 
are often valuable (as reviewed by Brabletz et al. 2018).  
EMT might not play a role in tumourigenesis but ins0074ead influence later stages of 
cancer. For example, the specific knockout (KO) of the EMT-TF TWIST1 in 
oncogene-induced breast cancer in mice, showed that tumorigenesis was the same 
between control and TWIST1 KO animals. However, tumours in TWIST1 KO mice 
presented reduced EMT markers and notably reduced frequency of lung metastases 
(Xu et al. 2017). Here, I demonstrated that TGF-β can induce EMT in a normal 
immortalised epithelial prostate cell line. TGF-β treatment also showed an 
aggravation of EMT markers in prostate adenocarcinoma cells, mimicking the effects 
of EMT in late stage cancers. I also highlighted the relevance of PRH studies in 
prostate cancer. Mutations and epigenetic regulations often cause PRH down-
regulation in patients’ samples as shown by the analysis of the cancer databases 
cBioportal and Meth HC. Furthermore, I showed that PRH expression is negatively 
correlated to the differentiation degree of prostate tumours. 
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Unlike TWIST1, Snail and Slug, which actively repress E-Cadherin expression and 
thereby induce EMT (Medici et al. 2008; Y. Wang et al. 2016), PRH appears to 
activate transcription of E-Cadherin in prostate cells. Microarray analysis of PRH 
knockdown in breast cell line MCF-7 showed down-regulation of E-cadherin 
(Kershaw et al. 2017). My research shows that PRH overexpression caused an up-
regulation of E-cadherin protein and its mRNA encoded by CDH1. In addition, PRH 
overexpression counteracts EMT by overexpressing E-cadherin. Therefore, PRH 
dysregulation would be expected to induce or facilitate EMT. 
One of the major contributors to the balance of EMT/MET (or EMP) observed in this 
study was TGF-. As explained before, TGF- can reach the tumour site through 
several routes. It can be produced by infiltrating inflammatory cells, platelets, stromal 
cells, additionally, it can be produced endogenously by cells from the carcinoma 
lineage (reviewed by David and Massagué 2018). TGF- protein availability to the 
receptor can also be regulated by several factors, among which is the sequestering 
of TGF- by components of the ECM, for example the Latent TGF-beta Binding 
Protein (LTBPs). These regulators can also  transport the protein activating signals 
to a distant site from the cell that originally produced it. The regulation of TGF-β 
signalling is discussed in more detail in the review by David and Massagué 2018. 
Additionally, I have demonstrated that TGF-β regulates the expression of PRH in 
prostate adenocarcinoma cells. This effect in late stages of prostate cancer aligns 
well with the observation of decreased PRH expression in patients’ prostate cancer 
samples. Interestingly, treatment of PRH over-expressing PC3 cells with TGF-β 
caused the abrogation of the re-epithelization effect of PRH. Together, this indicates 
that, in prostate adenocarcinoma, the balance shifts between these signalling 
pathways, augmenting TGF-β signalling during cancer progression. This generates 
several changes in cellular gene expression, including up-regulation of Snail and 
down-regulation of PRH, which drive EMT. Furthermore, by down-regulating PRH, 
which inhibits the expression of TGFBR2 and TGFB1, TGF-β creates a positive feed-
back loop, which would be expected to sensitise the cells to TGF-β. This makes it 
important to study the temporal expression of PRH during tumorigenesis and tumour 




Studies of TGFBR2 function in prostate cancer have shown conflicting data. The 
expression of a TGFBR2 dominant negative in PC-3MM2 reduced the tumour growth 
rate and metastatic incidence when these cells were injected into the prostate of 
nude mice (Zhang et al. 2005). Interestingly, over-expression of TGFBR2 in LNCaP 
cells restores the sensitivity of this cell line to TGF-β inhibitory effects on cell 
proliferation (Guo & Kyprianou 1998) and inhibits tumorigenicity by apoptosis 
induction (Guo & Kyprianou 1999). However, as these studies were conducted in 
different cell lines, important expression context is lost in the analysis. The TGF-β 
signal effect is known to vary with context, for example the abundance of receptors 
and regulators can alter TGF-β signal outcome (as reviewed by Massagué 2012, 
David and Massagué 2018). Therefore, the different effects of TGFBR2 observed 
could be a reflection of the contextual environment each cell line tested provided. 
Among other differences, according to the cancer cell line encyclopaedia, HHEX 
mRNA was detected less in LNCaP cells than in PC3 cells by mRNA seq. Based on 
the results presented here, it is not farfetched to speculate that differences in PRH 
expression between the two cell lines could be important in the contextual activation 
of the TGF-β pathway. This information is interesting and raises the question: in what 
contexts does TGF-β signalling repress PRH expression? Further experiments in 
additional cell lines and cancer models could help elucidate the answer to this in the 
future. 
I also propose that a TME component could be involved in the TGF-β induced 
downregulation of PRH. TGF-β pathway activation by platelets in prostate 
adenocarcinoma cells, triggered changes like the ones triggered by TGF-β 
treatment, including the down-regulation of PRH mRNA and protein levels. I also 
raise the possibility of PRH having an indirect effect on the recruitment of platelets. 
ChIP-seq showed that PRH binds to IL-6 promoter, and IL-6 can regulate the 
quantity of circulating platelets. Additionally, PRH is known to regulate genes from 
the VEGF signalling pathway in leukaemia cells (Noy et al. 2012) and PRH over-
expression has been shown to regulate VEGF signalling genes in endothelial cells 
(Nakagawa et al. 2003). This demonstrates the potential role of PRH in regulating 
the creation of new blood vessels, an important event in cancer progression. The 
repression of PRH could stimulate neovascularisation, and with it, platelets and other 
blood-borne factors might have increased access to the tumours. 
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In summary, TGF-β and PRH seem to co-regulate each other’s effects in prostate 
cancer EMT. TGF-β signalling (potentially activated by platelets) may down-regulate 
PRH expression directly by binding of pSmad3 protein to the HHEX promoter and 
indirectly by activation of CK2 and consequent PRH phosphorylation. PRH regulates 
the expression of multiple genes involved in the TGF-β signalling pathway, including 
TGFB2, TGFBR2 and Endoglin. PRH effects in prostate adenocarcinoma cells also 
included reduced migratory ability, reduced cell proliferation and reactivation of an 
epithelial phenotype. However, TGF-β signalling abrogates the reactivation of the 
epithelial marker E-cadherin by PRH over-expression, indicating that PRH is by no 
means the dominant mediator of TGF-β signalling. 
The existing information available about PRH in cancer plus the new information 
generated here shows that PRH interfaces with the establishment of at least three of 
the hallmarks of cancer. As mentioned above, PRH regulates the expression of 
VEGF signalling genes, possibly impacting angiogenesis. PRH also regulates 
cellular proliferation, showed here using EdU incorporation, and PRH expression is 
lower in advanced prostate adenocarcinomas samples and cell lines, so its down-
regulation can be interpreted as a mechanism that enables prostate cancer cells to 
evade growth suppressor signals. And finally, PRH regulates the EMT program in 
prostate cancer cell lines, therefore, its down-regulation could also facilitate the 
activation of invasion and metastasis in prostate cancer (figure 6.1). Additional 
experiments in animal models are required in order to investigate these points. For 
example, it would be interesting to study tumour formation by PC3 cells and PC3 
cells expressing PRH in nude mice as well as looking at the formation of metastases 




















EMT targeting is a novel strategy to overcome drug resistance in cancer treatment 
(reviewed by Du et al. 2016), as EMT is reported to be involved in drug resistance. 
PRH down-regulation was shown to induce EMT-like changes in immortalised 
prostate cells (Siddiqui et al. 2017). Here I have shown that PRH over-expression 
can re-activate the epithelial phenotype in prostate adenocarcinoma cells. PRH is 
therefore in a strategic position for studies of drug resistance mechanisms. The 
inducible PRH over-expression model I created in the PC3 cell line may be useful in 
drug screening. An established model that shows co-culture of stromal cells and 
cancer cells in 3D has relevant predictive value to the drug resistance profile of 
patients’ tumours (Saunders et al. 2017). This model is useful since it recreates a 
TME-like environment for the cancer cells in vitro. With the ability to regulate PRH 
expression in PC3 cells, this methodology could be applied to study the effects of 
PRH expression on drug resistance of prostate adenocarcinoma.  
PRH 
PRH PRH 
Figure 6.1. PRH interferes with three aspects of hallmarks of cancer. PRH suppresses growth signals, 
potentially blocks neovascularization and counter acts EMT in prostate cancer.  
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In the case of prostate cancer, castration therapy is widely implemented. This 
therapy can reduce tumour volume initially, however it may induce genetic evolution 
of the tumour and resistance to therapy. PRH deletion was observed in some 
prostate tumours, and in many cases in tumours that did not receive such therapies. 
This suggests that the lost of PRH happens in pre-treatment stages of prostate 
cancer, therefore PRH could be important in the process of tumourigenesis and 
carcinogenesis. With further experiments PRH could become an important marker 
that would, potentially, help to guide prostate cancer treatment in the future. Perhaps 
aiding the decision not to use ADT therapy to avoid tumour evolution and tackling the 
tumour with effective therapy from the beginning, instead of using palliative solutions 









Figure 6.2. Crosstalk between PRH and TGF-β. When TGF-β binds to the TGFβRII it forms a heterodimer 
with TGFβRI, TGFβRI then phosphorylates Smad3. pSmad3 can forms a heterodimer with Smad2 or a 
repressor complex with different corepressors. pSmad3 activity in PRH promoter may down-regulate HHEX 
gene expression. Alternatively, TGF-β signalling may down-regulate PRH activity by mechanisms that do not 
involve the regulation of HHEX gene transcription such as regulation of mRNA stability. PRH is a repressor of 
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Annex 1. Extravasation assay. A Boyden chamber was placed in a 24-wells plate, EMC gel was then 
plated on top of the pored membrane and left to set at 37°C degrees for 1 hour. HUVEC cells were seeded in 
the upper chamber with Endothelial cell media (Promega) and left in a tissue culture incubator until a 
confluent monolayer was formed. Once the monolayer was formed, the tested cells were seeded in the upper 
chamber in 2% FBS RPMI media and 10% FBS RPMI media was added to the lower chamber to create an 




Annex 2. pCLVi(3G)-PRH-CopGFP-IRES-Neo_BamHI-EcoRI plasmid map. 
